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Background: The Human Immunodeficiency Virus (HIV) is neuro-invasive and neurological
complications of HIV infection occur frequently through a variety of possible mechanisms. Stroke
in the setting of HIV is not uncommonly seen in young adults. High levels of von Willebrand
factor (VWF), a protein with key roles in platelet adhesion and aggregation, and low levels of A
Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13
(ADAMTS13), the protease that cleaves ultra large VWF multimers into smaller less
haemostatically active multimers, have been associated with an increased propensity for
thrombosis. Stroke is a potential complication of the aberrant activity of these two proteins. HIV
infection has also been associated with endothelial dysfunction, and VWF is a marker of the latter.
The investigation of VWF and ADAMTS13 may therefore provide new insights into the
pathogenesis of HIV-related stroke.
Aims: This study aimed to investigate the role of VWF and ADAMTS13 in the pathogenesis of
HIV-related young stroke in South Africa.
Methods: I undertook a case-control study consisting of 100 participants. This was a pilot study,
comprising three participant groups: HIV positive young strokes (n = 20), HIV negative young 
strokes (n = 40) and HIV positive non-stroke controls (n = 40). Plasma VWF (levels and activity)
and ADAMTS13 (levels) were measured on samples collected at day 6 or 7 post-stroke for cases or
on enrolment day for controls.
Results: HIV positive young strokes had significantly higher VWF levels than the HIV negative
young strokes. They also tended to have higher levels of VWF than the HIV positive young non-
stroke controls. HIV positive young strokes also had significantly lower levels of ADAMTS13
than the HIV positive young non-stroke controls. ADAMTS13 levels were notably low in both
stroke groups, with no significant differences between HIV positive and HIV negative strokes. 
Assays of VWF activity were normal in all three groups with no significant between-group 
differences. In HIV positive participants, VWF levels and CD4 counts were significantly
negatively correlated i.e. as CD4 counts decreased, VWF levels rose. No significant correlations
were found between CD4 counts and ADAMTS13.
Conclusions: Stroke in HIV infection is associated with a pro-thrombotic coagulation profile. 
High VWF levels and low ADAMTS13 levels contribute to creating this pro-coagulant state. The 
association may be causal i.e. the pro-thrombotic state resulted in the stroke. Alternatively, the 
observed changes may be a post-stroke acute phase response. Our findings favour a causative 
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Human Immunodeficiency Virus infection and the Acquired Immunodeficiency Syndrome 
(HIV/AIDS) is a worldwide epidemic, with Sub-Saharan Africa, including South Africa, worst
affected (UNAIDS 2011). HIV/AIDS results in multiple systemic complications. Neurological
complications occur commonly due to the virus itself, to opportunistic infections related to
immunosuppression, or to the complications associated with antiretroviral (ARV) drug therapy
(Hogan et al. 2011; Mc Arthur et al. 2005; Boisse et al. 2008). An increased frequency of stroke in
the setting of HIV has been reported and this has become a subject of increasing interest (Benjamin
et al. 2012). Stroke unrelated to HIV occurs more frequently in an older population. However,
HIV-related stroke affects mostly younger adults who form the bulk of the HIV-infected
population (Tipping et al. 2007; Ortiz et al. 2007). Because it affects mostly young adults, it results
in many years of disability and adversely affects the economy of already resource-poor countries.
Von Willebrand factor (VWF) and A Disintegrin and Metalloproteinase with a Thrombospondin
type 1 motif, member 13 (ADAMTS13) are two proteins involved in haemostasis. VWF is vital for
platelet adhesion and aggregation. It initiates platelet plug formation at sites of vascular injury.
ADAMTS13 cleaves the ultra large VWF (ULVWF) multimers into smaller multimers. The
ULVWF multimers are haemostatically active and may promote active thrombosis if present in
excess (Hassan et al. 2012; Denis et al. 2012). Thus ADAMTS13 maintains a balance between
bleeding and thrombosis. There is evidence that high VWF and low ADAMTS13 levels are
associated with an increased risk for thrombosis. The latter may play a role in stroke causation
(Bongers et al. 2006; Lip et al. 2002). However, the data on stroke are limited and hardly any
information is available on HIV-associated stroke. HIV infection is also associated with vascular
endothelial dysfunction and VWF is considered to be a marker of endothelial dysfunction (Blann
1993).
I therefore undertook this study to determine the role of VWF and ADAMTS13 in HIV-related 
young stroke. A cohort of 100 participants from a larger HIV-related young stroke study that is 
currently still underway was selected to participate in this smaller case-control study. This pilot 
study is, to our knowledge, the first of its kind. I recruited three participant groups: HIV positive 
young strokes [sample size (n) = 20], HIV negative young strokes (n = 40) and HIV positive non-
stroke controls (n = 40). Normal values for the markers of interest in this study were obtained from 












VWF (levels and activity) and ADAMTS13 (levels), were measured on plasma samples collected 
within 7 days of stroke onset in cases or within 7 days following enrolment of controls. I assessed 
the levels and activity of VWF and ADAMTS13 in our three participant groups. Using post-hoc 
analyses, I addressed the question as to whether any abnormal findings could be causative i.e. pre-
dated and predisposed to the stroke, or whether they were consequential upon the stroke e.g. due to 












CHAPTER 1 - REVIEW OF HIV/AIDS AND STROKE 
INTRODUCTION 
In this chapter, I shall provide a brief introduction to the Human Immunodeficiency Virus (HIV) 
and Acquired Immunodeficiency Syndrome (AIDS), together with a review of stroke. Thereafter, I 
shall discuss the relationship between stroke and HIV infection. 
1.1 Review of HIV and AIDS 
1.1.1 HIV and AIDS 
In 1981, the United States (US) Centres for Disease Control first described the Acquired 
Immunodeficiency Syndrome (Centres for Disease Control and Prevention 1981). Two years later,
a retrovirus was isolated from a patient who presented with prodromal clinical signs and symptoms
that often preceded AIDS (Barre-Sinoussi et al. 1983). This was subsequently named the Human 
Immunodeficiency Virus. It has been divided into two types, HIV Type 1 (HIV-1) and HIV Type 2
(HIV-2). HIV-1 is known to be responsible for the global pandemic, and HIV-2, the less
pathogenic of the two types, is found mainly in West Africa.
1.1.2 HIV burden of disease globally and locally in South Africa
At the end of 2010, it was estimated that approximately 34 million people were living with HIV
worldwide. Of these, 68% resided in Sub-Saharan Africa. South Africa is home to the largest
number of people living with HIV than any country worldwide - an estimated 5.6 million
(UNAIDS 2011). Sadly, there are nine countries in Southern Africa that account for less than 2%
of the world’s population, but are known to represent approximately a third of global HIV
infections (De Cock et al. 2012). The worldwide and African prevalence of HIV infection are











Figure 1.1 Prevalence of HIV worldwide (From: HIV: Geography of an Epidemic 2011)
Figure 1.2 Prevalence of HIV in Africa (From: HIV: Geography of an Epidemic 2011) 
HIV/AIDS undermines economic growth in South Africa, lowering the gross domestic product 
growth rate by 1.60% per year in the KwaZulu-Natal (KZN) province and 1.42% per year in the 












the young economically active individuals of South Africa. A large national prevalence survey of 
HIV infection in South Africa conducted from 2008 to 2009 showed that HIV prevalence was 
higher amongst females than males across most of the age-group subdivisions used in the study. 
HIV prevalence peaked in females aged 25-29 years at 32.7% and in males aged 30-34 years at 
25.8%. The prevalence rate was also reported to be highest in KZN and lowest in the Western 
Cape among the 15-49 year age group (Shisana et al. 2009) (see figures 1.3 and 1.4). 
 
 
Figure 1.3 HIV prevalence in South Africa by sex and age group for 2008 (From: Shisana et al. 2009) 
 
 
Figure 1.4 South African HIV prevalence among the 15-49 year age group by province for 2008 
(From: Shisana et al. 2009) Abbreviations: KwaZulu-Natal (KZN), Mpumalanga (MP), Free State (FS), North West (NW), Gauteng 















1.1.3 Neurological complications of HIV 
HIV is neuro-invasive and invasion of the nervous system occurs early in the course of the disease 
(Shapshak et al. 2011; Yao et al. 2010; Hogan et al. 2011). Both the central nervous system (CNS) 
and peripheral nervous system (PNS) may be affected, with the presentation of neurological 
symptoms occurring at any stage of infection. However, most neurologic disorders tend to manifest 
with advanced immunosuppression. Neurologic disease may be due to direct viral invasion which 
produces distinct neurological syndromes. It may also result from indirect immune-deficiency 
related opportunistic infections, AIDS-defining cancers, ARV drug therapy toxicity, and vascular 
events (Hogan et al. 2011; Mc Arthur et al. 2005; Boisse et al. 2008). 
 
The complications may be classified on the basis of their neuroanatomical localisation (Price 
1996). Table 1.1 lists the complications according to the CNS and PNS anatomy affected and 
further sub-classifies them temporally into early and late presentations of HIV/AIDS infection. 
 
Central nervous system Peripheral nervous system and muscle 
Meninges and other structures surrounding the CNS 
   Early and late-middle course 
      ‘Aseptic’ meningitis, and symptomless HIV infection 
   Late 
      Cryptococcal meningitis 
      Tuberculous meningitis 
      HIV headache 
 
Brain 
   Focal-late 
      Cerebral toxoplasmosis 
      PCNSL 
      PML 
   Diffuse-early 
      Post-infectious encephalomyelitis 
   Diffuse-late 
      AIDS dementia complex 
      CMV encephalitis 
   Stroke 
 
Spinal cord 
   Late 
      Vacuolar myelopathy (part of AIDS dementia complex) 
Nerve and root 
   Early 
      Brachial plexitis, focal neuropathy, and polyneuropathy 
   Middle 
      Sub-acute and chronic demyelinating polyneuropathy 
      Mononeuritis multiplex, benign 
   Late 
      Distal predominantly sensory polyneuropathy 
      CMV polyradiculopathy 
      Mononeuritis multiplex: late CMV 
      Nucleoside polyneuropathy 
 
Muscle 
   Late 
     Inflammatory myopathy 
     Non-inflammatory myopathies 
Table 1.1 Neurological complications of HIV based on their neuroanatomical localisation 
(Adapted from Table 2 in: Price 1996) Abbreviations: central nervous system (CNS), Human Immunodeficiency virus (HIV), Acquired 
Immunodeficiency Syndrome (AIDS), primary central nervous system lymphoma (PCNSL), progressive multifocal 











Stroke is a less commonly described neurological manifestation of HIV. Cerebral infarction is 
reported as occurring in between 4 and 34% of AIDS cases in autopsy series (Benjamin et al. 
2012). In the earlier years of the HIV epidemic, the specific association between AIDS and stroke 
was questioned (Pinto 1996). However, this has changed over the years. I shall review the literature 
on this question later in this chapter. 
1.2 Review of stroke 
1.2.1 Stroke versus TIA 
The term stroke refers to a clinical syndrome of acute neurological deficit, usually focal, with an 
underlying vascular origin (Muir 2009). The World Health Organisation (WHO) defines stroke 
as,“rapidly developing clinical signs of focal (at times global) disturbance of cerebral function, 
with symptoms lasting more than 24 hours or leading to death with no apparent cause other than 
that of vascular origin” (Hatano 1976). A transient ischaemic attack (TIA) is differentiated from 
stroke by the association of symptom resolution within 24 hours of onset (Muir 2009). However, 
there are reports of magnetic resonance imaging (MRI) detected acute infarction in many patients 
with neurologic deficits that resolve within 24 hours (Kidwell et al. 1999). The definition of TIA is 
thus undergoing revision. 
1.2.2 Types of stroke, causes of stroke and stroke risk factors
A stroke may be either ischaemic or haemorrhagic in nature. Ischaemic stroke occurs as a result of
occlusion of a cerebral artery by a thrombus or embolus. Haemorrhagic stroke is the result of blood
vessel rupture, with subsequent leaking of blood into the brain (Bryer et al. 2010). Haemorrhagic
stroke events will not be included in my study. Eighty-five to ninety percent of strokes are due to
ischaemic causes, with 10-15% of strokes attributed to intracerebral haemorrhage (ICH) (Muir
2009). Interestingly, in South Africa, primary ICH accounts for a larger percentage of strokes,
between 20-30%, as evidenced in a hospital based series (Connor et al. 2006).
The causes of either type of stroke are extremely varied and the range of commoner causes also 
differs with regard to age. Large vessel atherosclerosis giving rise to its thrombotic or embolic 
complications, small vessel disease and cardio-embolic stroke are the most common causes of 
ischaemic stroke in older persons. Other less common causes of ischaemic stroke include 
dissection of the cervical arteries, vasculitis, angiopathies, metabolic disorders, rare types of 
emboli (fat or gas), haematological disorders and intracranial vascular malformations. Strokes that 











abnormalities of cerebral arteries, intracranial venous thrombosis, brain tumours and haemostatic 
disorders (Cordonnier et al. 2008). 
The causes of stroke in younger persons will be discussed later in the text (see section 1.2.5). It is, 
however, important to note that the less common causes of stroke become more relevant in 
younger persons and that stroke in the young includes a long list of unusual causes. The role of 
HIV in the causation of stroke is also discussed as a separate entity later in this text and will be 
elaborated further on in the introduction (see section 1.3). 
For ischaemic stroke, age (≥ 45 years), sex (men > female), race and ethnicity (black > white),
genetic factors (single gene disorders that cause stroke and genetic disorders that include stroke as
a manifestation) and other less well documented risk factors such as geographic location and socio-
economic status are considered non-modifiable risk factors. The list of modifiable risk factors for
ischaemic stroke is extensive. It includes: hypertension, diabetes mellitus, smoking, coronary heart
disease, atrial fibrillation, left ventricular hypertrophy, abnormal waist to hip ratio (a reflection of
abdominal obesity), high cholesterol, insulin resistance/metabolic syndrome and physical
inactivity/sedentary behaviours. Other less common identified risk factors include: excessive
alcohol consumption, elevated VWF levels, elevated white blood cell counts, variation in C-
reactive protein (CRP) levels, elevated homocysteine levels, reactive oxygen species/oxidative
stress, increased fibrinogen levels and elevated factor VIII (Elkind 2011; Allen et al. 2008). VWF,
factor VIII and fibrinogen are all proteins that are essential for normal haemostasis and their roles 
will be illustrated in chapter 2. Hypertension, bleeding disorders, use of anticoagulant and
antiplatelet drugs, pre-existing cerebral aneurysms and arteriovenous malformations are some of
the risk factors for brain haemorrhage (Clark 2009).
The INTERSTROKE study, a large standardised case-control study of risk factors for stroke that 
included high, middle and low income countries (n = 3000), showed that hypertension, current 
smoking, abdominal obesity, diet and physical activity accounted for more than 80% of the global 
risk of all stroke (ischaemic and ICH) (O’Donnell et al. 2010). These findings are relevant to South 
Africa as it was one of the 22 countries that participated in the study. 
1.2.3 Stroke classification systems and management of stroke 
Many stroke classification systems have been devised over the years. The Oxfordshire Community 
Stroke Project (OCSP) classification is widely used and functions as an aid for the clinical 












patient’s presenting clinical features to classify acute ischaemic stroke into one of four distinct 
categories, viz. total anterior circulation infarct (TACI), partial anterior circulation infarct (PACI), 
lacunar infarct (LACI), and posterior circulation infarct (POCI). This classification system is 
obtained by dividing the blood supply into the anterior circulation (supplied by the internal carotid, 
middle and anterior cerebral arteries) and the posterior circulation (supplied by the vertebral and 
basilar arteries). In addition, these categories assist with predicting the extent of the stroke, the 
underlying cause of the stroke and the prognosis of the patient (Bamford et al. 1991). 
 
The Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification classifies stroke into 
one of five categories according to its aetiology and underlying pathophysiological mechanism, 
using clinical findings and results of investigations performed. These categories include: large 
artery atherosclerosis, cardio-embolism, small blood vessel occlusion, stroke of other determined 
aetiology or stroke of undetermined aetiology (Adams et al. 1993). 
 
The Atherosclerosis – Small vessel disease – Cardiac source – Other (A–S–C-O) classification is 
based on the stroke phenotypes. Stroke aetiology and the presence of all underlying disease are 
used in the evaluation. Patients are defined in terms of the four A-S-C-O phenotypes, with each 
phenotype assigned a grade (grade 1, 2, 3, 0 and 9) according to their contribution to the stroke 
causation (Amarenco et al. 2009). The advantage of the A-S-C-O classification for young strokes 
is that it highlights the uncertainty surrounding the role of factors such as the patent foramen ovale 
(PFO) in stroke causation. With this classification, many more young patients fall into the 
undetermined category (Cotter et al. 2012). 
 
The mainstay of modern stroke management is prompt admission to a hospital, preferably with a 
dedicated stroke unit, and early administration of recombinant tissue-type plasminogen activator 
for ischaemic stroke. For haemorrhagic stroke, the therapeutic options depend on the size of the 
bleed and may be either a choice of haemostatic agents or surgical evacuation of the haematoma 
(Marsh et al. 2010). 
 
1.2.4 Burden of stroke globally and locally in South Africa 
Stroke accounts for 5.5 million deaths worldwide and the loss of 44 million disability-adjusted life-
years (DALYs) annually (Mukherjee et al. 2011). In South Africa, heart disease, diabetes and 
stroke together constitute the second most important cause of death in adult South Africans, second 











estimated stroke prevalence is 200 to 300 per 100 000 population, based on community surveys 
conducted in countries that included South Africa, Togo and Tanzania
 
(Kengne et al. 2006). 
In their review of stroke in South Africa, Connor and Bryer concluded that stroke mortality was 
high in South Africa. The impact of the growing burden of stroke in rural areas could be gauged by 
the increased prevalence of people requiring help with activities of daily living and the latter 
exceeded that of high-income countries (Connor et al. 2006). Most importantly, on the 2nd 
October 2006, stroke was declared a catastrophic disease in South Africa, at the Joint World 
Congress on Stroke held in Cape Town, South Africa, highlighting its deleterious impact on the 
South African population (Culebras 2006). 
1.2.5 Stroke in the young 
The term “young stroke” is usually used to refer to strokes in people aged <45 years. The overall
incidence of stroke in young people ranges from 7-15 per 100 000 people/year for all types of
stroke (ischaemic and haemorrhagic) and the incidence is thought to be greater in developing
countries (Griffiths et al. 2011). A systematic review has shown that the incidence of stroke in
young adults is not as rare as previously thought and requires a new focus on specific preventive
programs in this group (Marini et al. 2010). In Sub-Saharan Africa most cases of stroke are
reported to occur in people 10 to 15 years younger than those in developed countries (Kengne et al. 
2006). In a review of young stroke, it was noted that even within the confines of “young stroke,”
the incidence does increase notably with age, especially with that of the age group above 34 years.
Some population-based studies have, however, indicated greater stroke incidence in patients aged
less than 30 years. In the same review article, the incidence rates of young stroke appeared greater
in men than women in the 35-44 year old age group (Griffiths et al. 2011).
The aetiology of stroke in the young is much more diverse than that occurring in the older 
population, with varied ischaemic causes that include large or small artery disease, cardio-
embolism, thrombophilias, infective and non-infective vasculitides, venous infarction, genetic and 
pregnancy-related causes (Naess et al. 2011; Martin et al. 1997). In young people, the 
identification of a PFO as a source of cardio-embolism is increasingly recognised, and therefore is 
an important abnormality to exclude during the investigation of young patients with stroke (Cerrato 
et al. 2004; Larrue et al. 2011). Diagnostic work-up should also include investigations for 
dissection of the carotid or vertebral arteries (Ferro et al. 2010). Nevertheless, despite extensive 
investigations, cryptogenic stroke – where no underlying cause can be established – accounts for 
up to 35%. Compared with the general stroke population, subarachnoid and intracranial 











young strokes. However, cerebral infarction remains the commonest mechanism (Griffiths et al. 
2011). The causes are listed in table 1.2. 
Non-atherosclerotic angiopathies 
 Cervicocephalic arterial dissection
 Fibromuscular dysplasia
 Moyamoya disease 
 Angiitis 
 Genetic and hereditary diseases (Fabry’s disease, CADASIL, MELAS, HERNS)
 Reversible cerebral vasoconstriction syndrome
 Susac’s syndrome 
 Sneddon’s syndrome
Cardio-embolism 
 Rheumatic valvular disease
 Patent foramen ovale 
 Atrial septal aneurysm
 Prosthetic valve
 Infective endocarditis 
 Arrhythmia (atrial fibrillation)
 Dilated cardiomyopathy (Chaga’s disease)
 Mitral valve prolapse 
 Atrial myxoma
 Marantic and Libman-Sacks endocarditis 
Large-artery atherosclerosis 
Small-vessel disease 
Haematologic conditions (pro-thrombotic states) 
 Antiphospholipid syndrome
 Hyperhomocysteinaemia
 Sickle cell disease
 Myeloproliferative disorders
 Factor V Leiden
 Prothrombin 20210A mutation
 Protein C, protein S deficiency 
 Antithrombin III deficiency
Migraine stroke 
Cryptogenic stroke 
Table 1.2 Aetiology of ischaemic stroke in young adults (Adapted from table 1 in: Yamamoto 2012) 
Abbreviations: cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL), mitochondrial 













Smoking, hypertension, hyperlipidaemia and diabetes mellitus are frequently associated with the 
risk of ischaemic stroke in young adults (Chatzikonstantinou et al. 2012; Dharmasaroja et al. 2011; 
Balci et al. 2011; Spengos et al. 2010). In developing countries, urbanisation appears to play a role 
in the rise of these conventional vascular risk factors (Brainin et al. 2007). Certain risk factors, 
such as genetic disorders, cardiac abnormalities, pro-thrombotic states, migraine, oral contraceptive 
use and illicit drug use have a greater influence on stroke occurrence in the younger than the older 
adult (Marini et al. 2010; Naess et al. 2010). 
 
Stroke morbidities are lower in the young, but these patients tend to live with their neurological 
deficits much longer, with the resultant loss of employment and diminished social interaction that 
accompanies this (Naess et al. 2011). Data on the risk factors and long-term prognosis in young 
stroke patients are needed. For this reason, the FUTURE study - a prospective cohort study 
investigating risk factors and assessing prognosis in a large cohort of young stroke patients - was 
set up in the hope of providing much more data than are currently available (Rutten-Jacobs et al. 
2011). 
 
Stroke prevalence in rural South Africa is higher than previously documented in other studies from 
Africa, with the prevalence of stroke survivors in the 35-44 year age category equal to 117/100 000 
aged ≥ 15 years (Connor et al. 2004). Stroke in young South Africans appear to be commoner in 
Black Africans infected with HIV (Hoffmann 2000a). In a review investigating socio-economic 
status and stroke, the impact of stroke was noted to be 3-fold higher in low-income countries 
compared with high and middle-income countries, when DALYs and mortality rates were 
compared (Addo et al. 2012). 
 
1.3 Stroke and HIV 
 
1.3.1 Background history and current opinions 
In 1990 a case-control study of autopsied patients who had died with AIDS concluded that stroke 
did not appear to be more common in patients with AIDS compared to those without AIDS at 
death. However, stroke needed to be considered in the differential diagnosis of neurological 
disease in these patients (Berger et al. 1990). Pinto (1996) reviewed the literature on the 
relationship between AIDS and stroke between mid-1976 and December 1994. Despite the 
extensive search period, no clear association between AIDS and stroke was identified (Pinto 1996). 












stroke and patients with HIV/AIDS (Dobbs et al. 2009; Burn 2006). I shall review this association 
in more detail. 
 
There are two well-described theories with regards to stroke. Benjamin et al. (2012) summarised 
these recently in their review on HIV infection and stroke. They firstly pointed out that the 
occurrence of stroke and HIV infection in a patient could often be attributed to the coincidence of 
two diseases. This was because both stroke and HIV infection incidence have increased in low-
middle income countries (Benjamin et al. 2012). The second opinion was that HIV infection is an 
independent risk factor for stroke, and additional vascular risk can be conferred due to the use of 
antiretroviral therapy (ART) (Dobbs et al. 2009; Sen et al. 2012; Benjamin et al. 2012). 
 
Modi et al. (2008) concluded the following after reviewing the literature for the evidence of an 
association between stroke and HIV: 
- Stroke occurs in association with HIV infection. However, this association appears to be 
mainly with advanced infection or AIDS. 
- Cerebral ischaemic stroke is commoner than haemorrhagic stroke. 
- Evidence of infarction at autopsy correlates poorly with clinical stroke. 
- In the absence of infection or tumour, a cerebral vasculopathy is likely. 
- The stroke is often attributable to an underlying treatable CNS infection with resultant 
vasculitis or due to embolism from a cardiac source. 
 
1.3.2 Stroke rates, demographic characteristics, risk factors and stroke types in HIV-related 
stroke 
Incidence and prevalence data on stroke in HIV-infected individuals are limited. More recent 
studies have estimated an annual incidence rate of 216 TIAs and strokes per 100 000 patient-years 
and 166 strokes per 100 000 patient-years in European studies (Evers et al. 2003; Corral et al. 
2009). Chow et al. (2012) recently reported an incidence rate of 5.27 per 1000 person-years in 
HIV-infected patients compared to 3.75 per 1000 person-years in non HIV-infected patients in a 
US based study. The demographic characteristics of patients with HIV-related stroke compared to 
those with HIV infection sans stroke are similar, but advanced immunosuppression is more 
common in the stroke group (Dobbs et al. 2009). 
 
A large observational cohort study conducted in the US, comparing ischaemic stroke incidence in 












age, a higher log-transformed viral load, and a history of CNS infections or malignancy, were 
significantly associated with increased risk of stroke. Significant factors that decreased the risk of 
stroke in the HIV-infected cohort in this study included: non-nucleoside reverse transcriptase 
inhibitor (NNRTI) use (as opposed to no NNRTI use), longer duration of any ART and an 
undetectable viral load, defined as HIV ribonucleic acid (RNA)   400 copies per millilitre (ml). 
The authors concluded that HIV was an independent predictor of ischaemic stroke, after they 
adjusted for known stroke risk factors (such as hypertension and smoking) and that an increase in 
stroke risk was most pronounced in HIV-infected women and younger age groups (18-49 years) 
(Chow et al. 2012). Brown et al. (2011) reported that risk factors traditionally associated with 
cardiovascular events were also associated with cardiovascular events in an HIV-infected 
population. Furthermore, smoking and hypertension were found to be highly prevalent among 
some HIV-infected cohorts and populations (Brown et al. 2011). Since cardiovascular risk and 
cerebrovascular risk cannot be viewed in isolation, this implies an association with stroke as well. 
Individuals with HIV are more likely to engage in high risk-taking behaviour and have a higher 
prevalence of smoking and illicit drug use (Burn 2006). Risk-taking behaviour is more common in 
the young and smoking and illicit drug use adds to the risk of stroke in these patients. 
 
Early on, when the ideas around HIV and stroke were still being formulated, there appeared to be a 
greater propensity for the occurrence of ischaemic stroke compared to that of haemorrhagic stroke 
(Pinto 1996). This is in keeping with what is generally seen in patients that are not infected with 
HIV. Multiple studies following Pinto’s initial review have reported a higher frequency of 
ischaemic stroke in their patient groups compared with haemorrhagic strokes (Mochan et al. 2003; 
Ortiz et al. 2007). 
 
1.3.3 Mechanisms involved in HIV-related stroke 
The mechanisms implicated in stroke causation in HIV-infected individuals are varied. 
Mechanisms include vasculopathy associated with opportunistic infections, opportunistic tumours, 
cardio-embolic sources and disorders of haemostasis. Mechanisms attributed to HIV itself such as 
HIV-associated cerebral vasculitis, HIV-associated vasculopathy, and the potentially toxic effect 
on the vascular endothelium that may occur with the use of long-term highly active antiretroviral 
therapy (HAART), have been described
 
(Benjamin et al. 2012; Ovbiagele et al. 2011; Corral et al. 
2009; Ross et al. 2009; Burn 2006; Connor et al. 2000). In many cases the causes remain 
unknown. These mechanisms will be discussed in more detail as many of them may play a 













a. Vasculopathy and HIV-related cerebral vasculitis 
The term HIV-associated vasculopathy, when applied in the context of the cerebral circulation, is 
an umbrella term for a number of arterial disease pathologies occurring in HIV-infected 
individuals, not attributable to any cause other than the HIV infection itself. The exact pathogenetic 
mechanisms remain unclear (Connor 2009). 
 
The evidence for HIV-associated small vessel vasculopathy is small: In a neuropathological study 
performed on patients with cerebral infarction in the Edinburgh HIV cohort, Connor and 
colleagues described the presence of a vasculopathy in ten patients, all characterised by the same 
histopathological features at autopsy (Connor et al. 2000). Similar histopathological changes were 
described in earlier research by Mizusawa and colleagues (Misuzawa et al. 1988). There is 
evidence for HIV-associated vasculopathy in large or medium extracranial and intracranial arteries 
in adults (Tipping et al. 2007). In a study conducted locally at the Groote Schuur Hospital (GSH), 
in Cape Town, South Africa, Tipping et al. (2007) reported an HIV-associated vasculopathy in 
20% of the HIV positive patients (n = 67) in their cohort who presented with stroke. 
 
Cerebral vasculopathies secondary to infection with viruses other than HIV have been associated 
with stroke. Varicella zoster virus (VZV) and cytomegalovirus (CMV) have been implicated 
(Nagel et al. 2010). Cerebral vasculitis solely due to HIV itself is a rare histological finding and its 
relationship with stroke causation is not clear (Nogueras et al. 2002; Hoffmann et al. 2000b). 
However, it remains to be seen how important this entity will become in stroke causation. 
 
b. Opportunistic infections and tumours 
Syphilis and HIV are both sexually transmitted illnesses and affect similar patient groups, thus 
leading to a greater propensity for co-infection (Karp et al. 2009; Lynn et al. 2004). Neurosyphilis 
manifesting as meningovascular syphilis is a known cause for stroke, with the vessel plaques in 
syphilitic arteritis usually longer and smoother than those seen in the vessels affected by 
atherosclerotic disease (Chahine et al. 2011). 
 
Tuberculosis (TB) is the most common opportunistic infection in HIV-infected individuals. 
Tuberculous meningitis (TBM), an extra-pulmonary manifestation of infection with TB, occurs 
with greater frequency in persons infected with HIV. However, the exact incidence and prevalence 
is not known (Garg et al. 2011). Lammie et al. (2009) report that stroke in TBM is common, with 
approximately 20% of patients developing a neurological deficit clinically, 13-57% with neuro-












by the presence of thick gelatinous exudates which display predominance for the basilar area of the 
brain, and cerebral infarcts may be a consequence of the entrapment of intracranial vessels within 
this exudate. However, the exudate is a thinner, minimal, serous type exudate, in HIV-infected 
individuals (Garg et al. 2011). 
 
Immunosuppression arising from HIV results in multiple AIDS-associated malignancies (Wood et 
al. 2005; Bonnet et al. 2008). Cancers cause stroke through a variety of mechanisms. In ischaemic 
stroke this may be due to the direct tumour effect with tumour embolism and compressive effect of 
the tumour on the blood vessels, coagulation disorders, infection and therapy-related. 
Intraparenchymal bleeding, venous occlusion/venous infarction, haemorrhage into a primary brain 
tumour or a metastasis, ruptured neoplastic aneurysms and subdural haematomas are all 
mechanisms which may give rise to intracranial haemorrhage resulting in stroke (Grisold et al. 
2009). 
 
c. Cardio-embolic sources 
In patients infected with HIV, cardio-embolism as a cause for ischaemic stroke varies from 9-18%. 
Potential causes for cardio-embolism include valvular heart disease, endocarditis, cardiomyopathy 
(HIV-related dilated or other cardiomyopathies), myocardial infarction and interstitial myocardial 
fibrosis (Ortiz et al. 2007; Tipping et al. 2007; Mochan et al. 2003; Hoffmann 2000a; Berger et al. 
1990). 
 
d. Disorders of haemostasis and HIV as a pro-thrombotic state 
Antiphospholipid syndrome (APS), associated with the presence of antiphospholipid (APL) 
antibodies in the patient’s blood, is a known cause for acquired thrombophilia and presents with 
thrombotic events (venous or arterial thromboembolism) and/or obstetric complications. These 
APL antibodies are acquired auto-antibodies directed against phospholipid-protein complexes in 
cell membranes (Sangle et al. 2011). Most reviews of HIV and APS identify the anticardiolipin 
antibodies (a type of APL antibody) as the more frequently detected antibody, yet APS and its 
manifestations are uncommon in HIV and the presence of APS in HIV does not necessarily 
correlate with the thrombosis risk or haematological manifestations of APS (Asherson et al. 2003; 
Sène et al. 2008; Hassoun et al. 2004). Ischaemic stroke is, however, one of the most common 
complications of APS. The association of stroke with people with APS is strongest in young adults 













HIV infection is associated with a pro-thrombotic state. There is increasing evidence that 
thrombotic events occur in persons infected with HIV with greater frequency than in healthy non 
HIV-infected persons (Klein et al. 2005). These often manifest clinically with thrombosis as the 
first presentation of the disease (Basavanagowdappa et al. 2011; Witz et al. 2000; Louw et al. 
2008; Modi et al. 2012). The association between HIV and a pro-thrombotic state may be 
attributed to a number of factors in persons infected with HIV, which include endothelial 
dysfunction/endothelial-related changes, as well as aberrant function of the coagulation system 
(Shen et al. 2004). 
 
Thrombosis occurs in both the venous and arterial vasculature. The literature suggests that chronic 
HIV infection is associated with a two to tenfold increased risk of venous thrombosis (Klein et al. 
2005). Reports on arterial thrombosis in HIV-infected patients frequently highlight that of coronary 
artery thrombosis/coronary artery disease, owing to the increased predisposition of these events in 
light of their association with combination ART (especially protease inhibitor) use in the treatment 
of HIV (Rickerts et al. 2000; Friis-Møller et al. 2003; D Ascenzo et al. 2012). Cerebrovascular 
arterial thrombosis presenting as stroke is especially important due to its increasing incidence in 
low-to-middle income countries and the morbidity and mortality with which it is associated (Feigin 
et al. 2011). The many causes for this pro-thrombotic state in HIV, including coagulation 
abnormalities and how they link with stroke causation, will be discussed in chapter 2 (see sections 
2.2, 2.3 and 2.4). 
 
e. Atherosclerosis in HIV 
Atherosclerosis is a major known risk factor for cardiovascular disease and stroke. Atherosclerosis 
occurs as a result of the interplay between the biologically active endothelium, inflammation 
involving both innate and adaptive immune responses, and the adipocyte-mediated inflammatory 
drive seen in obesity. The development of atherosclerosis in persons infected with HIV is a 
relatively new focus of research and multiple pathways for its causation have been proposed. HIV 
is a state of chronic immune activation and the predisposition to other concomitant infections in 
persons infected with HIV multiplies the inflammatory contribution. Atherosclerosis is an 
inherently inflammatory mediated process, so HIV – a state of chronic inflammation - may 
predispose to the development of atherosclerosis (Lo et al. 2012). Endothelial dysfunction has been 
related to the pathogenesis of atherosclerosis (Halcox et al. 2009; Vita 2011). Endothelial 
dysfunction in HIV (see later, g. Endothelial dysfunction: its relationship to stroke and HIV) and 
some HIV viral proteins (HIV-1 Tat and HIV Nef protein) have been linked to atherosclerosis as 
well (Lo et al. 2012). HAART plays an important role in the mechanism of atherogenesis in HIV 












f. HAART and stroke 
Much has been written about the association between HAART and the occurrence of vascular 
events, especially myocardial infarction. There is a confirmed link between HAART use and 
increased cardiovascular risk (Friis-Møller et al. 2003; Zou et al. 2007), although the link between 
HAART and stroke is not yet as clearly proven. The Data Collection on Adverse Events of Anti-
HIV Drugs (DAD) study - a prospective, observational cohort study of 23 468 HIV positive 
patients - has shown that patients on HAART have an increased risk of cardio- and cerebrovascular 
disease events. Furthermore, the incidence of these events increased with longer exposure to 
HAART. These factors were still evident even after controlling for traditional vascular risk factors 
(d’Arminio et al. 2004). However, a retrospective review that included the d’Arminio et al. (2004) 
DAD study group report concluded that higher rates of stroke were evident in persons infected 
with HIV in the HAART era, but that no specific association between HAART and stroke could be 
established (Sen et al. 2012). 
 
g. Endothelial dysfunction: its relationship to stroke and HIV 
The normal healthy endothelium is involved in vasodilatation and vasoconstriction through its 
ability to regulate muscle tone and secrete vasoactive substances such as prostacyclin, 
thromboxane A2, nitric oxide and endothelins. It also plays key roles in haemostasis and 
inflammation (Barrett et al. 2010; Subbarao et al. 2011). 
 
Endothelial dysfunction has been observed in stroke (Roquer et al. 2009). It is linked to the 
pathogenesis of stroke, most notably lacunar stroke and is regarded as an important mechanism of 
cerebrovascular damage (Knotnerrus et al. 2009; Sierra et al. 2011). Blum et al. (2012) showed a 
rise in markers of endothelial activation in the systemic circulation and the presence of fewer 
endothelial progenitor cells (both indicators of severe endothelial dysfunction) in patients with 
acute ischaemic stroke in their small study. They questioned whether these results reflected an 
underlying primary disturbance of endothelial dysfunction in the pathogenesis of acute ischaemic 
stroke, or an acute phase response to cerebral injury. Furthermore, they concluded that severe 
endothelial dysfunction may be linked to the vascular instability that still exists in the early days 
following acute stroke, and places patients at risk for more vascular events during that time period 
(Blum et al. 2012). 
 
Endothelial dysfunction is recognised as a vascular disease process occurring in HIV infection 
(Subbarao et al. 2011). Monsuez et al. (2009) summarised the most prevalent theories surrounding 












1. Direct endothelial cell injury induced by the HIV infection itself and its viral proteins. 
2. HIV-driven chronic inflammatory processes, aided by an increase in pro-inflammatory 
cytokine production. 
3. HIV-induced dyslipidaemia and metabolic syndrome. 
4. HAART-related mechanisms – HAART-induced dyslipidaemia and metabolic syndrome 
(indirect mechanism), and HAART causing direct endothelial injury (direct mechanism). 
 
The common presence of endothelial dysfunction in both stroke and HIV leads to the idea that a 
link exists between HIV-infected patients presenting with acute ischaemic stroke and endothelial 
dysfunction. The question requiring further investigation is how stroke, HIV infection and 
endothelial dysfunction relate to one another, as well as the sequence in which the pathogenic 
events occur. 
 
h. The ageing HIV population 
The population of people living with HIV is getting older (Vance et al. 2011; Pratt et al. 2010). 
Age is itself a risk factor for stroke and HAART has converted HIV into a chronic condition for 
many people. Living longer thus increases the risk of age as a traditional risk factor for stroke 
irrespective of HAART use. Apart from HAART use, older people are at greater risk of contracting 
HIV due to biological changes (thinner muc sal membranes allowing for easier virus entry) and 
the use of sexual performance enhancers (increased sexual activity in patients who form 
new/multiple sexual relationships following divorce or death of a spouse) (Vance et al. 2011). 
With ageing also comes the increase in traditional older age-associated vascular risk factors for 
stroke. 
 
i. Cryptogenic stroke 
Often, despite extensive investigation, no obvious cause for the stroke can be identified, and the 
aetiology is thus unknown and labelled as cryptogenic. Cryptogenic stroke is recognised in HIV-
related stroke (Hoffmann et al. 2000b; Burn 2006). However, the question always remains as to 
how extensive the investigations have been to identify a cause, before labelling the stroke 
“cryptogenic/idiopathic.’’ 
 
1.3.4 HIV-related young stroke 
HIV-infected individuals present with stroke at a younger age (Tipping et al. 2007; Ortiz et al. 












fact that new HIV infections occur predominantly in the 15-24 year old age group (Napierala 
Mavedzenge et al. 2011). 
 
Many studies conducted in African countries shed light on HIV-related young stroke. HIV was 
found to be an important risk factor for stroke in young Nigerians (Onwuchekwa et al. 2009). A 
recent Malawian study on stroke outcomes found that younger patients with strokes were often 
HIV-seropositive and that traditional vascular risk factors were uncommon in the same group. 
They concluded that HIV infection could be a risk factor for stroke for young people without other 
common stroke risk factors (Heikinheimo et al. 2012). Younger age has also been identified as an 
independent risk factor for ischaemic stroke in Central African patients with HIV/AIDS (Longo-
Mbenza et al. 2011). A Nigerian-based study by Owalobi et al. (2012) showed the increased 
frequency of HIV as a risk factor for stroke among young adults. A study conducted in black 
African patients in the KZN province of South Africa (the province with the highest estimated 
incidence of HIV seropositivity in Sub-Saharan Africa); found that the chances of having a stroke 
were greater in HIV positive as opposed to HIV negative individuals (Patel et al. 2005). Outside 
Africa, in a US-based study, Chow et al. (2012) documented that the increased risk of ischaemic 




HIV is omnipresent. It affects the human body in a number of ways, with the burden of disease 
attributed to HIV resulting in a global epidemic. The nervous system bears the brunt of infection 
with HIV in a variety of ways. Although controversial, the association between HIV infection and 
stroke cannot be dismissed. There are numerous mechanisms by which HIV may promote the 
occurrence of stroke in individuals infected with HIV. Younger adults appear to be particularly 
vulnerable. For all these reasons, the problem of HIV-related young stroke deserves further 
investigation. The double burden of HIV and stroke contributes significantly to morbidity and 













CHAPTER 2 - REVIEW OF HAEMOSTASIS, VWF, ADAMTS13 AND THEIR 




Stroke occurring in the setting of HIV infection in young people has major public health 
implications. It is linked to a high morbidity with a long duration of symptoms, a large burden of 
care for health personnel and the family members of patients affected by the stroke, and has a 
crippling effect on health resources. I was especially interested in the concept of HIV as a pro-
thrombotic state and the role of haemostatic and coagulation abnormalities in the pathogenesis of 
HIV-associated stroke. A literature review led me to the identification of VWF and ADAMTS13, 
two very important factors involved in haemostasis, and how they may be related to stroke and 
HIV. 
 
To understand these two dynamic proteins fully, I shall provide a summary of haemostasis to 
contextualise their role in maintaining vascular homeostasis of the body. In addition, I shall discuss 
some of the coagulation abnormalities reported in HIV and stroke respectively, including the link 
between certain coagulation abnormalities seen in both HIV and stroke. I shall summarise the key 
factors regarding VWF and ADAMTS13, their synthesis, biological factors, regulation of activity 
and roles in disease. I shall also review the literature regarding the relationships between these 




Haemostasis is the physiological process whereby haemorrhage at the site of vascular injury is 
arrested while still maintaining normal blood flow elsewhere in the circulation (Gale 2011). It is a 
dynamic process that is dependent on the interaction between the blood vessel wall, circulating 
platelets and blood coagulation factors (Mehta et al. 2009; Hoffbrand et al. 2011). Haemostasis 
involves two processes viz. primary haemostasis and secondary haemostasis that are 
interdependent, occur simultaneously and collaborate to bring about successful haemostasis. The 
fibrinolysis pathway is also vital for normal haemostasis. Pathological bleeding or pathological 
thrombus formation can occur if any aspect of haemostasis is disrupted (Gale 2011). An intact 
vessel wall has multiple mechanisms by which it prevents haemostasis under normal 












platelet aggregation; (2) thrombomodulin, which results in activated protein C inhibiting 
coagulation, and (3) tissue plasminogen activator, which promotes fibrinolysis (Mehta et al. 2009). 
 
2.1.1 Primary haemostasis 
This refers to the initial platelet aggregation and platelet plug formation that occurs at the site of 
vascular injury following platelet activation (Gale 2011). Platelets thus play a key role in primary 
haemostasis. Platelet membranes have multiple receptors for collagen, adenosine diphosphate, 
vessel wall VWF and fibrinogen, and their cytoplasm contains actin, myosin, glycogen, and many 
secretory organelles, the most important being the alpha (α) granules, dense granules and 
lysosomes (Barrett et al. 2010; Nurden 2011). α granules contain adhesive proteins e.g. VWF, 
clotting factors and their inhibitors, fibrinolytic factors and their inhibitors, proteases e.g. 
ADAMTS13 and anti-proteases, growth and mitogenic factors, chemokines and cytokines, 
antimicrobial proteins and membrane glycoproteins (Nurden 2011). 
 
In normal blood vessel conditions, platelets do not adhere to surfaces or aggregate with each other, 
but when vascular injury does occur, the endothelium is disrupted and platelets are exposed to the 
sub-endothelial matrix, with resultant adhesion and activation of platelets (Gale 2011). This 
process is dependent on the multiple receptors, especially certain glycoprotein (GP) receptors, 
found on the surface of platelets, and their corresponding ligands (see table 2.1 and figure 2.1). 
 
Platelet receptor Corresponding ligand 
GPIb/GPV/GPIX (forming the GPIb-IX-V complex) VWF 
GPVI Collagen 
αIIbβ3 (GP IIb/IIIa complex) Fibrinogen, VWF, fibronectin, vitronectin 
α2β1 (GP Ia/IIa complex) Collagen 
αvβ3 Vitronectin, thrombospondin, VWF, fibronectin, fibrinogen 
PAR1, PAR4 Thrombin 
Table 2.1 Platelet receptors and their corresponding ligands (Adapted from: Baker et al. 2011) 













Figure 2.1 Structure of a platelet with the surface receptors involved in haemostasis (From: Anitua et 
al. 2004)  
Intracellular organelles whose contents are secreted upon platelet activation and active metabolites synthesised during platelet activation 
are also indicated. Abbreviations: thromboxane A2 (TXA2), adenosine diphosphate (ADP), adenosine triphosphate (ATP), protease-
activated receptor (PAR), platelet-activating factor (PAF), calcium (Ca2+). P2Y1 and P2Y12 are purinergic G protein-coupled receptors 
that are stimulated by ADP. 
 
Platelet plug formation is a complex sequential process and has been reviewed by Clemetson et al. 
(2012) and Baker et al. (2011). Here is a short summary (refer to figure 2.2): 
 
The flowing platelets are slowed down first through the platelet receptor GPIb-IX-V complex and 
VWF. The VWF binds to the exposed collagen of the sub-endothelial matrix. The shear stress 
forces of the flowing blood stretch VWF, thus exposing binding sites on the VWF for the platelet 
GPIb receptor. Thus platelets are tethered down and adhere to the damaged endothelium. 
 
Next, the adherent platelet becomes activated on the vessel wall, releasing the contents of its 
granules. These secretory products, in turn, further activate the platelets through binding to the 
platelet receptors and further facilitate platelet binding to the sub-endothelial matrix. 
 
Platelet-platelet interactions, mainly via αIIbβ3 receptors on these particles, allow for platelet 












as does fibrinogen. Activated platelets become amoeboid in shape and tight junctions form where 
two platelets come into contact. 
 
 
Figure 2.2 Platelets in thrombus formation (From: Bhatt et al. 2003) 
a. Endothelial cells release nitric oxide (NO), prostacyclin and express cluster of differentiation 39 (CD39) on their cell surface. These 
inhibit platelet activation. CD39 converts adenosine diphosphate (ADP), a potent inducer of platelet activation, into adenosine 
monophosphate (AMP). b and c. Platelets adhere to the exposed sub-endothelium at sites of vascular injury. This takes place through 
interactions between collagen, von Willebrand factor (VWF) and fibronectin and their receptors on the platelets, integrin 21, 
glycoprotein (GP) Ib-IX and integrin 51, respectively. Thrombin and ADP cause platelets to change into an active conformation. d. 
Activated platelets secrete ADP, platelet-derived growth factor (PDGF), and fibrinogen from platelet storage granules, and thromboxane 
A2 (TXA2), produced by immediate biosynthesis. ADP and TXA2 cause circulating platelets to change shape and become activated. e. 
Fibrinogen binds to the glycoprotein IIb/IIIa receptors on the surface of activated platelets and fibrinogen bridges between the platelets 
are formed, resulting in platelet aggregation. A fibrin mesh (not shown) is formed and leads to the formation of a platelet thrombus. f. 












2.1.2 Secondary haemostasis 
Once the coagulation cascade has begun, the process of secondary haemostasis is under way. The 
end result is a meshwork of insoluble fibrin that is incorporated into and around the platelet plug 
(Gale 2011). Blood coagulation is usually initiated when the vascular endothelium is damaged or 
activated, resulting in the exposure of sub-endothelial tissue factor to the flowing blood. The two 
pathways of the coagulation cascade are the intrinsic and extrinsic pathways. A series of enzymatic 
reactions, mediated by a host of coagulation factors, results in the generation of thrombin, and the 
conversion of fibrinogen to fibrin (Ruttman 2006). Fibrinolysis – the process of clot dissolution – 
occurs at about the same time. There is a dynamic balance between haemostasis and clot formation 




Figure 2.3 Coagulation cascade (From: Tapper et al. 2000) 
Coagulation factors = blue and “a” indicates activation. Cofactors = red. Coagulation inhibitors = green. Proteins involved in fibrinolysis 
= brown. Arrows indicate proteolytic conversion. Solid and dotted lines indicate strong and weak interactions respectively. 
Abbreviations: factor (F), high molecular weight kininogen (HK), plasminogen activator inhibitor-1(PAI-1), plasma kallikrein (PK), 
thrombin activatable fibrinolysis inhibitor (TAFI), tissue factor pathway inhibitor (TFPI), tissue plasminogen activator (tPA), urokinase-












2.2 Coagulation abnormalities in HIV 
 
I have already discussed HIV as a pro-thrombotic state (see section 1.3.3). Defects have been 
described at multiple levels of the coagulation pathway, including protein C and protein S, 
antiphospholipid antibodies, antithrombin deficiency and von Willebrand factor. These defects 
have been noted to correlate with the degree of immunosuppression measured by cluster of 
differentiation 4 (CD4) cell counts (Saif et al. 2001). However, several of these defects have been 
reported to be epiphenomena rather than causal (Becker et al. 2011; Mochan et al. 2005). 
 
Heparin cofactor II is a specific thrombin inhibitor and deficiency thereof as well as disorders of 
plasmin (increased levels of plasminogen activator inhibitor) have been mentioned in the literature 
in individuals infected with HIV, predisposing them to thrombosis. Even HIV-related nephropathy 
gives rise to coagulation disturbances in persons infected with HIV (Saif et al. 2001). Further 
complicating the issue, many medical conditions that complicate advanced HIV also predispose to 
thrombosis e.g. malignancy, sepsis, meningitis etc. The aetiological mix is likely to vary depending 
on the site of thrombosis e.g. deep vein thrombosis (DVT) versus arterial ischaemia. 
 
2.3 Coagulation abnormalities and stroke 
 
In the absence of hypertension, diabetes, hyperlipidaemia, valvular heart disease or smoking as risk 
factors in a patient presenting with stroke, a hypercoagulable state should be suspected as a cause 
(Moster 2003). The factor V Leiden mutation is the most common inherited coagulopathy 
associated with stroke. Prothrombin has been associated with venous thrombosis (G20210A 
mutation), but its association with arterial stroke is controversial. Protein C and protein S have 
been implicated (Soare et al. 2010). Hyperhomocysteinaemia and antiphospholipid antibodies have 
been moderately associated with stroke (Moster 2003). 
 
2.4 Coagulation abnormalities in HIV and their link with stroke 
 
Untangling the cause of stroke in an HIV-infected person can be challenging. However, in the 
absence of other potential causes, coagulation defects should be considered. Antiphospholipid 
syndrome, HIV-associated malignancies and infections have been discussed earlier (see section 













Protein C and protein S are part of the body’s natural anticoagulant system (Bereczky et al. 2010). 
Deficiencies in these proteins are known to lead to an increased risk of venous thromboembolism, 
with a lesser association with arterial disease (Bereczky et al. 2010; Soare et al. 2010). Protein C 
and protein S deficiency have both been associated with arterial ischaemic stroke, with protein S 
deficiency linked to a greater propensity for stroke (Soare et al. 2010). Protein S deficiency has 
long been recognised in patients with HIV (Stahl et al. 1993; Mochan et al. 2005). Various studies 
found a 27-76% and 0-14% protein S and protein C deficiency respectively, in patients infected 
with HIV (Erbe et al. 2003). Qureshi et al. (1997) initially postulated that the increased risk of 
ischaemic stroke seen in young persons with HIV infection was due to the increased susceptibility 
of HIV-infected patients to meningitis and protein S deficiency. However, Mochan et al. (2005) 
found no relationship between protein S deficiency in HIV-infected patients and the occurrence of 
stroke. They attributed the presence of protein S deficiency in HIV positive patients with stroke to 
be an epiphenomenon of the HIV infection rather than a cause for ischaemic stroke (Mochan et al. 
2005). 
 
Antithrombin is a glycoprotein whose primary role in the coagulation cascade is the inhibition of 
activated factor IIa (thrombin) and Xa, and to a lesser extent factors IXa, XIa and XIIa (Maclean et 
al. 2007). The association between antithrombin deficiency and stroke is rare, with the evidence 
linking the two, weak (Soare et al. 2010). Saif et al. (2001) have identified reports of antithrombin 
deficiency in HIV-infected individuals who experienced thrombotic events, but a link with HIV-
infected individuals with stroke and the presence of antithrombin deficiency is lacking. 
 
2.5 von Willebrand factor (VWF) 
 
2.5.1 Overview of VWF 
VWF is a key protein in the coagulation cascade. In 1926, a Finnish physician, Erik von 
Willebrand, first described a new type of inherited bleeding disorder that was distinct from 
haemophilia (Von Willebrand 1926). This disorder was eventually named von Willebrand disease 
(VWD). The plasma protein implicated in the disease process was only identified 30 years later 
and was subsequently named von Willebrand factor (De Meyer et al. 2012a). 
 
VWF, a multimeric glycoprotein, is present in the plasma and is produced by the endothelium, 
providing a link with endothelial dysfunction that has been described in HIV (Subbarao et al. 
2011). It mediates the binding of platelets at sites of vascular injury and is important for platelet 












VWD is the most common inherited bleeding disorder characterised mainly by mucosal bleeding, 
but in more severe forms there may be joint, muscle and central nervous system involvement 
(Schneppenheim et al. 2011). Recently, much interest has been focused on VWF as a target for 
stroke therapy. With the more recent clarification of the structural composition of its cleaving 
enzyme, ADAMTS13 (see later, section 2.6), the relationship between VWF and ADAMTS13 has 
become a prominent topic in the current literature. 
 
2.5.2 Synthesis and structure of VWF 
VWF is a large multimeric glycoprotein with a long polypeptide chain and a molecular mass of 
approximately 270 kilodalton (kDa). The gene is located at the tip of the short arm of chromosome 
12 (locus 12p13.3) and biosynthesis occurs in endothelial cells and megakaryocytes (Hassan et al. 
2012; Mendolicchio et al. 2005; Peyvandi et al. 2011; McGrath et al. 2010). Details of its synthesis 
and secretion are reviewed in McGrath et al. (2010), Hassan et al. (2012), Peyvandi et al. (2011), 
Schneppenheim et al. (2011), Luo et al. (2012), Mendolicchio et al. (2005) and Sadler (2009). A 
pre-pro-polypetide is sequentially cleaved to yield pro-VWF monomers that dimerise in the 
endoplasmic reticulum. Post translational glycosylation occurs in the Golgi complex and ultimately 
VWF multimers are formed (McGrath et al. 2010; Hassan et al. 2012; Peyvandi et al. 2011; 
Schneppenheim et al. 2011; Luo et al. 2012; Mendolicchio et al. 2005; Sadler 2009). 
 
The VWF monomer precursor is composed of four types of domains i.e. A, B, C and D, which are 
constructed as identical repeats in the following order: D1, D2, D´, D3, A1, A2, A3, D4, B1, B2, 
B3, C1, C2 and CK (Luo et al. 2012; Franchini et al. 2006) (see figure 2.4). 
 
2.5.3 Storage and secretion of VWF 
VWF multimers are stored in its ultra large VWF (ULVWF) form in Weibel-Palade bodies in 
endothelial cells and in α-granules in platelets (Ruggeri 2007; Hassan et al. 2012; Mendolicchio et 
al. 2005; McGrath et al. 2010; Crawley et al. 2011). 
 
Both constitutive and regulated pathways for VWF secretion from endothelial cells exist. The 
regulated pathway is influenced by the presence of secretagogues. Secretagogues include 
histamine, thrombin, collagen, ADP, β-adrenergic agonists, calcium ionophore A23187, phorbol 
myristate acetate, desmopressin (used in the treatment of VWD), and other important mediators of 
thrombosis and inflammation (Johnsen et al 2008; Ruggeri 2007; Hassan et al. 2012; McGrath et 












via apical/luminal secretion or into the sub-endothelial mtrix via basolateral secretion (Reininger 
2008). 
 
VWF secretion from megakaryocyte-derived platelets only occurs via the regulated pathway 
(Ruggeri 2007). The circulating VWF in plasma is predominantly of endothelial cell origin as 
platelets secrete VWF only in response to activation via a stimulus of the regulated pathway 
(Bowie et al. 1986). 
 
VWF is secreted as large multimers (Sadler 2009). Both the mature VWF multimers and the VWF 
propeptide are secreted together in 1:1 stoichiometric amounts, with the propeptide dissociating 
following secretion. VWF multimers, however, have a half-life of approximately 12 hours 
(Peyvandi et al. 2011). Cleavage takes place at the A2 domain of the protein by ADAMTS13 
(Hassan et al. 2012). The large ULVWF multimers are the most haemostatically active. Therefore 
cleavage by ADAMTS13 gives rise to smaller multimers that are best suited to carry out the 
functions of VWF (Crawley et al. 2011). 
 
2.5.4 Function of VWF 
VWF has a multitude of biological functions. The multidomain structure of VWF provides the 
binding sites for various interactions. This is shown in figure 2.4. 
 
 
Figure 2.4 Schematic depiction of VWF and its domains indicating the binding sites of major 
binding partners, and the cleavage site for ADAMTS13 (From: De Meyer et al. 2012a) Abbreviations: factor (F), 












a. Binding to platelet GPIb and platelet integrin αIIbβ3 (see section 2.1.1) 
Under normal physiological conditions, soluble VWF and platelets co-exist in the circulation, 
without any undue interaction. However, when a vessel is injured, VWF binds to the exposed 
collagen of the sub-endothelial matrix, mainly through its A3 domain (Szántó et al. 2012; Hassan 
et al. 2012). VWF has two conformations: a globular form and an elongated form. With high shear 
stress e.g. at sites of vessel injury or stenosis and atherosclerosis, the circulating globular form 
unfolds into an elongated form, exposing its A1 domain for platelet binding (Denis et al. 2012) 
(see figure 2.5). 
 
 
Figure 2.5 Events associated with shear stress-induced conformational changes in VWF (From: 
Denis et al. 2012) Abbreviations: von Willebrand factor (VWF), A Disintegrin and Metalloproteinase with a Thrombospondin type 1 
motif, member 13 (ADAMTS13), cysteine (Cys). 
 
Initial binding to collagen at sites of vascular injury slows the VWF down, and also allows for this 
conformational change to take place (Szántó et al. 2012). With the binding sites now exposed, 
VWF binds to the platelets via the platelet GPIb receptor, more specifically, the GPIb-IX-V 
complex, with strong affinity resulting in initial platelet tethering, platelet-vessel wall adhesion and 
initiates the process of platelet activation. The next step, stable platelet adhesion, is facilitated by 
the binding of VWF to the αIIbβ3 integrin receptor on platelets that have been activated by thrombin 
(Hassan et al. 2012; Luo et al. 2012; Peyvandi et al. 2011). This has been described previously 














Figure 2.6 Schematic representation of VWF-mediated platelet adhesion and aggregation (From: 
De Meyer et al. 2012a) Abbreviations: glycoprotein (GP), von Willebrand factor (VWF), A Disintegrin and Metalloproteinase with a 
Thrombospondin type 1 motif, member 13 (ADAMTS13), Weibel-Palade (WP). 
 
b. Stabilisation of blood coagulation factor VIII and binding to collagens, sulfatides and 
heparin 
VWF binds to factor VIII thus stabilising the latter and protecting it from degradation by protein C 
(Peyvandi et al. 2011; Luo et al. 2012). By binding to sulfatides, it mediates red blood cell 
agglutination and also binds to heparin and collagen (Hassan et al. 2012). 
 
c. Other biological functions 
Multiple other non-haemostatic functions of VWF have been identified. These functions include 
the regulation of angiogenesis and mitogenic effects on smooth muscle cell proliferation (Luo et al. 
2012). 
 
2.5.5 Regulation of VWF plasma levels 
VWF expresses ABO antigens (the antigens found on the surface of red blood cells). ABO blood 
grouping is an important genetic determinant of plasma VWF levels: plasma VWF levels have 
been shown to be lowest in blood group O patients and highest in blood group AB patients 
(Vischer 2006; Gill et al. 1987). Polymorphisms, such as the C/G polymorphism at the -1793 












have been associated with elevated VWF levels and a higher associated risk of coronary heart 
disease. Non-genetic factors that can elevate plasma VWF levels over long periods include 
advancing age, impaired endothelial nitric oxide production, inflammation, diabetes, insulin 
resistance (metabolic syndrome) and increased reactive oxygen species production (associated with 
obesity). Increased arterial rigidity associated with ageing may increase endothelial VWF secretion 
(Vischer 2006). 
 
Rapid, short term increases in VWF secretion can occur through various secretion agonists such as 
histamine, collagen, epinephrine, as well as processes such as inflammation, endothelial damage, 
exercise and pregnancy (Hassan et al. 2012; McGrath et al. 2010; Sadler 1998; Petri et al. 2010; 
Boneu et al. 1975; Gonzales et al. 2009; Huq et al. 2012). Nitric oxide, reactive oxygen species 
and drugs such as statins may inhibit VWF release from endothelial cells and decrease plasma 
VWF levels (Vischer 2006; van Schie et al. 2010).  
 
2.5.6 VWF and its disease associations 
a. Von Willebrand disease and acquired von Willebr nd syndrome 
VWD is a bleeding disorder caused by inherited defects in the concentration, structure or function 
of VWF i.e. quantitative or qualitative defects in VWF. Patients with VWD are classified into 3 
main categories: type 1, 2 and 3. Type 1 is associated with a partial quantitative deficiency, with 
type 3 indicating a virtually complete deficiency of VWF (Sadler et al. 2006; Schneppenheim 
2011). 
 
The acquired von Willebrand syndrome is a rare bleeding disorder that can be caused by 
lymphoproliferative and myeloproliferative disorders, immune-mediated diseases, cardiovascular 
disorders, malignancies, hypothyroidism and altered shear stress. These give rise to structural or 
functional defects of VWF (Tiede et al. 2011; Luo et al. 2012). 
 
b. VWF and its association with liver disease and tumours 
VWF may play a role in the pathophysiology of certain liver diseases. Higher VWF levels have 
been correlated with poorer outcome in hepatic cirrhosis. VWF may also influence the 
pathophysiology of other liver diseases such as alcoholic hepatitis. Abnormal VWF levels and 












c. VWF and its association with cardiovascular disease: coronary artery disease (CAD) and 
peripheral arterial disease (PAD) 
A number of studies have investigated the predictive value of VWF for coronary artery disease in 
healthy subjects (Folsom et al. 1997; Rumley et al. 1999; Meade et al. 1994; Thögerson et al. 
1998; Whincup et al. 2002; Morange et al. 2004; Danesh et al. 2004). In general, VWF is thought 
to be a poor prognostic marker for CAD in the healthy population. However, it may have a better 
predictive value for CAD in high-risk patients with diabetes and/or pre-existing atherosclerosis 
(Vischer 2006). In acute coronary syndromes (especially acute myocardial infarction), VWF has 
been found to be elevated and its presence has been noted in fresh coronary thrombi (Goto et al. 
1997; Goto et al. 1999; Li et al. 2000; Yamashita et al. 2006; Hoshiba et al. 2006; Spiel et al. 
2008). 
 
The data concerning the association between VWF and PAD are limited. Smith et al. (2000) found 
that median levels of fibrinogen and VWF were higher in older patients who developed PAD than 
those who did not. Woodburn et al. (1996) showed that high pre-operative VWF levels were 
associated with poorer outcome of graft surgery. Cassar et al. (2005) reported higher levels of 
VWF in patients with intermittent claudication and critical limb ischaemia, compared with 
controls. They concluded that coagulation activation and endothelial stimulation were significantly 
increased in patients with PAD (Cassar et al. 2005). 
 
d. VWF, endothelial dysfunction and atherosclerosis 
Damage to, or activation of, endothelial cells results in increased VWF release (Boneu et al. 1975). 
Plasma VWF has been identified as a marker of endothelial dysfunction (Blann 1993). Endothelial 
dysfunction impairs the ability of endothelial cells to function appropriately in the coagulation 
process, influencing pathological thrombus formation and atherosclerosis (Boneu 1975). 
Endothelial dysfunction has been shown to be an early step in the development of atherosclerosis, 
increasing the risk for cardiovascular disease substantially (Sitia et al. 2010). Horvath et al. (2004) 
and Lip et al. (1997) both advocate VWF measurement as a useful marker for detecting endothelial 
dysfunction and a surrogate measure for atherosclerosis. Serial measurements may be used as a 
marker of disease progression (Horvath et al. 2004; Lip et al. 1997). Horvath et al. (2004) showed 
significant differences in the levels of VWF in acute coronary syndromes and acute strokes 
compared with patients who had chronic vascular diseases. However, VWF levels in both acute 
and chronic vascular disease were higher compared with healthy controls (Horvath et al. 2004). 












2.5.7 VWF and stroke 
In comparison to coronary artery disease, less is known about the relationship between VWF and 
ischaemic stroke. Available data are conflicting. This section attempts to best describe the differing 
results and the context in which they were found. It is important to bear in mind that these studies 
have mainly been carried out in older participants, often with upper limits in the range of 75 years 
old. Also, I could not find any studies that examined this relationship in the context of patients with 
HIV infection. Thus the role of VWF in HIV-related young stroke patients is a novel study. 
 
a. Increased levels of VWF in case-control studies 
Some case-control studies have shown increased levels of VWF in patients with ischaemic stroke. 
Studies conducted in the early 1980s initially provided evidence for an association between 
elevated VWF levels and ischaemic cerebrovascular events (Lip et al. 1997). Bongers et al. (2006), 
in their study of 124 first-ever ischaemic stroke patients versus 125 age-and sex-matched controls, 
showed that VWF antigen (VWF:Ag) and activity levels were significantly higher in cases than in 
controls. When the VWF levels of all participants were analysed, the relative risk (RR) of stroke 
was significantly increased (RR = 3.21) in those with the highest quartile range of VWF:Ag levels. 
These data reflected the analysis of VWF in the acute phase (between 7-14 days) following stroke 
presentation. VWF:Ag levels were not increased in the patients three months post stroke (Bongers 
et al. 2006). 
 
Lip et al. (2002) also found significantly raised plasma levels of VWF at 48 hours and 1 week 
respectively, following an acute stroke. The levels were compared with age-matched healthy 
controls. However, they raised the question as to whether this elevation in VWF could not be 
attributed to an acute phase response post-stroke (Lip et al. 2002). Similarly, Catto et al. (1997) 
reported elevated levels of VWF initially and 3 months following stroke compared with a healthy 
population, and found that elevated VWF levels were associated with an increased risk of death 
after six months follow-up. Stott et al. (2001) also showed raised VWF levels in patients in the 
ischaemic stroke group in their study. They also suggested the association may be due to an acute 
phase response (Stott et al. 2001). 
 
Other case-control studies on VWF and ischaemic stroke also report increased levels of VWF in 













VWF propeptide and mature VWF are secreted equimolarly from endothelial cells, therefore VWF 
propeptide levels reflect the rate of mature VWF secretion (Wagner et al. 1987). Van Schie et al. 
(2010) showed that increased VWF propeptide and mature VWF were both individually 
significantly associated with the occurrence of ischaemic stroke. 
 
Hanson et al. (2011) reviewed this relationship in the context of the varying aetiologic subtypes of 
ischaemic stroke. There are few data in the literature looking at this. Using the TOAST 
classification system, patients with stroke attributable to large vessel disease and cardio-embolism 
displayed the highest levels of VWF compared with stroke caused by small vessel disease in the 
acute phase of the stroke. VWF levels at 3 months were highest in those patients whose stroke was 
associated with cardio-embolism and cryptogenic causes (Hanson et al. 2011). 
 
b. VWF as a predictor of stroke 
In case-control studies, we can never be sure whether the high VWF levels reported post-stroke are 
a cause or a consequence of the event. It is thus necessary to review this association in prospective 
studies. 
 
The Atherosclerosis Risk in Communities (ARIC) study evaluated the role of a variety of markers 
of haemostatic function, including VWF, with the risk of ischaemic stroke. The investigators 
concluded that participants (191 stroke cases and 14 522 non-stroke controls) who had VWF levels 
in the upper quartile range of VWF, had a 1.7-fold greater risk of developing ischaemic stroke than 
those with VWF values in the lowest quartile range (Folsom et al. 1999). However, other 
cardiovascular risk factors may have confounded these results. 
 
In the Rotterdam study, a large population-based cohort study with 6250 participants, the risk of all 
stroke (ischaemic and haemorrhagic) and the risk of ischaemic stroke alone, increased with 
increasing VWF levels. The association was independent of cardiovascular risk factors 
(Wieberdink et al. 2010). 
 
Tzoulaki et al. (2007) showed that elevated plasma VWF levels were associated with future 
cardiovascular disease even after adjusting for cardiovascular risk factors, sub-clinical 












the other haemostatic and rheological markers measured in their cohort were higher in people who 
developed myocardial infarction and stroke, compared with those who remained free of 
cardiovascular disease. However, they did not advocate the use of VWF as a clinical marker for 
assessing cardiovascular risk but suggested instead that there might be a place for the measurement 
of multiple markers in clinical practice to aid with cardiovascular risk assessment (Tzoulaki et al. 
2007). 
 
Conway et al. (2003) found that plasma VWF levels were a significant predictor of stroke and 
vascular events (stroke, myocardial infarction or vascular death in atrial fibrillation) in patients 
with atrial fibrillation. The risk of stroke was greatest with the highest levels of VWF. However, 
after adjusting for traditional risk factors, the relationship between VWF and stroke was no longer 
significant (Conway et al. 2003). 
 
c. Studies with a lack of association between VWF and stroke 
Other studies, however, did not show an association between VWF and stroke. In a large study of 
only men (n = 2208) and a median follow-up of 13 years, Smith et al. (2005) examined the 
contribution of various haemostatic markers to the risk of coronary artery disease and ischaemic 
stroke. VWF level was measured in nearly 2000 of these participants but no association between 
VWF and ischaemic stroke risk was noted (Smith et al. 2005). Johansson et al. (2002) also showed 
no association between VWF and the development of first-ever ischaemic stroke in their 
prospective study. Similarly Yip et al. (2007) and Cherian et al. (2003) failed to demonstrate an 
association in their case-control studies. 
 
d. VWF levels in ischaemic versus haemorrhagic stroke 
Few studies have examined VWF levels in relation to haemorrhagic stroke. Liu et al. (1993) 
reported higher VWF levels in patients with thrombotic strokes compared to patients with 
haemorrhagic strokes. Others showed an increase in VWF levels in both ischaemic and 
haemorrhagic stroke in the acute phase (Bath et al. 1998). No significant association between VWF 













e. Murine VWF stroke studies 
Murine (mouse) studies on the role of VWF in ischaemic stroke have provided much needed clues 
to understanding this relationship in humans. A murine study showed that VWF deficiency protects 
mice from ischaemic stroke, without causing intracerebral haemorrhage. In this study, they 
demonstrated that 24 hours after reperfusion, VWF-deficient mice had significantly smaller 
infarctions, approximately reduced to 60% of the infarct volumes of the wild-type controls, and 
fewer neurologic deficits when compared with the wild-type control mice (Kleinschnitz et al. 
2009). 
 
Other murine studies investigated the role of platelet receptors for VWF and their role in stroke 
development. Stoll et al. (2010) recently established that the GPIbα platelet receptor (of the GPIb-
IX-V complex) and its interaction with VWF played a central role in initiating thrombus formation 
in the ischaemic brain. Inhibition of VWF binding to GPIbα by blockade of the receptor binding 
site with before- and after-transient middle cerebral artery occlusion, has been shown to protect 
mice from ischaemic brain infarction. The resulting brain infarct volume was significantly reduced 
compared with control mice (Kleinschnitz et al. 2007). 
 
Animal model studies have shown that VWF deficiency plays a protective role in arterial 
thrombosis, with VWF-platelet interactions responsible for a protective effect on atherogenesis. 
Human studies have been inconclusive in this regard, but VWF is still considered significant in the 
human body’s interplay between haemostasis and atherosclerosis (van Galen et al. 2012). 
 
f. VWF, metabolic syndrome and stroke 
The metabolic syndrome refers to a cluster of risk factors that include dyslipidaemia, hypertension, 
insulin resistance and abdominal obesity as the core components of the syndrome. These increase 
the risk of atherosclerotic vascular disease (Towfighi et al. 2008; Kassi et al. 2011). The role of 
chronic pro-inflammatory and pro-thrombotic states in the syndrome have recently been added 
(Eckel et al. 2005; Kassi et al. 2011). Elevation of fibrinogen and plasminogen activator inhibtor 1 
has been implicated as the cause of the pro-thrombotic risk (Eckel et al. 2005). 
 
However, the role of VWF in the metabolic syndrome has not been well researched. Endothelial 
dysfunction and the metabolic syndrome have been linked (Fornoni et al. 2005; Tziamolos et al. 












et al. 2008). VWF has been linked to endothelial dysfunction and to stroke, therefore VWF 
measured in the metabolic syndrome may be predictive of stroke. 
 
g. VWF gene polymorphisms and stroke 
A number of polymorphisms have been reported on the gene encoding VWF, but their 
relationships to ischaemic stroke have not been conclusively proven (Stankovic et al. 2010; Smith 
et al. 2010; van Schie et al. 2012; Dai et al. 2001). 
 
h. New VWF based stroke therapeutic interventions 
Therapeutic interventions in stroke are now also investigating VWF antagonism as a target in 
stroke therapy. Compounds such as 82D6A3, 6B4, h6B4, AJvW2, AJW200, GPG-290, ARC1779, 
ALX-0081 and ALX-0681 are being investigated as possible inhibitors of VWF-mediated platelet 
adhesion (De Meyer et al. 2012a). Stoll et al. (2008) have highlighted the VWF-GPIb interaction 
as an important target for future stroke prevention and treatment. 
 
2.5.8 VWF and HIV 
a. VWF, HIV-related endothelial dysfunction, metabolic syndrome, platelet reactivity and 
opportunistic infections 
We have already established that VWF is a marker of endothelial dysfunction (Horvath et al. 
2004). Raised VWF correlates with platelet adhesiveness and VWF may enhance a thrombotic 
tendency by promoting platelet adhesion and aggregation, especially in stenotic vessels, where 
shear stress is increased (Qizlbash et al. 1997). There is evidence that HIV infection promotes 
chronic arterial inflammation and injury. The latter, in turn, gives rise to endothelial dysfunction, 
atherosclerosis and thrombosis (Fourie et al. 2011). It is conceivable that in this chronic 
inflammatory state, VWF levels may parallel that of the degree of endothelial dysfunction, thus 
further increasing the propensity for thrombosis. 
 
The possible associations between VWF, metabolic syndrome and stroke discussed earlier are 
especially relevant in the context of HIV-related stroke (see section 2.5.7). In a retrospective case-
control study by Ances et al. (2009), a higher percentage of HIV-associated cryptogenic stroke 
cases met the criteria for metabolic syndrome, when compared to HIV positive controls (36% 












protease inhibitor (PI) or non-PI based. More patients with HIV-associated cryptogenic stroke 
tended to be on a PI-based regimen compared with non-stroke contols (Ances et al. 2009). 
 
Platelets and HIV infection are linked. Platelets are able to internalise HIV particles, platelet-bound 
HIV-1 may infect permissive cells and chronic thrombocytopaenia is one of the haematological 
complications of HIV infection. Increased platelet reactivity has been documented in patients on 
HAART and those that are HAART-naïve (Gresele et al. 2012). Satchell et al. (2010) detected 
significant differences in platelet reactivity in HIV-infected patients compared with HIV negative 
controls. Abacavir (an antiretroviral drug) containing regimens and increased platelet activity have 
also been linked (Satchell et al. 2011; Francisci et al. 2011). Since activated platelets release VWF, 
altered platelet function in the setting of HIV may be a reason for the raised VWF levels in HIV-
infected individuals. Further studies are required to confirm this. 
 
Cytomegalovirus (CMV) is an opportunistic infection frequently seen in individuals infected with 
HIV (Steininger et al. 2006). There is evidence that cells infected with CMV show increased 
secretion of soluble VWF and increased cell-surface expression of VWF (Rahbar et al. 2005). 
 
b. VWF and ART 
The relationships between HIV infection, HAART and endothelial adhesion markers e.g. vascular 
cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), P-selection, E-selectin, 
plasminogen activator inhibitor-1, thrombomodulin and VWF, have received much attention over 
the past decade. De Gaetano Donati et al. (2004) provide an excellent review in this field. Previous 
studies have documented elevated levels of VWF and other endothelial activation markers in ART-
naïve patients (Lafeuillade et al. 1992; Seigneur et al. 1997). The possible mechanisms that lead to 
this increase are multifactorial and may be related to endothelial dysfunction itself, chronic 
inflammatory states, the influence of opportunistic diseases, pro-thrombotic states and other factors 
that contribute to this aberrant bodily homeostasis caused by infection with HIV. The latter were 
discussed in chapter 1. 
 
In contrast, other studies have shown a decrease in VWF levels following ART initiation (Wolf et 
al. 2002; Aukrust et al. 2000). However, van Vonderen et al. (2009) have noted that not all 
markers of endothelial function improve following ART initiation and some even becoming further 












drug classes and individual drugs within each class or to direct damage of endothelial cells by 
HAART (de Gaetano Donati et al. 2004; van Vonderon et al. 2009). However, data are limited. 
Wolf et al. (2002) documented that 5 months following ART initiation, the levels of VWF were 
lower in plasma compared to pre-ART levels but did not completely reach normal levels. This held 
true for groups receiving either the PI or NNRTI-based regimens (Wolf et al. 2002). Therefore 
HAART was not fully able to counteract the influence of HIV on endothelial dysfunction. Thus, 
our protein of interest, VWF, could continue to exert its pro-thrombotic/pro-atherosclerotic/pro-
inflammatory effects. 
 
VWF levels are also influenced by viral load, CD4 count and overall immune status, with higher 
viral load and lower CD4 count correlating with elevated VWF levels (Lafeuillade et al. 1992; 
Seigneur et al. 1997). 
 
2.6 A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13 
(ADAMTS13) 
 
2.6.1 Overview of ADAM, ADAMTS and ADAMTS13 proteins 
A Disintegrin and Metalloproteinase (ADAM) proteins are a group of transmembrane proteins that 
display a host of functions which range from regulation of the nervous system to signalling in the 
tumour micro-environment. Their functional ability is aided by their structure which is made up of 
several domains. These include an amino (N)-terminal propeptide domain, a metalloprotease 
domain, a disintegrin domain, a cysteine-rich region with an epidermal growth factor (EGF)-like 
sequence and a cytoplasmic carboxy (C)-terminal tail involved in intracellular signalling (see 
figure 2.7) (Yang et al. 2006; Murphy 2008; Benarroch 2012). A Disintegrin and 
Metalloproteinase with Thrombospondin motifs (ADAMTS) proteins lack EGF-like repeats and a 
transmembrane domain and are therefore secreted, in contrast to ADAM proteins that are 
membrane-bound. They also possess one or more thrombospondin type 1 (TSP) and variable 
additional C-terminal domains compared with ADAM proteins (Levy et al. 2005; Cal et al. 2002). 
 
Furlan et al. (1996) and Tsai (1996) were the first investigators to describe the VWF-cleaving 
protease and its activity in human plasma in 1996. Following in-depth structural and functional 
analysis and identification as an ADAMTS protein, ADAMTS13 received its status as a novel 
member of the ADAMTS family in 2001. ADAMTS13 is the 13
th












of the ADAMTS family. It differs from other members of the ADAMTS family by the presence of 
2 C-terminal CUB domains (Levy et al. 2005). Its ability to perform a multitude of functions arises 
from the presence of its many different domains (Bornstein 2001; McLane et al.1998; Levy et al. 




Figure 2.7 Schematic depiction of ADAM, ADAMTS and ADAMTS13 (From: Levy et al. 2005) 
A Disintegrin and Metalloproteinase (ADAM), A Disintegrin and Metalloproteinase with Thrombospondin motifs (ADAMTS) and A 
Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13 (ADAMTS13) are shown with the following 
structural components: signal peptide (SP), propeptide (pro), protease, metalloprotease (location of zinc-binding motif in red), 
disintegrin, disintegrin-like (dis-like) domain, cysteine-rich (cys-rich) domain, thrombospondin type-1 (TSP) motif, epidermal growth 
factor (EGF)-like repeat, transmembrane (TM) domain, CUB domain. 
 
2.6.2 Synthesis and structure of ADAMTS13 
The gene that encodes for ADAMTS13 is located on chromosome 9q34 (Levy et al. 2001). It 
encodes a protein composed of 1427 amino acids with a calculated molecular mass of 145kDa 
(Levy et al. 2005). Synthesis takes place predominantly in the liver, with synthesis and release also 
identified in endothelial cells (Levy et al. 2001; Zheng et al. 2001; Uemura et al. 2005; Turner et 
al. 2006). Suzuki et al. (2004) also showed that ADAMTS13 messenger RNA was expressed in 
platelets. A lesser degree of expression was identified in placenta and skeletal muscle (Zheng et al. 
2001). 
 
The 1427 amino acid-containing protein is synthesised as a precursor polypeptide made up of a 
signal peptide, a short 41 amino acid propeptide and a series of domains (Lämmle et al. 2005; 
Majerus et al. 2003). The mature form of ADAMTS13 begins with the metalloprotease domain 
which confers its catalytic ability (Lämmle et al. 2005). Refer to figure 2.7 for an overview of 












2.6.3 Storage and release of ADAMTS13  
ADAMTS13 is a unique protease in that it normally circulates with VWF in an active form. 
However, it is only under conditions of high shear stress that ADAMTS13 is activated to carry out 
proteolysis (Tsai 2012). ADAMTS13 is also stored in platelet α granules and is released upon 
platelet activation (Nurden 2011). 
 
2.6.4 Function of ADAMTS13 
ADAMTS13 cleaves VWF. It was previously known as the VWF-cleaving protease. 
Haemostatically active ULVWF multimers are cleaved into smaller multimers that are less 
haemostatically active. Thus ADAMTS13 controls VWF size such that its activity is suitably 
matched for the haemostatic problem (Crawley et al. 2011). However, this is an intricate process 
facilitated by the integrated action of the various ADAMTS13 domains. I shall not discuss the 
details of these processes. For a complete review of the process, see Crawley et al. (2011), Xiang 
et al. (2011), Tsai (1996), and Denis et al. (2012). 
 
VWF is exposed to elevated shear stress in areas of vascular injury, in stenosed blood vessels, 
when blood passes through the microvasculature and when it becomes tethered on exposed sub-
endothelial collagen following vascular injury. It is this high shear stress that unfolds the globular 
VWF into an elongated, active string-like form (refer back to figure 2.5). Following unfolding, 
numerous other binding sites (exosites) are exposed and the interaction between the enzyme and 
substrate continues. Cleavage of VWF takes place at the Tyr1605-Met1606 bond located within the 
central VWF A2 domain (Crawley et al. 2011; Denis et al. 2012; Xiang et al. 2011). 
 
2.6.5 Regulation of ADAMTS13 activity 
The main regulator of ADAMTS13 activity is flow shear stress, with elevated rheologic shear 
forces causing conformational change of its substrate, VWF (Shelat et al. 2005; Crawley et al. 
2011). Other factors that influence the interaction between VWF and ADAMTS13 include: certain 
structural elements of VWF, heparin sulphate, platelets or GPIbα, sodium chloride, inflammatory 
cytokines, chloride ions, haemoglobin, thrombin, factor Xa and plasmin (Shelat et al. 2005). 
 
2.6.6 ADAMTS13 and its disease associations 
a. Thrombotic Thombocytopaenic Purpura (TTP) 
TTP was first described in a 16 year old girl by Dr Eli Moschcowitz in 1924 (Moschcowitz 1924). 
TTP is a type of thrombotic microangiopathy that manifests with ischaemic neurologic, renal and 












features: miroangiopathic haemolytic anaemia with schistocytes in the peripheral blood smear, 
thrombocytopaenia, neurologic signs and symptoms, fever and renal impairment (Moake 2002; 
Lämmle et al. 2005). Deficiency of ADAMTS13 gives rise to TTP and occurs secondary to a 
congenital deficiency of ADAMTS13 or to deficiency brought about by autoimmune inhibitors 
(acquired TTP) targeted at ADAMTS13 (Tsai 2010). The platelet thrombi in TTP are thus rich in 
VWF as a result of impaired VWF cleavage by ADAMTS13 and insufficient processing of the 
ULVWF multimers (Moake 2002; Pos et al. 2011). 
 
b. Congenital, acquired (idiopathic and secondary) and HIV-related TTP 
Numerous mutations in the gene that encodes for ADAMTS13 have been identified and are 
implicated in the congenital forms of TTP (Lotta et al. 2010; Kokame et al. 2004; Levy et al. 
2001). Acquired TTP is TTP that is not attributed to any form of genetic aberration. Idiopathic TTP 
and secondary TTP fall into this category. In idiopathic acquired TTP, auto-antibodies hinder 
ADAMTS13 activity by inhibiting its enzymatic function or by clearing it from the circulating 
blood (Pos et al. 2011). TTP that occurs in the presence of a predisposing factor is labelled 
secondary TTP. Autoimmune haemolysis, disseminated intravascular coagulation (DIC), cancer, 
eclampsia, drug toxicity (e.g. treatment with calcineurin inhibitors), haematopoietic stem cell 
transplantation, HIV infection or malignant hypertension may predispose patients to secondary 
TTP (Sadler 2008). 
 
HIV is associated with an increased incidence of TTP (Blazes et al. 2004). It is the most common 
virus precipitating TTP (Opie 2012). Its presentation has been associated with advanced HIV 
infection (Novitzky et al. 2005). There is, however, heterogeneity with regard to ADAMTS13 
activity and inhibitors in patients with HIV-related TTP (Gunther et al. 2007). Acquired inhibitors 
(auto-antibodies) have been detected in HIV-related TTP, but not in all studies (Gunther et al. 
2007; Meiring et al. 2012; Miller et al. 2005). Gunther et al. (2007) proposes either a 
“consumptive deficiency” mediated by direct endothelial cell injury caused by HIV itself, or 
damage due to inflammatory cytokines seen in infection with HIV as an alternative mechanism. 
These mechanisms lead to an excessive release of VWF, with resultant inability of ADAMTS13 to 
cope with the increased cleaving burden (Gunther et al. 2007). 
 
c. Other causes of ADAMTS13 deficiency and increased amounts of soluble ULVWF 
multimers 
The presence of ULVWF multimers with or without severely reduced levels of ADAMTS13 has 












transplantation and immunosuppression with cyclosporin and sickle cell disease (Tsai 2010; Turner 
et al. 2012). However, these high ULVWF multimer levels and ADAMTS13 deficiency states do 
not necessarily always cause severe thrombosis and their significance in the clinical setting is 
uncertain (Tsai 2010). 
 
d. ADAMTS13 and its association with coronary artery disease (CAD) and atherosclerosis 
There is an association between ADAMTS13 and CAD. Kaikita et al. (2006) and Matsukawa et al. 
(2007) have reported reduced ADAMTS13 activity in acute myocardial infarction. They also noted 
that an early reduction in ADAMTS13 levels following acute myocardial infarction predicted 
future thrombotic events (Kaikita et al. 2006; Matsukawa et al. 2007). The imbalance between 
VWF and ADAMTS13 activity confers a state of prolonged thrombogenicity on patients with 
unstable angina (Fuchigami et al. 2008). 
 
In a recent study by De Meyer et al. (2012b), ADAMTS13 was shown to play an important role in 
ischaemia/reperfusion injury in myocardial infarction. Following ischaemia/reperfusion injury to 
the myocardium, ADAMTS13-deficient mice developed larger myocardial infarcts than their 
ADAMTS13-replete wild-type counterparts (De Meyer et al. 2012b). 
 
Schettert et al. (2010) reported on associations between ADAMTS13 genotypes and cardiovascular 
disease. Polymorphisms in the ADAMTS13 gene (especially the ADAMTS13 A900V variant) was 
associated with decreased ADAMTS13 activity and an increased risk of death in patients with 
CAD (Schettert et al. 2010). 
 
Mouse models of ADAMTS13 and atherosclerosis have shown that ADAMTS13 can reduce 
excessive vascular inflammation and plaque formation during early atherosclerosis, and that more 
extensive atherosclerotic plaque formation occurs in ADAMTS13-deficient mice fed a high-fat diet 
(Gandhi et al. 2012; Jin et al. 2012). These findings provide a link between ADAMTS13 and 
atherosclerosis and, therefore, stroke aetiology. 
 
2.6.7 ADAMTS13 and stroke 
a. Current data 
There are limited data but these do suggest an association between ADAMTS13 and stroke. The 
field, however, is expanding. Bongers et al. (2006) were the first to determine the levels of 












activity levels in ischaemic stroke patients. Also, the ischaemic stroke risk was lowest in patients 
with the highest measured ADAMTS13 activity levels (Bongers et al. 2006). 
 
In an experimental model, ADAMTS13-deficient mice displayed an increased susceptibility to 
focal cerebral ischaemia. The infusion of a high dose of recombinant ADAMTS13 into a wild-type 
mouse immediately before reperfusion reduced the final infarct volume (Zhao et al. 2009). Fujioka 
et al. (2010) also demonstrated that ADAMTS13 deficiency exacerbates ischaemic brain injury in 
their murine model. These studies highlight a potential therapeutic role of ADAMTS13 as a neuro-
protector in stroke treatment (Nieswandt et al. 2010). 
 
Fujioka et al. (2012) have recently reported the effect of ADAMTS13 on inflammation after brain 
ischaemia. Following ischaemia-reperfusion, mice deficient in ADAMTS13 had larger brain 
infarcts and a greater increase in high-mobility group box 1 (HMGB1), a marker of post-stroke 
inflammation, compared with wild-type mice. ADAMTS13 may therefore regulate inflammation 
following brain ischaemia and therefore protect the nervous system from ischaemia-reperfusion 
injury (Fujioka et al. 2012). 
 
Enhanced formation of reactive oxygen species and peroxynitrite can occur in the clinical setting 
of stroke, coronary artery disease and chronic inflammatory disease, amongst other conditions. 
Peroxynitrite hinders the proteolytic cleaving action of ADAMTS13, thus possibly contributing to 
a pro-thrombotic state (Lancelloti et al. 2010). This may represent another mechanistic link 
between ADAMTS13 and stroke. 
 
b. VWF and ADAMTS13 joint influence on stroke risk 
Previous studies have mainly investigated VWF and stroke association in isolation. Few have 
looked at the joint influence on VWF and ADAMTS13 on stroke risk. As mentioned previously, 
Bongers et al. (2006) were the first to investigate the effect of ADAMTS13 levels on ischaemic 
stroke risk. They also confirmed the negative association of VWF and ADAMTS13 levels as 
reported in other studies (Bongers et al. 2006). 
 
Andersson et al. (2012) characterised the joint risk in a gender-specific study of young women 
aged 18-49 years. They showed that high VWF and low ADAMTS13 plasma levels were both 
associated with an increased risk of ischaemic stroke and myocardial infarction. This risk was 
further increased with the use of oral contraceptives. The joint risk conferred by having both high 












individual abnormal VWF and ADAMTS13 levels (Andersson et al. 2012). A similar finding of 
greater cardiovascular disease risk in individuals with the combination of lowest ADAMTS13 and 
highest VWF levels was observed in a study that included patients with stroke, coronary artery 
disease and peripheral arterial disease (Bongers et al. 2009). The study of Andersson et al. (2012) 
differed, however, from many studies by its exclusive female population and younger age group. 
The latter were studied to minimise the influence of atherosclerotic risk (Andersson et al. 2012). 
 
c. ADAMTS13 polymorphisms and stroke risk 
A number of mutations in the ADAMTS13 gene have been identified (Shelat et al. 2005). The 
Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS) investigated the association between 
various single nucleotide polymorphisms of the ADAMTS13 gene and ischaemic stroke in a group 
of patients from western Sweden. The rs4962153 single nucleotide polymorphism was 
significantly associated with an increased risk of ischaemic stroke and the subtype of cryptogenic 
strokes (Hanson et al. 2009). 
 
2.6.8 ADAMTS13 and HIV 
We have already described the link between HIV and TTP. Early initiation of HAART and plasma 
exchange therapy for HIV-infected patients with TTP has been proposed (Hart et al. 2011). 
ADAMTS13 deficiency and diminished activity have also been reported in other HIV-associated 
thrombotic microangiopathies (Malak et al. 2008). This adds to the evidence linking ADAMTS13 
and HIV infection. No studies exist examining this relationship directly in HIV-infected 




Vascular haemostasis is a complex dynamic process. Infection with HIV can compromise the 
haemostatic process. Certain coagulation abnormalities may cause stroke and some of these 
abnormalities are often recognised in HIV-infected individuals. 
 
VWF is an intricate protein with multiple roles. Deficiencies or aberrant function of this molecule 
may give rise to life threatening conditions such as von Willebrand disease. Increased levels of 
VWF have been associated with stroke. However, the data on this subject are limited and 
mechanisms for the association are uncertain. VWF levels may predict stroke, but further 
investigation is required before we can advocate its routine testing in clinical settings. HIV, with its 












link for the association between raised levels of VWF and HIV infection. A link between HIV-
related stroke and VWF is therefore plausible and will be investigated in the younger adults in this 
study. 
 
ADAMTS13 is a protease whose biological structure and function has generated much recent 
research interest. It is clinically important in a host of illnesses, and has revolutionised the 
understanding of TTP since its discovery. The role that it plays in VWF cleavage is pivotal to its 
involvement in the pathogenesis of stroke. ADAMTS13 functioning is altered by HIV infection 
and stroke occurs more frequently in young, HIV positive individuals. Thus, we can propose a 

















In the previous two chapters, we reviewed the literature on HIV and stroke and identified important 
gaps in our current knowledge. This short chapter is intended to provide the reader with our aims 




Our main aim was to investigate the role of VWF and ADAMTS13 in the pathogenesis of HIV- 
related young stroke. In order to minimise the influence of confounding variables in our study, we 




The evidence indicates that HIV infection is associated with abnormalities in the coagulation 
system and that these result in a pro-thrombotic state. HIV infection also appears to be associated 
with an increased occurrence of stroke and a younger age of presentation with cerebrovascular 
events. I therefore proposed the follow ng hypotheses: 
 
3.2.1 Hypothesis 1  
HIV positive young stroke participants will have a pro-thrombotic coagulation profile 
characterised by higher levels of VWF compared with HIV negative young stroke participants. 
This hypothesis will be tested by measuring the quantity of VWF in the plasma of these two 
groups, using the VWF antigen (VWF:Ag) assay. 
 
A secondary hypothesis (1a) related to this, is that HIV positive young stroke participants whose 
stroke is “idiopathic” (i.e. cannot be attributed to any other identifiable cause) will have a pro-
thrombotic coagulation profile characterised by higher levels of VWF compared with HIV negative 














3.2.2 Hypothesis 2 
HIV positive young stroke participants will have a pro-thrombotic coagulation profile 
characterised by higher levels of VWF compared with HIV positive young control participants 
who have not had a stroke. This will also be determined using the VWF:Ag assay. 
 
3.2.3 Hypothesis 3 
HIV positive young stroke participants will have a pro-thrombotic coagulation profile 
characterised by higher levels of VWF activity compared with HIV negative young stroke 
participants. This will be measured using the VWF collagen binding (VWF:CB) assay. 
 
A secondary hypothesis (3a) predicts that HIV positive young stroke participants whose stroke is 
“idiopathic” will have a pro-thrombotic coagulation profile characterised by higher levels of VWF 
activity compared with HIV negative young “idiopathic” strokes. 
 
3.2.4 Hypothesis 4 
HIV positive young stroke participants will have a pro-thrombotic coagulation profile 
characterised by higher levels of VWF activity (VWF:CB assay) compared with HIV positive 
young non-stroke control participants. 
 
3.2.5 Hypothesis 5 
HIV positive young stroke participants will have a pro-thrombotic coagulation profile 
characterised by lower levels of ADAMTS13 compared with HIV negative young stroke 
participants. This will be measured using the ADAMTS13 antigen (ADAMTS13:Ag) assay. 
 
A secondary hypothesis (5a) is that HIV positive young stroke participants with “idiopathic” 
strokes will have a pro-thrombotic coagulation profile characterised by lower levels of 
ADAMTS13 compared with HIV negative young “idiopathic” strokes. 
 
3.2.6 Hypothesis 6 
HIV positive young stroke participants will have a pro-thrombotic coagulation profile 
characterised by lower levels of ADAMTS13 compared with HIV positive young non-stroke 













3.2.7 Hypothesis 7 
Levels of VWF (7a) and VWF activity (7b) will be negatively correlated with CD4 counts in HIV 
positive participants with and without strokes i.e. with advancing immunosuppression, VWF levels 
will increase. 
 
ADAMTS13 levels (7c) will be positively correlated with CD4 counts in HIV positive participants 
with and without strokes i.e. with advancing immunosuppression, ADAMTS13 levels will 
decrease. 
 

















In this chapter, I shall describe the study design, participant groups, inclusion and exclusion 
criteria, participant recruitment and laboratory methods used to analyse the samples. I shall also 
discuss the question of sample size and the statistical tests used to analyse the data. Finally, 
summary flow diagrams of the methods will be presented. The study was approved by the 
University of Cape Town (UCT)/Groote Schuur Hospital (GSH) Human Research Ethics 
Committee (HREC) (HREC REF 178/2010). 
 
4.1 Study design and research setting 
 
The study was an observational case-control study. It formed part of a larger on-going study of 
HIV-related young stroke. It was based in Cape Town, South Africa, in the study hospitals of the 
University of Cape Town, as well as the community health centres in the greater metropolitan area 
of the city. 
 
4.2 Participant group allocation 
 
The participants in this study were divided into 3 groups. All of the participants who had suffered a 
stroke were categorised as case groups and those participants without stroke were categorised into 
control groups. The groups were enrolled according to the inclusion and exclusion criteria, as 













Inclusion criteria Exclusion criteria 
Applicable to all participants 
 Participants had to be aged ≥ 18 or ≤ 45 years 
 Participants had to have signed informed consent 
 
Applicable to case participants only 
 Participants had to have had a recent ischaemic stroke i.e. 
only participants referred within 7 days from stroke onset 
were eligible 
 If HIV positive, a confirmed diagnosis of HIV infection 
at the time of enrolment and no history of HAART use 
 If HIV negative, a confirmed diagnosis that participant 
was not HIV positive 
 
Applicable to control participants only 
 Participants had to have had no history of current or prior 
stroke 
 Participants had to have a confirmed diagnosis of HIV 
infection at the time of enrolment 
 No history of HAART use at the time of enrolment 
Applicable to all participants 
 Age < 18 or > 45 years 
 Patient refusal to participate 
 Inability to obtain consent 
 Subarachnoid, subdural or epidural haemorrhage 
 Pregnancy 
 
Applicable to case participants only 
 If stroke was a haemorrhagic stroke 
 If meningitis was the cause of the stroke 
Table 4.1 Inclusion and exclusion criteria Abbreviations: Human Immunodeficiency Virus (HIV), highly active 
antiretroviral therapy (HAART). 
 
4.2.1 Cases 
a. HIV negative young stroke patients 
All of the participants in this group were HIV negative and had had a confirmed stroke within 7 
days of the time of enrolment into the study. 
 
b. HIV positive young stroke patients (HAART-naïve) 
All of these participants were HIV positive, had had a confirmed stroke, and had not yet started 
treatment with HAART when enrolled in the study. 
 
4.2.2 Control group 
a. HIV positive young non-stroke patients (HAART-naïve) 
All of the participants in this group were HIV positive, had not suffered a stroke and had not yet 













4.3 Sample size and power calculation 
 
VWF has been studied in the setting of stroke (see chapter 2, section 2.5.7). Participant numbers 
were small in these studies. There has been little research on ADAMTS13 in the setting of stroke 
(see chapter 2, section 2.6.7). Furthermore, to our knowledge, these factors have not been studied 
directly in the setting of HIV, let alone in the setting of HIV-related stroke. This therefore is a pilot 
study and, to our knowledge, the first of its kind. 
 
Our study numbers were limited to 100 participants due to a number of factors. These included 
short study duration, financial limitations and lack of available human resources. A total of 91 
suitable stroke participants (20 HIV positive and 71 HIV negative) and 40 suitable HIV positive 
non-stroke controls were enrolled during our study period. We therefore best matched according to 
age and sex, 40 HIV negative stroke participants to the two HIV positive groups (stroke and non-
stroke) to complete our predefined number of 100 participants (See figures 4.4 and 4.5). Table 4.2 
summarises the participant group allocation. 
 
 
HIV positive young 
stroke (HAART-
naïve) 
HIV negative young 
stroke 




No. of participants 20 40 40 100 
Table 4.2 Participant groups Abbreviations: highly active antiretroviral therapy (HAART), number (No.). 
 
Power calculations were therefore performed using the fixed sample sizes which we had for each 
group. With α = 0.05 and between-group comparisons fixed at a 1:2 ratio (20:40 participants), table 
4.3 presents the power that could have been attained if the effect sizes measured in our study 













Fixed factors Power Effect size 
Between group comparisons: 
Always 20:40 participant ratio (n = 60) 
α = 0.05 
50 % 0.55 
60 % 0.62 
70 % 0.70 
75 % 0.74 
80 % 0.79 
85 % 0.84 
90 % 0.91 
95 % 1 
Table 4.3 Power and corresponding effect sizes based on our sample size Abbreviation: sample size (n). 
 
The table shows that our study is capable of detecting a 0.79 effect size with 80% power, given the 
total sample size used (n = 60) for each between-group comparisons. 
 
It is important to reiterate that this study is a pilot study. A larger study would not have been 
feasible or appropriate at the time. However, as a result of this study, we shall have the data that 
can be used to calculate sample sizes and power calculations for future larger studies (see chapter 
8, section 8.3). 
 
4.4 Recruitment of participants 
 
My study was part of a larger study, in which a total of 240 participants were enrolled between 
May 2010 and August 2012. All the files were reviewed and participant selection for this study 
was narrowed down. Patients on HAART were included in the larger study but excluded in my 
study which looked specifically at HAART-naïve participants. Overall a total of 20 HIV positive 
young stroke HAART-naïve participants were considered eligible. Please refer to the flow chart in 
figure 4.4 for details of the recruitment process, attrition and exclusions. The second flow chart 
(figure 4.5) describes the selection of participants in my study for this project. 
 
4.4.1 Cases 
All participants were recruited from tertiary and secondary-level public hospitals located in the 
Western Cape. The four hospitals were: Groote Schuur Hospital, New Somerset Hospital (NSH), 
Victoria Hospital (VHW), and GF Jooste Hospital (GFJ). The treating physicians at these hospitals 












met the inclusion criteria, the patient’s primary physician would refer the patient to the study. 
These patients were then assessed initially by one of the study doctors, either myself or Dr Alan 
Stanley, a senior registrar in neurology and a colleague involved in the greater study. The purpose 
of this assessment was to ascertain participants’ suitability for the study (see inclusion and 
exclusion criteria, table 4.1). Only participants referred to us within seven days of the onset of their 
stroke were eligible for the study. To standardise the timing of blood sampling, blood samples for 
the study were all obtained on day 6 or 7 post-stroke onset. 
 
Participants enrolled during their hospital admission for treatment of their stroke, received the 
usual standard of care. They did not receive remuneration for participating in the study. However, 
some patients who had been discharged within 7 days of their stroke onset and who were 
subsequently enrolled in the study as outpatients were reimbursed for their transport costs. 
 
4.4.2 Controls 
The majority of the control participants were recruited from the Gugulethu Community Health 
Centre (CHC), a primary health care facility located in the township of Gugulethu, Cape Town. 
The CHC runs a wellness clinic for HIV positive patients who are relatively healthy, apart from 
infection with HIV. Patients attend this clinic prior to ART initiation. Consent was granted by the 
Gugulethu CHC facility manager to allow participant recruitment in this way. The nursing staff of 
the clinic identified patients who they felt met the inclusion and exclusion criteria for control 
participants. Potential participants were informed about the study and were asked if they would be 
interested in participating. Those who were agreeable were contacted telephonically. They were 
then invited to attend the GSH research clinic where they were enrolled. If I was on site at the 
CHC, I would inform pat ents of the study directly. Control participant recruitment at the CHC 
spanned a short period, from June – August 2012. 
 
One control participant was initially recruited as a case as her presentation mimicked that of a 
hemiparetic stroke. Only after further investigation, was stroke ruled out. This patient was, 
however, HIV positive and had consented to study participation. She was therefore included in the 
control group. All control participants were reimbursed R150 for transport costs and lunch. 
 
4.5 Ethical considerations and consent 
 
All study procedures for the main/larger HIV-related young stroke project were approved by the 












(HREC REF:178/2010). An amendment to include the specific laboratory analyses of this study 
was approved on 12
th
 March 2012. The participant information leaflet and consent forms (in 
English and isiXhosa) were approved by the Ethics Committee and are available on request. The 
study adhered to the principles laid down in the Helsinki Declaration of 2008 (World Medical 
Association 2008) and South African Medical Research Council guidelines for research on human 
subjects (South African Medical Research Council 2002). 
 
Potential participants were provided with a full explanation of the study and the procedures 
involved. It was emphasised that the study would not in any way compromise their normal 
standard of care. In fact, participants in the study underwent a more thorough investigation of their 
stroke than they would otherwise have received in the course of a “routine” hospital admission. 
Participants were informed that they would be free to withdraw from the study at any stage without 
necessarily having to give a reason. Nor would this affect their current treatment or jeopardise any 
future treatments they might need. In the event of the participant being unable to provide informed 
consent, a close family member/guardian/treatment partner was interviewed, informed of the study 
and invited to agree on the patient’s behalf. The process of informed consent was in the language 
of choice of the participant/relative. A copy of the signed consent was given to the patient. Study 
data were kept in locked files and identified by a research code number. Confidentiality of the data 
was protected at all times. 
 
4.6 Assessment of participants 
 
After consent was obtained, all participants underwent a thorough assessment that included a 
demographic questionnaire, history and full physical examination, and blood tests. Patients were 
assessed in the language of their choice (isiXhosa, English or Afrikaans). Data were collected on 
standardised forms for patients and controls, respectively. A full-time research nurse assisted with 
the assessments and translations where necessary. 
 
4.6.1 Cases 
a. History taking and examination 
The history included an ascertainment of the participant’s baseline clinical characteristics, with the 
emphasis on identifying potential cerebrovascular risk factors. In HIV positive participants, a more 
in-depth history was obtained in relation to the HIV diagnosis and possible treatments. A general 













b. Stroke assessment tools and classification 
All cases were assessed according to a set of three standardised stroke assessment tools: the 
National Institutes of Health Stroke Scale (NIHSS), the modified Rankin Scale and the Barthel 
Index (Brott et al. 1989; van Swieten et al. 1988; Mahoney et al. 1965). The NIHSS is a 15-item 
clinical stroke assessment tool. It is used to evaluate and document neurological status in acute 
stroke, and assists with predicting lesion size and assessing stroke severity. I completed an online 
tutorial and test to become certified in using this scoring system. This reduced the bias in the 
assessment of participants, as both I and the other doctor enrolling patients completed the online 
assessment. The modified Rankin Scale is a valid and clinically relevant functional assessment tool 
that describes the range of global disability of a stroke sufferer and is used to assess recovery from 
stroke (Banks et al. 2007). The Barthel Index is a disability scale used to measure outcome 
following a stroke. It does so by measuring the patient’s performance in 10 activities of daily living 
(Sulter et al. 1999). 
 
c. Investigations 
A number of investigations were carried out on case participants as they required extensive work-
up for the cause of their stroke. As these patients were young, the investigative work-up was 
guided by the GSH stroke unit protocol/guidelines devised for the work-up of a young stroke 
(Bryer 2008/2009). All the participating hospitals implemented the same guidelines under the 
supervision of the attendant physicians. A Young Stroke Investigation Tick Sheet was devised as 
reminder to the attendant physicians of the necessary investigations that needed to be performed. 
Abnormal findings were discussed with the patient and treated according to normal standards of 
hospital care. 
 
Blood investigations: These included: a full blood count (FBC), the international normalised ratio 
(INR), partial thromboplastin time (PTT), erythrocyte sedimentation rate (ESR), creatinine, 
electrolytes, urea, total cholesterol and lipid profile, fasting glucose, C-reactive protein (CRP), 
rapid plasma reagin (RPR) test/Venereal Disease Research Laboratory (VDRL) test, fluorescent 
treponemal antibody absorption (FTA) test, antinuclear antibody (ANA) test, anti-double stranded 
DNA (Anti-DS DNA) test, anti-neutrophil cytoplasmic antibody (ANCA) test, anticardiolipin and 
lupus anticoagulant. If a recent CD4 count for HIV positive young stroke participants was 
available in previous patient records (within 15 days before or after stroke onset), this 













Lumbar puncture: A lumbar puncture for the collection of cerebrospinal fluid (CSF) was part of 
the routine work-up for a young patient with stroke. CSF protein, glucose and cell count were 
measured. Cryptococcal Latex Agglutination Test (CLAT) work-up and RPR/FTA tests were done, 
and the CSF sample was cultured to detect bacterial or fungal infection. Some specimens were sent 
for TB culture if TB was suspected, and viral polymerase chain reaction (PCR) for varicella zoster 
virus (VZV) or herpes simplex virus (HSV) were performed in patients where these were clinically 
suspected. An additional 5ml of CSF was collected for tests that were part of the larger HIV-
related young stroke project. The latter were not required for my study. 
 
Imaging: The presence of stroke in patients was confirmed with neuro-imaging. Computed 
tomography (CT) scan of the brain was routinely performed, with further imaging such as MRI of 
the brain performed where necessary. A chest x-ray, CT angiogram of the head and neck vessels, 
and cardiac echocardiogram study were performed. Carotid duplex doppler studies for estimation 
of the carotid intima-media thickness (CIMT) were also part of the larger HIV-stroke study. 
 
4.6.2 Controls 
Demographic data were collected, as for the cases. They also underwent a full clinical and 
neurological examination. Stroke scores and classification systems did not apply here. Controls 
were HAART-naïve and attended their local HIV Wellness clinic. They were considered to be in 
relatively good general health, apart from infection with HIV. Investigations in this group were 
limited to a FBC, ESR, INR, PTT, RPR and CD4 count. On occasions, old patient records were 
accessed to obtain a recent CD4 count measurement. The only imaging performed in the controls 
was that of the carotid duplex doppler testing with CIMT measurement. The latter was required for 
analysis in the larger HIV-related young stroke project. A specially trained ultra-sonographer was 
employed to perform these studies. Any controls with abnormalities that required further 
investigation or treatment were referred to the appropriate health care facility. 
 
4.6.3 Laboratory analysis of study specimens 
Blood samples from all participants were used to determine the levels and activity of VWF and 
ADAMTS13. A total of 30ml of blood was drawn from each participant, and preserved in a citrate 
tube to prevent clotting. The samples were stored on ice immediately after collection. They were 
centrifuged at 4000 revolutions per minute (rpm) for 10 minutes before being aliquotted into 
cryoprecipitate tubes in volumes of around 500 microlitres (µl) each. These were stored at -80 













4.7 Specific specimen laboratory analysis 
 
The specific assays required for the analyses of VWF and ADAMTS13 for my study were 
performed in the laboratory of Professor Muriel Meiring, Associate Professor and Specialist 
Scientist of the Department of Haematology and Cell Biology of the University of the Free State, 
South Africa, and Head of the Haematology Division of the Bloemfontein National Health 
Laboratory Service (NHLS) laboratory. Her laboratory has a special interest in VWD, TTP, and 
more specifically, HIV-associated TTP, and is internationally accredited. 
 
The specimens were transported on dry ice by air freight from Cape Town to Bloemfontein and 
reached the laboratory on the same day. They were immediately transferred to the -80ºC freezer at 
the Bloemfontein NHLS laboratory and stored before being analysed in 3 batches over a period of 
6 months. The specific tests are described next. 
 
4.7.1 VWF antigen (VWF:Ag) assay 
This enzyme-linked immunosorbent assay (ELISA) measures the actual amount of VWF in 
plasma. 
 
An ELISA plate was coated at 4ºC overnight with a rabbit anti-human VWF antibody [DAKO, 
South Africa, 1:6000 dilution in phosphate buffered saline (PBS) solution: 5.84 grams per litre 
(g/L) NaCl, 4.76 g/L Na2HPO4 and 2.64 g/L NaH2PO4.2H2O, pH 7.2]. The VWF in the plasma 
being tested was captured by this antibody and measured. Following antibody coating, 100µl of 
1:50 dilution of plasma (study participants’) was then added in duplicate to the wells and incubated 
for 2 hours at 37ºC. The plasma was diluted in PBS/0.1% Tween-20 (Merck, South Africa). After 4 
washing steps with PBS/0.1% Tween-20, a rabbit anti-VWF antibody conjugated to peroxidase 
(DAKO, South Africa, 1:8000 dilution in PBS/0.1% Tween-20), was added and incubated for one 
hour at room temperature. This conjugated antibody completes the “sandwich” technique of 
ELISA tests by binding to the remaining free antigenic determinants of VWF. The bound enzyme 
peroxidase is revealed by its activity in a predetermined time on the substrate ortho-
phenylenediamine (OPD) in the presence of hydrogen peroxide (10ml of 0.2 molar (M) Na2HPO4, 
10 ml of 0.1 M Citric Acid, 200µl of 50 milligram per litre (mg/L) OPD, and 8µl of 30% H2O2). 
The intensity of the colour produced is directly related to the VWF concentration present in the 
plasma. After 3 minutes the reaction was stopped by adding 4 M H2SO4 [sulphuric acid; 30 
microlitre per well (µl/well)]. The absorbance was then measured at 490 nanometre (nm) minus 











Africa). A standard curve of calibrated human plasma (WHO 6
th
 FVIII/VWF standard) was used as 
the standard against which the participant plasmas were measured. The accompanying Gen5 
software was used to analyse the data. Figure 4.1 illustrates the ELISA process for the VWF:Ag 
assay. 
“Results were expressed as percentages. The normal range for VWF:Ag levels that probably 
represents that of the general population in South Africa is from 50 to 150%. This correlates with 
reference ranges of other laboratories in literature. Each laboratory needs to use its own normal 
range with which to compare patient samples (Meiring et al. 2012).” 
This test is mostly used in the diagnosis of patients with suspected VWD. It is now frequently used 
for research studies as interest in VWF has increased significantly over the past few years. 
Figure 4.1 ELISA process for the VWF antigen assay Abbreviations: von Willebrand factor (VWF), ortho-
phenylenediamine (OPD). 
4.7.2 VWF collagen binding (VWF:CB) assay 
The VWF:CB assay is based on the ability of the larger multimers of VWF to preferentially bind to 
collagen. It is an ELISA-based assay and is done in conjunction with the VWF:Ag test. An ELISA 
plate was coated with 2.5 microgram per millilitre (µg/ml) Collagen type III in PBS. The 
participants’ plasma was added in the same concentration as with the VWF:Ag assay. The rabbit 
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anti-VWF antibody conjugated to peroxidase was added in a 1:3000 dilution in PBS. The same 
standard was used to measure the collagen binding activity. Figure 4.2 illustrates the test process. 
The values were also expressed as percentages. Again, the normal range for VWF:CB activity 
levels in the laboratory is from 50 to 150%. 
This test is frequently used as a screening test in patients with VWD. It assists with diagnosis of 
the subtype of VWD, especially that of types 2A and 2B VWD. It is used extensively in research 
related to VWF and VWD. 
Figure 4.2 ELISA method for the VWF collagen binding assay Abbreviations: von Willebrand factor (VWF),
phosphate buffered saline (PBS), ortho-phenylenediamine (OPD). 
4.7.3 ADAMTS13 antigen (ADAMTS13:Ag) assay 
This ELISA-based assay measures the level of the VWF-cleaving protease, ADAMTS13, in human 
plasma. 
An ELISA plate was coated overnight with a mouse monoclonal antibody against ADAMTS13 
(R&D Systems, 1:1000 dilution PBS, 100µl/well). The following morning, the plate was washed 
with PBS/0.1% Tween-20 and the plasma samples were added in duplicate (100 µl/well) in a 1:10 
dilution in PBS/2% bovine serum albumin (BSA), and incubated for 2 hours at 37ºC. This was 
followed by another wash step. Subsequently, a rabbit polyclonal immunoglobulin G (IgG) 
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antibody against ADAMTS13 (Santa Crux Biotechnology, CA, USA) was added (1:100 dilution) 
and incubated for 1 hour at room temperature. A polyclonal goat anti-rabbit antibody conjugated 
with horseradish peroxidase (HRP) was then added after another wash step and incubated for 1 
hour at room temperature. This antibody was added in a 1:2000 dilution. OPD (50mg/L) was used 
as the substrate for HRP (the same concentration as with the VWF levels). Once again, as 
described in the VWF antigen assay, a standard curve of calibrated human plasma (WHO 6
th
 
FVIII/VWF standard) was used as the standard against which the participants’ plasma samples 
were measured. Figure 4.3 depicts the ELISA process of this assay. 
Results are expressed as percentages. The ADAMTS13 assays lack international standardised 
ranges. The normal range is once again dependent on a number of factors and individual 
laboratories tend to devise their own normal range based on their testing. The normal range of our 
laboratory was between 50 – 150%. 
The ADAMTS13 antigen assay is used predominantly in the clinical setting for investigating 
patients with suspected TTP. As with VWF, the recent interest in ADAMTS13 has increased the 











Figure 4.3 ELISA procedure of the ADAMTS13 antigen assay Abbreviations: A Disintegrin and 
Metalloproteinase with a Thrombospondin type 1 motif, member 13 (ADAMTS13), immunoglobulin G (IgG), horseradish peroxidase 
(HRP), ortho-phenylenediamine (OPD). 
4.8 Data management and analysis 
All data collected from participants in the larger HIV-related young stroke study were entered in a 
Microsoft ACCESS programme. This programme enables the user to create a database. For my 
own study, a modified database was created using the Microsoft EXCEL programme. The database 
was prepared for analysis and any outstanding information obtained. A final thorough, and 
methodical data check procedure was undertaken prior to analysis to ensure that all data were 
entered correctly. 
Dr Maia Lesosky, a medical biostatistician based at the University of Cape Town, Department of 
Medicine, was consulted on several occasions for assistance with data analysis. She was consulted 
in the early phase of this study to assist with power calculations. At the end of my participant 
recruitment phase, she was once again consulted for assistance with data analysis. The following 
computer software packages were used for statistical analysis: Statistical Package for the Social 






Mouse monoclonal antibody against ADAMTS13 
Rabbit polyclonal IgG antibody against ADAMTS13 
Polyclonal goat anti-rabbit antibody conjugated with HRP 
ADAMTS13 















Sciences (SPSS) version 21 and Statistica version 11. The level of statistical significance was set at 
α = 0.05. 
 
4.9 Summary of methods: Flow diagrams of the study process 
 
The flow diagrams in figures 4.4 and 4.5 summarise the participant recruitment process, the 






































participants enrolled between August 2010 - August 2012 
(Pool of patients from which I selected participants for my smaller 
study) 
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HAART-naive 
48 
HIV positive controls 
on HAART 
Some patients 
referred to study 
were excluded 
because inclusion 
criteria not met. 
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attending doctor not 
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HIV positive controls 
7 excluded: 6 uncertain HIV 
status (no confirmatory data 
available) and 1 less than 18 years 
old (incorrect birth date) 
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HIV positive strokes 
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In this chapter, I shall describe the characteristics of the study participants. The basic demographic 
data, information regarding the stroke episode in those participants who suffered a stroke, details of 
co-morbidities and associated relevant medical history will be reported. In addition, the CD4 count 
of HIV positive participants and the physical characteristics of the participants will be presented. 
Using this information, I was able to determine how comparable the 3 participant groups were and 
to ascertain the presence of potential confounding factors or variables. 
 
5.1 Analysis of data 
 
The distribution of numerical variables was determined initially and thus the appropriate measures 
of central tendency and summary statistical analyses were applied depending on whether the data 
displayed symmetry or not i.e. were normally or non-normally distributed. Visual inspections of 
histograms, coupled with the interpretation of the Shapiro-Wilk test for normality, were used to 
assess whether data were normally distributed or not. We chose to use the findings of the Shapiro-
Wilk test over that of the Kolmogorov-Smirnov test of normality, as the former is more reliable in 
the setting of small sample sizes. Numeric data that were not normally distributed underwent log 
transformation and square root transformation in an attempt to normalise them and allow for the 
use of parametric statistical tests. However, none of the demographic variables displayed a normal 
distribution post transformation and thus non-parametric measures of central tendency such as the 





 quartile values. In addition, the Mann-Whitney U test was the non-parametric 
test used for the analysis of the non-symmetric numeric data to obtain inferential statistical data. 
 
Categorical variables were analysed as percentage distributions and Chi-Squared analysis was used 
to evaluate all categorical data for the presence of any statistically significant associations between 
these variables and the 3 participant groups. 
 
Results that are statistically significant or tending towards significance will be presented with their 
associated inferential statistic values accompanying them in the text and in the tables that follow. 
The following abbreviations will apply: p = p value, U = U statistic, r = effect size, χ
2
 = chi-












5.2 Participant characteristics 
 
5.2.1 Demographic characteristics (see tables 5.2, 5.3 and 5.4) 
A total of 100 participants were included in this study. The breakdown into the 3 main groups is 
indicated in table 5.1. 
 
 
HIV positive young 
stroke (HAART-
naïve) 
HIV negative young 
stroke 




No. of participants 20 40 40 100 
Table 5.1 Participant groups Abbreviations: highly active antiretroviral therapy (HAART), number (No.). 
 
The following demographic data were collected for all participants: age, sex, “race,” access to 
basic amenities, educational status and employment. Information regarding participants’ access to 
water and electricity, their type of dwelling, education level attained, and employment status 
helped us to characterise their socio-economic environment. Each demographic variable will be 
discussed next and the results are summarised in tables 5.2, 5.3 and 5.4. In all the sections that 
follow, the HAART-naïve HIV positive young stroke participants, HIV negative young stroke 
patients and the HIV positive HAART-naïve young non-stroke controls, will be referred to as HIV 
positive young stroke (HIV pos str), HIV negative young stroke (HIV neg str) and HIV positive 
young controls respectively (HIV pos con), for easier readability. There was no need to 
differentiate between ARV use as all our participants were HAART-naïve. 
 
a. Age, sex and “race” (see table 5.2) 
Age: Our definition of “young stroke” for this study was patients aged between 18 and 45 years. 
The participants’ ages ranged from age 19 to 45 years. Age data were not normally distributed. 
Median age for the entire sample was 35 years (IQR 30 – 38 years). The Mann-Whitney U test 
showed no significant differences between the 3 groups. 
 
Sex: The final sample comprised a total of 55 females and 45 males. All the subgroups displayed a 
predominance of female over male participants. Using Chi-Squared analysis, no statistically 













“Race”: Due to participant recruitment only being carried out at public health facilities and the 
specific areas in Cape Town from which we recruited, our participants were predominantly 
classified “Black”, with some “Coloured” participants. The past system of race 
classification/inequality and its current resonating effects, still have an influence on the 
demography of patients attending public health facilities in this country. Chi-Squared analyses 
showed that statistically significant differences existed when comparing the HIV positive young 
control group to both the HIV positive young stroke group [χ
2
 (1, n = 60) = 5.66, p = 0.017] and 
the HIV negative young stroke group [χ
2
 (1, n = 80) = 17.58, p < 0.0001] respectively. This was 
expected as the HIV positive young control group consisted only of individuals classified “Black” 
African. The HIV positive young stroke group and the HIV negative young stroke group did not 
differ significantly with respect to “race.” 
 
 
HIV pos str 
(n = 20) 
HIV neg str 
(n = 40) 
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(n = 40) 
All 
participants 













Mdn age (yrs) 
IQR (yrs) 
35 
29.5 - 36.8 
36.5 
30.5 - 41 
33.5 
29.3 - 38 
35 
30 - 38 



















p = 0.21 
χ2 = 5.66 
df = 1 
p = 0.017 
χ2 = 17.58 
df = 1 
p < 0.0001 
Table 5.2 Age, sex and “race” distribution Abbreviations: HIV positive young stroke (HIV pos str), HIV negative 
young stroke (HIV neg str), HIV positive young controls (HIV pos con), sample size (n), versus (vs.), median (Mdn), interquartile range 
(IQR), years (yrs), p value (p), chi-squared statistic (χ2), degrees of freedom (df). 
 
b. Domestic environment (see table 5.3) 
Home: Participants had to choose 1 of 5 types of dwelling to describe where they lived. The 
choices were a brick house, a flat, a backyard dwelling, a shack and or other option. Only one 
participant fell into the latter category as he was homeless. Most participants resided in brick 
houses (55%) and shacks (32%). The majority of HIV positive young stroke participants resided in 
shacks (45%). This is in stark contrast to the HIV negative young stroke participants, 75% of 
whom occupied brick houses. The HIV positive young controls displayed an almost even 
distribution of residency in brick houses (45%) and shacks (47.5%). Of the study participants who 
were HIV positive (n = 60), shacks (46.6%) and brick houses (41.6%) dominated as types of 
dwellings. Chi-Squared analysis showed that these between-group differences with regards to type 
of home lived in were statistically significant. Thus, HIV positive participants had poorer types of 












young stroke group [χ
2
 (4, n = 60) = 14.28, p = 0.006] and HIV negative young stroke vs. HIV 
positive young controls [χ
2
 (4, n = 80) = 14.32, p = 0.006]. 
 
Electricity: Participants indicated whether they had access to electricity or not at home. In both the 
HIV negative young stroke and HIV positive young control groups, 95% of the participants had 
access to electricity. However, only 75% of participants in the HIV positive young stroke group 
had access to electricity. There was thus a trend towards significance when comparing the HIV 
positive young stroke group to the HIV negative young stroke group [χ
2
 (1, n = 60) = 3.42, p = 
0.065] and when comparing the HIV positive young stroke group with the HIV positive young 
control group [χ
2
 (1, n = 60) = 3.42, p = 0.065]. Access to electricity was therefore less in the HIV 
positive young stroke group. 
 
Water: Participants had to identify which of these three water sources they had access to at home: 
an internal water source (a tap inside their home), external water source (a tap near the outside of 
their home that belonged to the participant) or a communal tap (a tap where multiple members of 
the community could fetch water from). There were statistically significant differences when 
comparing all 3 groups. The HIV negative young stroke group had the greatest access to internal 
water when compared with the HIV positive young stroke group [χ
2
 (2, n = 60) = 12.75, p = 0.002], 
as well as when compared with the HIV positive young control group [χ
2
 (2, n = 80) = 13.79, p = 
0.001]. The HIV positive young control group had better access to internal and external water 
sources when compared with the HIV positive young stroke group [χ
2
 (2, n = 60) = 6.80, p = 
0.033]. 
 
Toilet: Participants had to identify one of three options: an inside toilet (a toilet inside their home), 
an external toilet (a toilet outside their home that belonged to the participant) or a communal toilet 
(a toilet that was accessible to all members of the community). More than 50% of the participants 
had access to an internal toileting option, with the majority who did have access belonging to the 
HIV negative young stroke group. As with water accessibility, there were statistically significant 
between-group differences. The results showed that toilets inside the home were mainly accessible 
to the HIV negative young stroke group. HIV negative young stroke group vs. HIV positive young 
stroke group [χ
2
 (2, n = 60) = 6.02, p = 0.049] and HIV negative young stroke group vs. HIV 
positive young control group [χ
2













In summary, participants in the HIV negative young stroke group had better access to basic 




HIV pos str 
(n = 20) 
HIV neg str 
(n = 40) 
HIV pos 
con 
(n = 40) 
All 
participants 
(n = 100) 
HIV pos str 
vs.  
HIV neg str 
HIV pos str 
vs. 
HIV pos con 
HIV neg str 
vs. 































χ2 = 14.28 
df = 4 
p = 0.006 
p = 0.28 
χ2 = 14.32 
df = 4 
















χ2 = 3.42 
df = 1 
p = 0.065 
χ2 = 3.42 
df = 1 
p = 0.065 





















χ2 = 12.75 
df = 2 
p = 0.002 
χ2 = 6.80 
df =2 
p = 0.033 
χ2 = 13.79 
df = 2 





















χ2 = 6.02 
df = 2 
p = 0.049 
χ2 = 7.22 
df = 2 
p = 0.027 
χ2 = 15.04 
df = 2 
p = 0.001 
Table 5.3 Domestic environment A frequency count is given, with percentages in parentheses. Abbreviations: HIV positive 
young stroke (HIV pos str), HIV negative young stroke (HIV neg str), HIV positive young controls (HIV pos con), sample size (n), 
versus (vs.), not applicable (NA), p value (p), chi-squared statistic (χ2), degrees of freedom (df). 
 
c. Education and employment (see table 5.4) 
Data regarding schooling and employment status were also used as indicators of participants’ 
education level and their capacity/ability to be economically active. 
 
Highest level of education attained: Participants were asked to indicate the highest level of 
education they had attained at the time of enrolment into the study. The options ranged from no 
schooling to university level education. 78% of all the participants completed high school i.e. 12 













Employment status: Participants were asked to comment on whether they were employed at the 
time of enrolment into the study. No differences were detected when performing between-group 
comparisons. Despite more than 75% of the total group completing high school, just under two-
thirds of participants were employed (63%). 
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HIV neg str 
(n = 40) 
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participants 
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p = 0.64 p = 0.92 p = 0.25 
Table 5.4 Education and employment status A frequency count is given, with percentages in parentheses. 
Abbreviations: HIV positive young stroke (HIV pos str), HIV negative young stroke (HIV neg str), HIV positive young controls (HIV 
pos con), sample size (n), versus (vs.), not applicable (NA), p value (p), primary (prim), technical (tech). 
 
5.2.2 Stroke characteristics (see table 5.5) 
This section only applies to those 60 participants who had had a stroke. The characteristics of these 
participants’ strokes are discussed next and summarised in table 5.5. 
 
Oxfordshire Community Stroke Project (OCSP) classification: The OCSP classification is used 
to classify strokes into 4 categories based on the blood vessel territory of the cerebral circulation 
that is involved. It aids in clinical localisation and is also useful for prognostic purposes. A full 
description was provided in chapter 1 (see section 1.2.3). 
 
Our stroke participants displayed a predominance of strokes classified into the LACI and PACI 
categories, 40% and 31.7% respectively. These are the stroke categories normally associated with a 
better prognosis. Close to half (47.5%) of all the HIV negative young stroke participants had 
strokes classified as LACI, whereas only a quarter (25%) of the HIV positive young stroke 
participants were categorised in the LACI group. Both groups had a similar distribution of PACIs, 
30% and 35%, for the HIV negative and HIV positive young stroke groups, respectively. Of the 












respectively. The remaining distribution amongst the HIV positive young stroke group was equal, 
with both TACI and POCIs representing 20% of the remaining participants each. We could infer 
from the OCSP classification that the majority of the HIV negative young stroke group participants 
had a good prognosis following their stroke. Chi-Squared analysis showed no statistically 
significant between-group differences when the pooled combination of the various OSCP 
classifications in each group were analysed. 
 
Stroke cause: In our study, the cause of a stroke was determined after investigative work-up 
according to standard guidelines as described in chapter 4 (section 4.6), and all cases were 
reviewed by experienced neurologists. 
 
In our study, stroke aetiology was varied. Chi-Squared analysis showed a statistically significant 
difference between the HIV positive young stroke group and HIV negative young stroke group [χ
2
 
(9, n = 60) = 19.46, p = 0.022]. In the HIV negative young stroke group, almost half (42.5%) of the 
participants’ were classified into the “idiopathic” group. This means that despite undergoing a 
comprehensive diagnostic work-up, the cause of the stroke was still unidentified. 8 participants 
(20%) and 7 participants (17.5%) in the HIV negative young stroke group had strokes that were 
attributable to a cardio-embolic source and dissection, respectively. Hypertensive small vessel 
disease (7.5%), Takayasu’s arteritis (2.5%), neurosyphilis (2.5%), varicella vasculopathy (2.5%), 
an occluded internal carotid artery (2.5%), and large vessel atherosclerosis (2.5%) accounted for 
the remainder of the causes in the HIV negative young stroke group. In the HIV positive young 
stroke group, similar to the HIV negative young stroke group, close to one half (45%) of 
participants had no identified cause for their stroke. Therefore they are considered to be afflicted 
with a HIV-associated “idiopathic” stroke, and the entity of HIV-associated vasculopathy 
furthermore accounted for stroke causation in three of the participants classified into the HIV-
associated “idiopathic” stroke group. In 30% of HIV positive stroke participants, a varicella 
vasculopathy was identified as the cause of their stroke. This was confirmed by the presence of 
varicella zoster virus in the CSF. The remaining causes included cardio-embolic stroke (10%), 
neurosyphilis (10%) and aortic aneurysm (5%) for the HIV positive young stroke group. 
 
Using Chi-Squared analysis, dissection [χ
2
 (1, n = 7) = 3.96, p = 0.047] and varicella vasculopathy 
[χ
2
 (1, n = 7) = 9.78, p = 0.002] were the two causes that were found to be statistically significantly 
different between the 2 groups, with dissection only in the HIV negative young stroke group, and 













Of the sixty stroke participants, no cause could be found in 43.3% of the cases. The second most 
common cause of stroke was cardio-embolism (16.67%). As discussed in chapter 1, the aetiology 
of stroke in both HIV positive and HIV negative groups differs, but it is evident in our study group 
that “idiopathic” stroke still occupies a large piece of the stroke causation puzzle in young stroke 
patients. 
 
Stroke complications: Out of the total 60 stroke participants, three patients had had a 
complication that had arisen secondary to their stroke. Of these three, two patients (one from either 
stroke group) died as a result of the extensive neurological impact of their stroke, and one HIV 
negative stroke participant suffered a malignant middle cerebral artery infarct with cerebral 
oedema and a depressed level of consciousness. 
 
 
HIV pos str 
(n = 20) 
HIV neg str 
(n = 40) 
All stroke 
participants 
(n = 60) 
HIV pos str  
vs. 




























hypertensive small vessel disease 
Takayasu’s arteritis 
aortic aneurysm 
occluded internal carotid artery 


































χ2 = 19.46 
df = 9 
















2 (3.33 %) 
p = 0.69 
Table 5.5 Stroke characteristics A frequency count is given, with percentages in parentheses. Abbreviations: HIV positive 
young stroke (HIV pos str), HIV negative young stroke (HIV neg str), sample size (n), versus (vs), Oxfordshire Community Stroke 
Project (OCSP), lacunar infarct (LACI), partial anterior circulation infarct (PACI), total anterior circulation infarct (TACI), posterior 













5.2.3 Co-morbidities and relevant medical history (see tables 5.6, 5.7, 5.8 and 5.9) 
a. Chronic diseases 
The presence of certain co-morbidities, chronic diseases, known stroke risk factors, and a relevant 
past medical and family history were ascertained in all participants. Many of the chronic conditions 
known to influence stroke risk and aetiology have already been described in the literature review of 
this thesis (see chapter 1, section 1.2). I will briefly describe the distribution of these conditions in 
our participants. The statistical analysis of these variables is presented in table 5.6. 
 
Hypertension (HPT): The diagnosis of HPT is according to the criteria presented in the South 
African hypertension guideline 2011 (Seedat et al. 2011). Stroke participants were classified as 
having HPT if they had a diagnosis of HPT prior to their stroke episode or if they were diagnosed 
during their hospital admission for stroke management. Control participants were classified as 
suffering from hypertension if they were previously known to be hypertensive at the time of 
enrolment into the study. Blood pressure measurements for control participants were only 
performed on the day of enrolment and therefore any elevated blood pressure readings were not 
considered an indicator of HPT as they may have been spuriously elevated. These patients were, 
however, advised to report to their nearest primary health care facility for repeat blood pressure 
measurements. 
 
Only 20% of all participants had diagnosed HPT at the time of enrolment into the study. Chi-
Squared analysis showed a significant between-group difference when comparing the HIV 
negative young stroke group to HIV positive young control group [χ
2
 (1, n = 80) = 4.78, p = 0.029]. 
More participants in the HIV negative young stroke group had HPT, than those in the HIV positive 
young control group. 
 
Diabetes: The diagnosis of diabetes is based on the criteria for diagnosis of diabetes found in the 
2012 Society for Endocrinology, Metabolism and Diabetes of South Africa (SEMDSA) revised 
guideline for the management of type 2 diabetes (Amod et al. 2012). Similar to the classification of 
HPT, stroke participants were classified as having diabetes if they already had a diagnosis of 
diabetes prior to their stroke episode or if they were diagnosed during their hospital admission. 
Control participants were classified as suffering from diabetes if they were previously known to be 
diabetic at the time of enrolment into the study. A fasting blood glucose test performed on control 













Only 7% of all participants had been diagnosed with diabetes at the time of enrolment into the 
study. All of these belonged to the HIV negative young stroke group. This brought about a 
significant difference when comparing the between-group diabetes prevalence in the HIV negative 
young stroke group to the HIV positive young control group [χ
2
 (1, n = 80) = 5.64, p = 0.018]. 
 
Peripheral vascular disease (PVD): Participants were asked whether they had a known diagnosis 
of PVD and questioned about signs and symptoms associated with PVD if not diagnosed with the 
condition. None of the participants was known to have peripheral vascular disease at the time of 
enrolment. 
 
Elevated cholesterol: This was diagnosed according to the South African dyslipidaemia guideline 
consensus statement (Klug et al. 2012). Only one participant was identified as having elevated 
cholesterol at enrolment. This participant belonged to the HIV negative young stroke group and as 
expected there were no statistically significant between-group differences. 
 
Cardiovascular disease (CVD): Only 2 out of 20 HIV positive young stroke patients had CVD 
(10%) and 6 out of 40 HIV negative young stroke patients had CVD (15%). The types of 
cardiovascular disease varied, and included coronary artery disease, cardiomyopathy, valvular 
heart disease, rheumatic heart disease, aortic aneurysm and even cardiac injury secondary to a 
previous praecordial stab. None of the HIV positive control participants had CVD. HIV negative 
young stroke participants therefore had significantly more diagnoses of CVD than the HIV positive 
young control group [χ
2
 (1, n = 80) = 4.51, p = 0.034]. 
 
 
HIV pos str 
(n = 20) 
HIV neg str 
(n = 40) 
HIV pos con 
(n = 40) 
All 
participants 
(n = 100) 
HIV pos str  
vs. 
HIV neg str 
HIV pos str  
vs. 
HIV pos con 
HIV neg str  
vs. 
HIV pos con 
HPT 3 (15%) 13 (32.5%) 4 (10%) 20 (20%) p = 0.26 p = 0.89 
χ2 = 4.78 
df =1 
p = 0.029 
Diabetes 0 7 (17.5%) 0 7 (7%) p = 0.12 NA 
χ2 = 5.64 
df =1 
p = 0.018 
Elevated 
cholesterol 
0 1 (2.5%) 0 1 (1%) p > 0.99 NA p > 0.99 
CVD 2 (10%) 6 (15%) 0 8 (8%) p = 0.89 p = 0.20 
χ2 = 4.51 
df = 1 
p = 0.034 
Table 5.6 Co-morbidities and relevant medical history A frequency count is given, with percentages in 
parentheses. Abbreviations: HIV positive young stroke (HIV pos str), HIV negative young stroke (HIV neg str), HIV positive young 
controls (HIV pos con), sample size (n), versus (vs.), not applicable (NA), hypertension (HPT), cardiovascular disease (CVD), p value 












b. Other co-morbid diseases 
Apart from chronic illness, the presence of other co-morbid diseases that could have influenced our 
results, were collected. These diseases are discussed below. 
 
Current TB: The manifestations of infection with TB can influence stroke risk and the 
coagulation profile as described in chapter 1 (see section 1.3.3). Five participants were known to be 
infected with TB at the time of study enrolment. They were all confirmed TB positive on sputum 
microscopy. Two participants each were divided amongst the HIV negative young stroke group 
and HIV positive young control group respectively. The remaining TB sufferer was in the HIV 
positive young stroke group. There were no statistically significant differences between the groups 
with regards to current TB infection. 
 
Coagulopathy: Only one participant in the HIV positive young stroke group reported the presence 
of a previous coagulation problem viz. a DVT. None of the participants had any history of a 
coagulation disorder. Thus the groups were similar. 
 
Cancer: One of the participants in the HIV negative young stroke group suffered from 
oesophageal cancer. 
 
c. Previous stroke history 
A history of a previous stroke was documented in all participants and its prevalence is discussed 
below. Table 5.7 summarises this information. 
 
Previous stroke: 4 participants had experienced a previous stroke prior to enrolment into this 
study. They all belonged to the HIV negative young stroke group and there were no statistically 
significant between-group differences. 
 
 
HIV pos str 
(n = 20) 
HIV neg str 
(n = 40) 
HIV pos con 
(n = 40) 
All 
participants 
(n = 100) 
HIV pos str 
vs. 
HIV neg str 
HIV pos str 
vs. 
HIV pos con 
HIV neg str 
vs. 
HIV pos con 
Previous 
stroke 
0 4 (10%) 0 4 (4%) p = 0.36 NA p = 0.12 
Table 5.7 Previous stroke history A frequency count is given, with percentages in parentheses. Abbreviations: HIV positive 
young stroke (HIV pos str), HIV negative young stroke (HIV neg str), HIV positive young controls (HIV pos con), sample size (n), 













d. Smoking, alcohol and substance use history 
Cigarette smoking and excessive alcohol intake are both known risk factors for stroke. A history of 
illegal substance use was also obtained. However, these data should be interpreted with some 
caution as participants might have withheld or denied such information for fear of legal action. Our 
findings are described next and the data are summarised in table 5.8. 
 
Smoking: A total of 44% of all study participants were current smokers at the time of enrolment. 
HIV negative young stroke participants displayed the highest percentage of current smokers 
(52.5%). This was followed by a 45% prevalence of smoking among HIV positive controls and the 
lowest prevalence of 25% amongst the HIV positive young stroke participants. Chi-Squared 
analysis showed no statistically significant between-group differences. 
 
Alcohol use: Current alcohol use peaked in HIV positive controls at a prevalence of 57.5%, with 
42.5% and 35% prevalence in the HIV negative young stroke and HIV positive young stroke 
groups respectively. Similar to current smoking, close to 50% of study participants were using 
alcohol at the time of enrolment. Statistical analysis revealed no statistically significant between-
group differences. 
 
Substance use: Use of illegal substances, as reported by study participants, was minimal. A total 
of 5 participants used illegal substances, 2 of whom were in the HIV negative young stroke group 
and 3 in the HIV positive young control group. Substances used were limited to marijuana and 
cocaine. Once again, no statistically significant differences were identified between the groups. 
 
 
HIV pos str 
(n = 20) 
HIV neg str 
(n = 40) 
HIV pos con 
(n = 40) 
All 
participants 
(n = 100) 
HIV pos str 
vs. 
HIV neg str 
HIV pos str 
vs. 
HIV pos con 
HIV neg str 
vs. 
HIV pos con 
Smoking 5 (25%) 21 (52.5%) 18 (45%) 44 (44%) p = 0.080 p = 0.22 p = 0.65 
Alcohol use 7 (35%) 17 (42.5%) 23 (57.5%) 47 (47%) p = 0.78 p = 0.17 p = 0.26 
Substance 
abuse 
0 2 (5%) 3 (7.5%) 5 (5%) p = 0.80 p = 0.53 p > 0.99 
Table 5.8 Smoking, alcohol and substance use history A frequency count is given, with percentages in 
parentheses. Abbreviations: HIV positive young stroke (HIV pos str), HIV negative young stroke (HIV neg str), HIV positive young 













e. Family history 
Data with regards to a family history of stroke and coronary artery disease (CAD) were also 
collected from participants. This is summarised in table 5.9. 
 
Family history of stroke: 14% of the total study participants reported a family history of stroke. 
Chi-Squared analysis revealed no statistically significant between-group differences. 
 
Family history of CAD: Only 6 % of all participants reported any family history of CAD, with no 
statistically significant between-group differences with regards to a family history of CAD. 
 
 
HIV pos str 
(n = 20) 
HIV neg str 
(n = 40) 
HIV pos con 
(n = 40) 
All 
participants 
(n = 100) 
HIV pos str 
vs. 
HIV neg str 
HIV pos str 
vs. 
HIV pos con 
HIV neg str 
vs. 








1 (5%) 4 (10%) 1 (2.5%) 6 (6%) p = 0.87 p = 0.80 p = 0.36 
Table 5.9 Family history of stroke and CAD A frequency count is given, with percentages in parentheses. 
Abbreviations: HIV positive young stroke (HIV pos str), HIV negative young stroke (HIV neg str), HIV positive young controls (HIV 
pos con), sample size (n), versus (vs.), coronary artery disease (CAD), p value (p). 
 
5.2.4 Laboratory investigations (see table 5.10) 
CD4 count: This was ascertained for all HIV positive participants. All except one participant had a 
recent CD4 count measured from or on the day of their stroke occurrence/or enrolment into the 
study. The 1 exception belonged to the HIV positive young control group. The remaining HIV 
positive control participants had a CD4 count measured on the day of enrolment into the study (day 
0). The one participant in whom no count was obtained did, however, have a recorded CD4 count 
296 days before enrolment into the study. We opted to exclude this participant from any analysis 
involving CD4 counts as the result was outdated. All the HIV positive stroke participants had had a 
CD4 count measured within a period from day 0 to day 15 following their stroke onset. The 
majority of the CD4 counts in this group were measured within the first seven days following the 
stroke. Only 2 participants had CD4 counts measured on day 8 and day 15 following the stroke 
episode, respectively. 
 
The CD4 count distribution for all the HIV positive participants included in this analysis (n = 59) 












stroke group and HIV positive young control group were plotted separately. The median CD4 
count for the 59 HIV positive participants included in this analysis was 326 cells per cubic 
millimetre (cells/mm
3
). The Mann-Whitney U test showed a tendency towards a statistically 
significant difference between the two HIV positive young participant groups (U = 271.5, p = 0.06, 
r = 0.25). The median CD4 count for the HIV positive young stroke group was 234 cells/mm
3
, with 
the median CD4 count of the HIV positive young control group (n = 39) being 383 cells/mm
3
. The 
IQR for both groups were also different. This shows that the HIV positive young stroke group 




HIV pos str 
(n = 20) 
HIV pos con 
[n = 39 (40-1)] 
All HIV positive 
participants 
[n = 59 (60-1)] 
HIV pos str 
vs. 




100.8 - 381.3 
383 
205 - 520 
326 
160 - 451 
U = 271.5 
p = 0.058 
r = 0.25 
Table 5.10 CD4 count Abbreviations: HIV positive young stroke (HIV pos str), HIV negative young stroke (HIV neg str), HIV 
positive young controls (HIV pos con), sample size (n), versus (vs.), interquartile range (IQR), cells per cubic millimetre (cells/mm3), p 
value (p), U statistic (U), effect size (r). 
 
5.2.5 Physical characteristics of participants (see tables 5.11 and 5.12) 
Weight: Despite our protocol requiring all participants to be weighed on the day of enrolment, a 
total of 8 participants had missing weight measurements. The weights for the 92 participants who 
were weighed did not show a symmetrical distribution, as did the weight measurements of the 3 
groups individually. The median weight of all was 69 kilograms (kg) (IQR 61 – 85kg). The weights 
of the HIV positive young stroke group were significantly different from those of the HIV negative 
young stroke group [Mann-Whitney U test (U = 160, p = 0.014, r = 0.34)]. The HIV positive 
young stroke participants (Mdn = 61kg, IQR 51.6 – 72kg) weighed significantly less than their 
counterparts in the HIV negative young stroke group (Mdn = 76.5kg, IQR 64 - 86.3kg). 
 
 
HIV pos str 
(n = 15) 
HIV neg str 
(n = 38) 
HIV pos con 
(n = 39) 
All 
participants 
(n = 92) 
HIV pos str 
vs. 
HIV neg str 
HIV pos str 
vs. 
HIV pos con 
HIV neg str 
vs. 




51.6 - 72 
76.5 
64 - 86.3 
65 
60.5 - 89 
69 
61 - 85 
U = 160 
p = 0.014 
r = 0.34 
p = 0.14 p = 0.19 
Table 5.11 Weight Abbreviations: HIV positive young stroke (HIV pos str), HIV negative young stroke (HIV neg str), HIV 
positive young controls (HIV pos con), sample size (n), versus (vs.), interquartile range (IQR), kilograms (kg), p value (p), U statistic 












Body mass index (BMI): We calculated the BMI of our participants in order to obtain a better 
overall estimate of participants’ body habitus. Participants were assigned to one of four groups: 
underweight (BMI < 18.5), normal weight (BMI = 18.5 - 24.9), overweight (BMI = 25 – 29.9) or 
obese (BMI ≥ 30). We were unable to calculate the BMI for eight of our participants due to lack of 
either a weight or height measurement. From table 5.12 we can see that close to half of the HIV 
positive participants had normal BMI, 46.67% and 43.59% in the HIV positive young stroke and 
HIV positive young control group respectively. The numbers of normal weight and obese 
participants were similar in the HIV negative young stroke group (14 and 15 respectively). In both 
the HIV negative young stroke group and the HIV positive young control group, more than 50% of 
the participants whose BMI was measured were categorised into the overweight and obese group. 
Due to the varying BMI levels, data were not symmetrically distributed, with the median for the 
total group just reaching the overweight range (Mdn = 25.4, IQR 21.4 - 30.5). The Mann-Whitney 
U test comparing the median BMI of the HIV positive young stroke group with that of the HIV 
negative young stroke group, tended towards significance (U = 179, p = 0.036, r = 0.29). Using 
Chi-Squared analysis, no statistically significant differences were found when the distribution of 
the different BMI categories in all three participant groups was compared to one another. 
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(n = 15) 
HIV neg str 
(n = 38) 
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All 
participants 
















18.5 - 28 
26.8 
22.3 - 31.9 
25.2 
21.5 - 30 
24.5 
21.4 - 30.5 
U = 179 
p = 0.036 
r = 0.29 































p = 0.086 p = 0.13 p = 0.88 
Table 5.12 BMI A frequency count is given, with percentages in parentheses. Abbreviations: HIV positive young stroke (HIV pos 
str), HIV negative young stroke (HIV neg str), HIV positive young controls (HIV pos con), sample size (n), versus (vs.), body mass 
index (BMI), median (Mdn), interquartile range (IQR), p value (p), U statistic (U), effect size (r). 
 
5.2.6 Participant characteristics for the “idiopathic” stroke groups 















HIV positive young 
“idiopathic” stroke 
HIV negative young 
“idiopathic” stroke 
Total “idiopathic” stroke 
participants 
No. of participants 9 17 26 
Table 5.13 “Idiopathic” stroke participant groups Abbreviation: number (No.) 
 
All the statistical analyses that have been carried out on the three main participant groups described 
in sections 5.2.1 – 5.2.5 have been carried out on this subset of participants. The median age for the 
total “idiopathic” stroke group is 36 years (IQR 32 – 42 years). The participant characteristics were 
found to be very similar to their counterpart groups which include all stroke causes, i.e. the HIV 
positive young stroke group and the HIV negative young stroke group. None of the subject 
characteristics was found to be significantly different when performing between-group 
comparisons for the “idiopathic” stroke groups. 
 
5.3 Summary of participant characteristics 
 
All three of the participant groups were comparable with regards to age and sex. 
 
Obvious discrepancies existed in relation to home circumstances and access to basic amenities with 
HIV positive individuals bearing the brunt of a poor socio-economic status. 
 
The presence of any co-morbid diseases did not prove to be statistically significantly different 
when conducting between-group comparisons amongst the two stroke groups and amongst that of 
the two HIV positive groups. There were, however, statistically significant co-morbid disease 
differences between the HIV negative young stroke group and the HIV positive young control 
group, but they did not affect our study as we did not conduct any comparisons between these two 
groups for our hypotheses. 
 
There were no significant differences when comparing current alcohol use, smoking and substance 
use amongst the three groups. 
 
There were no significant differences when comparing a family history of stroke or CAD between 













HIV negative participants were nutritionally better off than HIV positive participants. Weight and 
BMI measurement showed that HIV negative participants weighed significantly more and had 
higher BMI values than their HIV positive counterparts. 
 
Stroke causation varied amongst the two stroke groups, but stroke classification was not 
significantly different between the two groups. Complications secondary to stroke were also rare in 
our study participants. 
 
The between-group comparison of the CD4 count between the two HIV positive groups tended 




The results of all biological data needed to be interpreted in the context of the participants’ 
background, their social environment and their medical history. We will therefore discuss the 

















In this chapter I shall first describe the distribution of the test results of VWF and ADAMTS13 for 
the entire participant population (n = 100). I shall then present the results of the tests for the 
individual hypotheses comparing the three participant groups: HIV positive young stroke (n = 20), 
HIV negative young stroke (n = 40) and HIV positive young controls (n = 40). 
 
6.1 Analysis of data 
 
This was carried out as described in chapter 4 (see section 4.8) and chapter 5 (see section 5.1). 
Based on an inspection of the frequency distribution histograms of the data and the Shapiro-Wilks 
tests for normality, neither VWF nor ADAMTS13 data were normally distributed. Log 
transformation of the VWF antigen (VWF:Ag) assay results resulted in a normal distribution of 
these data, but neither log transformation nor square root transformation of the VWF collagen 
binding (VWF:CB) and ADAMTS13 antigen (ADAMTS13:Ag) data resulted in normalisation of 
these data. We therefore used non-parametric tests to analyse all the data relating to the 
hypotheses. Results that were statistically significant or tending towards significance will be 
presented with their associated inferential statistic values in the text and in the tables that follow. 






None of the variables that were considered to be possible confounders in our study was 
significantly different when conducting between-group analyses (see chapter 5). It was therefore 
not necessary to control for the influence of these confounding variables when testing our 
hypotheses. 
 
6.2 Overall results (see table 6.1) 
 
This section compares all the results of the 100 participants for each test performed. All results are 
presented as a percentage, with 50 - 150% being the normal range (see chapter 4, section 4.7) All 
descriptive statistics for the individual tests are summarised in table 6.1. Figure 6.1 depicts the 













6.2.1 VWF:Ag assay 
This quantitative assay measures the actual amount of VWF in the participant’s plasma. A 
frequency plot of VWF showed an asymmetric distribution, with the graph skewed to the left. The 
median was 134.5% (IQR 103.3 – 178%) and falls within the normal range. However, when 
categorised according to the frequency distribution around the normal range, two fifths of all 
participants had values that were outside the normal range. The majority of these abnormal results 
(n = 40) were above normal values (>150%). 
 
6.2.2 VWF:CB assay 
Larger VWF multimers preferentially bind to collagen. The VWF:CB assay is thus a functional 
assay that quantifies the ability of the large multimers of VWF to bind to collagen (Meiring et al. 
2007). Results were asymmetrically distributed and skewed to the left. The median was 84.5% 
(IQR 52.3 - 134.5%). Despite a median and IQR within the normal range, once again, just over two 
fifths of the total group of participants had abnormal values. Of the latter, approximately half were 
above the upper limit of normal of 150% and half were below the lower limit of normal of 50%. 
 
6.2.3 ADAMTS13:Ag assay 
This test measures the level of ADAMTS13 in human plasma. The results were distributed 
asymmetrically and markedly skewed to the left. The median was 0% (IQR 0 - 41.5%) for all 
participants. This was due to a “floor effect.” Only 7 participants had values that were within the 




(n = 100) 
VWF:CB assay 
(n = 100) 
ADAMTS13:Ag assay 
(n = 100) 
Median (%) 134.5 84.5 0 
IQR (%) (25th – 75th quartile) 103.3 - 178 52.3 - 134.5 0 - 41.5 
Range (%) (minimum – maximum) 48 - 427 0 - 294 0 - 1075 
% values within normal range 
(50% - 150 %) 
60% 59% 7% 
% values > 150% 39% 19% 15% 
% values < 50% 1% 22% 78% 
Table 6.1 Overall test results Abbreviations: von Willebrand factor (VWF), A Disintegrin and Metalloproteinase with a 
Thrombospondin type 1 motif, member 13 (ADAMTS13), VWF antigen (VWF:Ag), VWF collagen binding (VWF:CB), ADAMTS13 














Figure 6.1 A comparison of the median values of the three assays for all 100 participants 
Abbreviations: von Willebrand factor (VWF), A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13 
(ADAMTS13), VWF antigen (VWF:Ag), VWF collagen binding (VWF:CB), ADAMTS13 antigen (ADAMTS13:Ag). 
 
6.3 Results of hypotheses 
 
Box and whisker plots will be used to illustrate the results graphically. Figure 6.2 is a key to 




























6.3.1 Hypothesis 1 
Hypothesis 1: HIV positive young stroke participants would have a pro-thrombotic coagulation 
profile characterised by higher levels of VWF compared with HIV negative young stroke 
participants. This hypothesis was tested by measuring the quantity of VWF in the plasma of these 
two groups using the VWF:Ag assay. 
 
Participant numbers in each group: 




HIV positive n = 20 
HIV negative n = 40 
All young strokes n = 60 
Table 6.2 Number of participants in each group for hypothesis 1 
 
Distribution of results for all young strokes (n = 60): 
 Not normally distributed. 
 Range: 70 - 374% 
 Median = 138.5% 
 IQR (25th - 75th quartile): 111.3 – 182% 
 
Distribution of results for individual young stroke groups: 
The VWF levels of the individual young stroke groups were also not normally distributed, with a 
bimodal distribution in the HIV positive young stroke group (n = 20) and skewing to the left in the 
HIV negative young stroke group (n = 40). The median VWF level in the HIV positive young 
stroke group was elevated above the upper limit of the normal range, whereas the median of the 
HIV negative young stroke group remained within the upper limits of the normal range. 
 
Hypothesis testing: The two groups were significantly different [Mann-Whitney U test (U = 263, 
p = 0.032, r = 0.28)]. Outlier values were identified in our study sample. However, even after 
performing the analysis with those values excluded, our findings were very similar and we 
therefore chose to include the outliers in our final analysis. Table 6.3 summarises the results and 














HIV positive young 
stroke 
(n = 20) 
HIV negative young 
stroke 
(n = 40) 
All stroke 
participants 
(n = 60) 
HIV positive young 
stroke 
vs. 
HIV negative young 
stroke 
Median (%) 173.5 135 138.5 
U = 263 
p = 0.032 
r = 0.28 
IQR (%) 
(25th – 75th quartile) 
 
118.3 - 215.5 
 
107.5 - 168 
 




83 - 374 
 
70 - 327 
 
70 - 374 
Table 6.3 VWF:Ag assay results for all stroke participants Abbreviations: von Willebrand factor (VWF), VWF 
antigen (VWF:Ag), sample size (n), versus (vs.), interquartile range (IQR), p value (p), U statistic (U), effect size (r). 
 
 
Figure 6.3 Comparison of VWF:Ag assay levels between the two stroke groups * Indicates outlier 
values. Abbreviations: von Willebrand factor (VWF), VWF antigen (VWF:Ag). 
 
Hypothesis 1 is confirmed: HIV positive young stroke participants have higher levels of VWF 













Hypothesis 1a: HIV positive young stroke participants whose stroke was “idiopathic” (i.e. could 
not be attributed to any other identifiable cause) would have a pro-thrombotic coagulation profile 
characterised by higher levels of VWF compared with HIV negative young stroke participants 
whose stroke was also “idiopathic.” 
 
Participant numbers in each group: 
 Participant group 
Number of 
participants 
Percentage of total 
young strokes  
Young “idiopathic” 
strokes 
HIV positive n = 9 45% 
HIV negative n = 17 42.5% 
All young 
“idiopathic” strokes 
n = 26 43.3% 
Table 6.4 Number of participants in each group for hypothesis 1a 
 
Distribution of results for all young “idiopathic” strokes (n = 26): 
 Non-normal, skewed distributed. 
 Range: 70 - 327% 
 Median = 142% 
 IQR (25th - 75th quartile): 112.5 – 198% 
 
Distribution of results for individual young “idiopathic” stroke groups: 
The VWF levels for the individual young “idiopathic” stroke groups were non-normally 
distributed. The median for the HIV positive young “idiopathic” stroke group is above the upper 
limit of normal at 175% (IQR 122.5 – 203%), whereas that of the HIV negative young “idiopathic” 
stroke group falls within the normal range at 139% (IQR 103.5 - 187.5%). These values are similar 
to that seen in hypothesis 1 for all young stroke participants. 
 
Hypothesis testing: There was no statistically significant difference between the two groups when 
a Mann-Whitney U test was performed. The presence of outliers did not change our findings and 
were therefore included in the final analysis. Table 6.5 summarises the results and figure 6.4 














HIV positive young 
“idiopathic” strokes 
(n = 9) 
HIV negative young 
“idiopathic” strokes 
(n = 17) 
All “idiopathic” 
stroke participants 
(n = 26) 
HIV positive young 
“idiopathic” strokes  
vs. 
HIV negative young 
“idiopathic” strokes 
Median (%) 175 139 142 
p = 0.35 
IQR (%) 
(25th – 75th quartile) 
122.5 - 203 103.5 - 187.5 112.5 - 198 
Range (%)  
(minimum – maximum) 
102 - 234 70 - 327 70 - 327 
Table 6.5 VWF:Ag assay results for all “idiopathic” stroke participants Abbreviations: von Willebrand 
factor (VWF), VWF antigen (VWF:Ag), sample size (n), versus (vs.), interquartile range (IQR), p value (p). 
 
 
Figure 6.4 Comparison of VWF:Ag assay levels between the two “idiopathic” stroke groups          
* Indicates outlier values. Abbreviations: von Willebrand factor (VWF), VWF antigen (VWF:Ag). 
 
Hypothesis 1a is not confirmed: In the “idiopathic” stroke groups, the VWF:Ag levels of the HIV 













6.3.2 Hypothesis 2 
Hypothesis 2: HIV positive young stroke participants would have a pro-thrombotic coagulation 
profile characterised by higher levels of VWF compared with HIV positive young non-stroke 
control participants. This was determined using the VWF:Ag assay. 
 
Participant numbers in each group: 





Strokes n = 20 
Non - stroke n = 40 
All young HIV positive n = 60 
Table 6.6 Number of participants in each group for hypothesis 2 
 
Distribution of results for all young HIV positive (n = 60) 
 Not normally distributed, skewing to the left 
 Range: 48 – 427% 
 Median = 134.5% 
 IQR (25th - 75th quartile): 102 – 193% 
 
Distribution of results for individual HIV positive groups: 
Distribution of the VWF levels in the HIV positive young non–stroke control group was 
asymmetrical and remained within the upper limit of the normal range. The bimodal distribution in 
the HIV positive young stroke group was mentioned earlier under hypothesis 1 (see section 6.3.1). 
 
Hypothesis testing: The two groups were not significantly different, but tended close to statistical 
significance [Mann-Whitney U test (U = 280.5, p = 0.061, r = 0.24)]. Calculations with and 
without outlier values did not change the results. We therefore included the outliers in our final 














HIV positive young 
stroke 
(n = 20) 
HIV positive young 
controls 
(n = 40) 
All HIV positive 
participants 
(n = 60) 
HIV positive young 
stroke 
vs. 
HIV positive young 
controls 
Median (%) 173.5 129 134.5 
U = 280.5 
p = 0.061 
r = 0.24 
IQR (%) 
(25th – 75th quartile) 
118.3 - 215.5 94.8 - 175 102 - 193 
Range (%)  
(minimum – maximum) 
83 - 374 48 - 427 48 - 427 
Table 6.7 VWF:Ag assay results for all HIV positive participants Abbreviations: von Willebrand factor 
(VWF), VWF antigen (VWF:Ag), sample size (n), versus (vs.), interquartile range (IQR), p value (p), U statistic (U), effect size (r). 
 
 
Figure 6.5 Comparison of VWF:Ag assay levels between the two HIV positive groups * Indicates 
outlier values. Abbreviations: von Willebrand factor (VWF), VWF antigen (VWF:Ag). 
 
Hypothesis 2 is not confirmed: HIV positive young stroke participants do not have higher levels 
of VWF compared with HIV positive young non-stroke control participants. However, the 













6.3.3 Hypothesis 3 
Hypothesis 3: HIV positive young stroke participants would have a pro-thrombotic coagulation 
profile characterised by higher levels of VWF activity compared with HIV negative young stroke 
participants. This was measured using the VWF:CB assay. 
 






HIV positive n = 20 
HIV negative n = 40 
All young strokes n = 60 
Table 6.8 Number of participants in each group for hypothesis 3 
 
Distribution of results for all young strokes (n = 60): 
 Not normally distributed. 
 Range: 0 - 294% 
 Median = 68.5% 
 IQR (25th - 75th quartile): 42.8 – 112% 
 
Distribution of results for all young strokes (n = 60): 
For the individual stroke groups, the data were asymmetrically distributed, with pronounced 
skewing to the left. The medians for both individual stroke groups remained within the normal 
range. Both groups had 25
th
 percentiles values that were extremely close; 42% in the HIV positive 
young stroke group, and 42.8% in the HIV negative young stroke group. These lower than normal 
25
th
 percentile values were in keeping with the overall low value for the total stroke participant 
group. Their individual 75
th
 percentile values did, however, differ markedly; 166% in the HIV 
positive young stroke group, and 108.8% in the HIV negative young stroke group. We therefore 
see a slight deviation above normal limits in those individuals infected with HIV and suffering 
from stroke simultaneously. 
 
Hypothesis testing: Despite these differences, the two groups were not statistically significantly 
different. This finding held true when the analysis was conducted with and without outlier values. 














HIV positive young 
stroke 
(n = 20) 
HIV negative young 
stroke 
(n = 40) 
All stroke 
participants 
(n = 60) 
HIV positive young 
stroke 
vs. 
HIV negative young 
stroke 
Median (%) 81 67.5 68.5 
p = 0.37 
IQR (%) 
(25th – 75th quartile) 
42 - 166 42.8 - 108.8 42.8 - 112 
Range (%) 
(minimum – maximum) 
0 - 294 0 - 277 0 - 294 
Table 6.9 VWF:CB assay results for all stroke participants Abbreviations: von Willebrand factor (VWF), VWF 
collagen binding (VWF:CB), sample size (n), versus (vs.), interquartile range (IQR), p value (p). 
 
 
Figure 6.6 Comparison of VWF:CB assay levels between the two stroke groups * Indicates outlier 
values. Abbreviations: von Willebrand factor (VWF), VWF collagen binding (VWF:CB). 
 
Hypothesis 3 is not confirmed: HIV positive young stroke participants do not have higher levels 
of VWF activity compared with HIV negative young stroke participants. On these criteria, 
therefore, HIV positive young stroke participants did not have a pro-thrombotic coagulation profile 













Hypothesis 3a: HIV positive young stroke participants whose stroke was “idiopathic” would have 
a pro-thrombotic coagulation profile characterised by higher levels of VWF activity compared with 
HIV negative young stroke participants whose stroke was “idiopathic.” 
 
Participant numbers in each group: 





HIV positive  n = 9 
HIV negative  n = 17 
All young idiopathic 
strokes 
n = 26 
Table 6.10 Number of participants in each group for hypothesis 3a 
 
Distribution of results for all “idiopathic” young strokes (n = 26): 
 Non-normal, skewed distributed. 
 Range: 0 - 294% 
 Median = 78% 
 IQR (25 - 75th quartile): 54 – 100% 
 
Distribution of results for individual young “idiopathic” stroke groups: 
The distributions of the individual young “idiopathic” stroke groups were also non-normal. The 
median for the individual HIV positive and HIV negative young “idiopathic” stroke groups were 
both within the normal limits at 85% (IQR 58.5 - 157.5%) and 68% (IQR 53.5 - 93.5%), 
respectively. These values are similar to that seen in hypothesis 3 for all stroke participants. 
 
Hypothesis testing: There was no statistically significant difference between the two groups upon 
completion of a Mann-Whitney U test. Table 6.11 summarises the results and figure 6.7 depicts 














HIV positive young 
“idiopathic” strokes 
(n = 9) 
HIV negative young 
‘idiopathic” strokes 
(n = 16) 
All “idiopathic” 
stroke participants 
(n = 26) 
HIV positive young 
“idiopathic” strokes 
vs. 
HIV negative young 
“idiopathic” strokes 
Median (%) 85 68 78 
p =  0.26 
IQR (%) 
(25th – 75th quartile) 
58.5 - 157.5 53.5 - 93.5 54 - 100 
Range (%) 
(minimum – maximum) 
13 - 294 0 - 150 0 - 294 
Table 6.11 VWF:CB assay results for all “idiopathic” stroke participants Abbreviations: von Willebrand 
factor (VWF), VWF collagen binding (VWF:CB), sample size (n), versus (vs.), interquartile range (IQR), p value (p). 
 
 
Figure 6.7 Comparison of VWF:CB assay levels between the two “idiopathic” stroke groups         
* Indicates outlier values. Abbreviations: von Willebrand factor (VWF), VWF collagen binding (VWF:CB). 
 
Hypothesis 3a is not confirmed: In the “idiopathic” stroke groups, the VWF activity (VFW:CB 















6.3.4 Hypothesis 4 
Hypothesis 4: HIV positive young stroke participants would have a pro-thrombotic coagulation 
profile characterised by higher levels of VWF activity compared with HIV positive young non-
stroke control participants. This was measured using the VWF:CB assay. 
 
Participant numbers in each group: 





Strokes n = 20 
Non - stroke n = 40 
All young HIV positive n = 60 
Table 6.12 Number of participants in each group for hypothesis 4 
 
Distribution of results for all young HIV positive (n = 60): 
 Not normally distributed, skewing to the left 
 Range: 0 – 294% 
 Median = 102.5% 
 IQR (25th - 75th quartile): 60 – 154.3% 
 
Distribution of results for individual HIV positive groups: 
The VWF:CB assay results in the HIV positive young non-stroke control group were normally 
distributed. However, the VWF:CB assay results in the HIV positive young stroke group were non- 
normally distributed. Both groups had median values within the normal range. The IQRs of the two 
groups did not differ much, with the 25
th
 percentile value of the HIV positive young stroke group 
only slighter below the normal limit at 42%. 
 
Hypothesis testing: The two groups were not significantly different. Table 6.13 summarises the 














HIV positive young 
stroke 
(n = 20) 
HIV positive young 
controls 
(n = 40) 
All HIV positive 
participants 
(n = 60) 
HIV positive young 
stroke 
vs. 
HIV positive young 
controls 
Median (%) 81 107 102.5 
p = 0.26  
IQR (%) 
(25th – 75th quartile) 
42 - 166 68.5 - 154.3 60.3 - 154.3 
Range (%)  
(minimum – maximum) 
0 - 294 0 - 270 0 - 294 
Table 6.13 VWF:CB assay results for all HIV positive participants Abbreviations: von Willebrand factor 
(VWF), VWF collagen binding (VWF:CB), sample size (n), versus (vs.), interquartile range (IQR), p value (p). 
 
 
Figure 6.8 Comparison of VWF:CB assay levels between the two HIV positive groups Abbreviations: 
von Willebrand factor (VWF), VWF collagen binding (VWF:CB). 
 
Hypothesis 4 is not confirmed: HIV positive young stroke participants do not have higher levels 
of VWF activity compared with HIV positive young non-stroke control participants. On these 
criteria, therefore, HIV positive young stroke participants did not have a pro-thrombotic 













6.3.5 Hypothesis 5 
Hypothesis 5: HIV positive young stroke participants would have a pro-thrombotic coagulation 
profile characterised by lower levels of ADAMTS13 compared with HIV negative young stroke 
participants. This was measured using the ADAMTS13:Ag assay. 
 
Participant numbers in each group: 




HIV positive n = 20 
HIV negative n = 40 
All young strokes n = 60 
Table 6.14 Number of participants in each group for hypothesis 5 
 
Distribution of results for all young strokes (n = 60): 
 Not normally distributed. 
 Range: 0 - 674% 
 Median = 0% 
 IQR (25th -75th quartile): 0 – 5.5% 
A value of 0% does not necessarily mean that the participant has no ADAMTS13 present in their 
plasma, but it does imply that the amount is very low and is not detectable with the test we used. 
 
Distribution of results for individual young stroke groups: 
Both groups were non-normally distributed and skewed to the left. The medians of the two groups 
were both 0% and IQRs were both low. However the IQR (0 - 1.5%) of the HIV positive young 
stroke group indicated that ADAMTS13 levels in those participants were mostly non-detectable. In 
addition, the maximum ADAMTS13 level detected in the HIV positive young stroke group was 
measured at 674%. This value is in stark contrast to the maximum value of 123% measured in the 
HIV negative young stroke group. We can therefore see that none of the HIV negative young 
stroke participants had an excess amount of ADAMTS13 in their peripheral blood. 
 
Hypothesis testing: Mann-Whitney U analysis revealed no statistically significant difference 
between the two stroke groups. Table 6.15 summarises the results and figure 6.9 depicts them in a 













HIV positive young 
stroke 
(n = 20) 
HIV negative young 
stroke 
(n = 40) 
All stroke 
participants 
(n = 60) 
HIV positive young 
stroke 
vs. 
HIV negative young 
stroke 
Median (%) 0 0 0 
p = 0.71 
IQR (%) 
(25th – 75th quartile) 
0 - 1.5 0 - 6 0 - 5.5 
Range (%)  
(minimum – maximum) 
0 - 674 0 - 123 0 – 674 
Table 6.15 ADAMTS13:Ag assay results for all stroke participants Abbreviations: A Disintegrin and 
Metalloproteinase with a Thrombospondin type 1 motif, member 13 (ADAMTS13), ADAMTS13 antigen (ADAMTS13:Ag), sample 
size (n), versus (vs.), interquartile range (IQR), p value (p). 
 
 
Figure 6.9 Comparison of ADAMTS13:Ag levels between the two stroke groups * Indicates outlier 
values. Abbreviations: A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13 (ADAMTS13), 
ADAMTS13 antigen (ADAMTS13:Ag). 
 
Hypothesis 5 is not confirmed: HIV positive young stroke participants do not have lower levels 
of ADAMTS13 compared with HIV negative young stroke participants. On these criteria, 
therefore, HIV positive young stroke participants did not have a pro-thrombotic coagulation profile 













Hypothesis 5a: HIV positive young stroke participants whose stroke was “idiopathic” would have 
a pro-thrombotic coagulation profile characterised by lower levels of ADAMTS13 compared with 
HIV negative young stroke participants whose stroke was “idiopathic.” This was measured using 
the ADAMTS13:Ag assay. 
 
Participant numbers in each group: 





HIV positive  n = 9 
HIV negative  n = 17 
All young idiopathic 
strokes 
n = 26 
Table 6.16 Number of participants in each group for hypothesis 5a 
 
Distribution of results for all “idiopathic” young strokes (n = 26): 
 Non-normal, skewed distributed. 
 Range: 0 - 123% 
 Median = 0% 
 IQR (25th - 75th quartile): 0 – 3% 
 
Distribution of results for individual young “idiopathic” stroke groups: 
The distribution of the ADAMTS13:Ag levels for the individual “idiopathic” stroke groups was 
also non-normal as in hypothesis 5. The median for the HIV positive young “idiopathic” stroke 
group and the HIV negative young “idiopathic” stroke group are both equal to 0% with extremely 
small IQRs for both individual groups. 
 
Hypothesis testing: Statistical analysis with a Mann-Whitney U test did not reveal any statistically 
significant difference between the two groups. Table 6.17 summarises the results and figure 6.10 

















(n = 9) 
HIV negative young 
“idiopathic” strokes 
(n = 17) 
All “idiopathic” 
stroke participants 
(n = 26) 
HIV positive young 
“idiopathic” strokes  
vs. 
HIV negative young 
“idiopathic” strokes 
Median (%) 0 0 0 
p = 0.43 
IQR (%) 
(25th – 75th quartile) 
0 - 0 0 - 6 0 - 3 
Range (%) 
(minimum – maximum) 
0 - 123 0 - 48 0 - 123 
Table 6.17 ADAMTS13:Ag assay results for all “idiopathic” stroke participants Abbreviations: A 
Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13 (ADAMTS13), ADAMTS13 antigen 
(ADAMTS13:Ag), sample size (n), versus (vs.), interquartile range (IQR), p value (p). 
 
 
Figure 6.10 Comparison of the ADAMTS13:Ag levels between the two “idiopathic” stroke 
groups * Indicates outlier values. Abbreviations: A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 
13 (ADAMTS13), ADAMTS13 antigen (ADAMTS13:Ag). 
 
Hypothesis 5a is not confirmed: In the “idiopathic” stroke groups, the ADAMTS13:Ag levels of 













6.3.6 Hypothesis 6 
Hypothesis 6: HIV positive young stroke participants would have a pro-thrombotic coagulation 
profile characterised by lower levels of ADAMTS13 compared with HIV positive young non-
stroke control participants. This was measured using the ADAMTS13:Ag assay. 
 
Participant numbers in each group: 





Strokes n = 20 
Non - stroke n = 40 
All young HIV positive n = 60 
Table 6.18 Number of participants in each group for hypothesis 6 
 
Distribution of results for all young HIV positive (n = 60): 
 Not normally distributed, skewing to the left 
 Range: 0 – 1075% 
 Median = 0% 
 IQR (25th - 75th quartile): 0 – 165.8% 
 
Distribution of results for individual HIV positive groups: 
The ADAMTS13 distributions of the individual young HIV positive groups were also not normal. 
The median value of 23.5% for the HIV positive young control group is in stark contrast to that of 
the median of 0% in the HIV positive young stroke group. The IQRs also differed remarkably 
when comparing the two groups, as did the range of values. One of the participants in the HIV 
positive young control group had a value of 1075%. This was the highest value of all the 
participants and was seven times the upper limit of the normal range. The HIV positive young 
controls appeared to have higher plasma levels of ADAMTS13 compared with their HIV positive 
counterparts with stroke. Despite this difference, it is important to note that the HIV positive young 
control group still had a median value that was substantially lower than the lowest limit of the 
normal range of 50%. 
 
Hypothesis testing: The two groups were significantly different [Mann-Whitney U test (U = 262, 












significant results that were similar to the results presented here, and thus the decision was made to 
include the outlier values in our final analysis. Table 6.19 summarises the results and figure 6.11 
depicts them in a box and whisker plot. 
 
ADAMTS13:Ag assay 
HIV positive young 
stroke 
(n = 20) 
HIV positive young 
controls 
(n = 40) 
All HIV positive 
participants 
(n = 60) 
HIV positive young 
stroke 
vs. 
HIV positive young 
controls 
Median (%) 0 23.5 0 
U = 262 
p = 0.018 
r = 0.31 
IQR (%) 
(25th – 75th quartile) 
0 - 1.5 0 - 240.8 0 - 165.8 
Range (%)  
(minimum – maximum) 
0 - 674 0 - 1075 0 - 1075 
Table 6.19 ADAMTS13:Ag assay results for all HIV positive participants Abbreviations: A Disintegrin 
and Metalloproteinase with a Thrombospondin type 1 motif, member 13 (ADAMTS13), ADAMTS13 antigen (ADAMTS13:Ag), 
sample size (n), versus (vs.), interquartile range (IQR), p value (p), U statistic (U), effect size (r). 
 
 
Figure 6.11 Comparison of ADAMTS13:Ag levels between the two HIV positive groups * Indicates 
outlier values. Abbreviations: A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13 (ADAMTS13), 
ADAMTS13 antigen (ADAMTS13:Ag). 
 
Hypothesis 6 is confirmed: HIV positive young stroke participants have lower levels of 












6.3.7 Hypothesis 7 
Hypothesis 7: Levels of VWF (7a) and VWF activity (7b) would be negatively correlated with 
CD4 counts in all HIV positive participants (with and without strokes) i.e. with advancing 
immunosuppression (lower CD4 counts), VWF levels would increase. ADAMTS13 levels (7c) 
would be positively correlated with CD4 counts in all HIV positive participants (with and without 
strokes) i.e. with advancing immunosuppression (lower CD4 counts), ADAMTS13 levels would 
decrease. 
 
Participant numbers in each group: 
 Participant group 
Number of 
participants whose 
CD4 count was 
correlated with VWF 
Young HIV 
positive 
Strokes n = 20 
Non - stroke n = 39 
All young HIV positive n = 59 
Table 6.20 Number of participants in each group for hypothesis 7 
 
Results of the correlations and hypothesis testing: 
VWF levels in HIV positive participants were significantly negatively correlated with CD4 count 
[Spearman’s Rank Order correlation rs(59) = 0.36, p = 0.006] (see figure 6.12). This negative 
correlation remained significant when the analysis was performed in the HIV positive control 
group on its own. VWF activity was very weakly negatively correlated with CD4 count but did not 
reach statistical significance (7b). No obvious correlation existed between ADAMTS13 levels and 














Figure 6.12 VWF levels and CD4 count correlation in all HIV positive participants Abbreviations: 
von Willebrand factor (VWF), VWF antigen (VWF:Ag), cells per cubic millimetre (cells/mm3). 
 
Hypothesis 7a is confirmed: VWF levels in HIV positive participants are significantly negatively 













6.4 Summary of results of hypotheses 
 
Hypothesis 1, 6 and 7a were the three hypotheses that were found to be statistically significant. The 
HIV positive young stroke group had significantly higher VWF levels than the HIV negative 
young stroke group (U = 263, p = 0.032, r = 0.28). The HIV positive young stroke group had 
significantly lower levels of ADAMTS13 than the HIV positive young non-stroke control group (U 
= 262, p = 0.018, r = 0.31). VWF levels in HIV positive participants were significantly negatively 
correlated with CD4 count [Spearman’s Rank Order correlation rs(59) = 0.36, p = 0.006]. 
 
Hypothesis 2 came close to, but did not quite reach, significance (U = 280.5, p = 0.061, r = 0.24). 
The HIV positive young stroke group had a higher median level of VWF than the HIV positive 
young control group. 
 
Hypothesis 3, 4 and 5 were not proven to be statistically significant. In addition, the sub-


















In this chapter, I shall discuss the participant characteristics relating to the demographic findings, 
stroke presentation and associated medical findings of the 3 participant groups. 
 
7.1 Discussion of participant characteristics 
 
7.1.1 Demographic characteristics 
All three groups were comparable with regards to age and sex. A striking feature in the 
characterisation of the participants was the socio-economic differences between the HIV positive 
and HIV negative groups on all measures used (type of home, access t  electricity, water and toilet 
facilities). HIV positive participants had poorer socio-economic circumstances with poorer access 
to basic amenities. In the small population sample we have studied, HIV/AIDS is clearly linked to 
poverty and social deprivation. Interestingly, the HIV positive and HIV negative groups were 
comparable with regards to education and employment status i.e. they had similar total number of 
years of education and similar rates of employment/unemployment. In the South African context, 
number of years of education is not synonymous with quality of education. Twelve years of 
education in a school in a deprived area is not equivalent to schooling in a more affluent area. 
There were equal levels of employment/unemployment in both groups, but again, the type and 
quality of the employment was not specifically reported and could have differed markedly. 
 
7.1.2 Stroke characteristics 
There were 60 young stroke participants, 20 HIV positive and 40 HIV negative. The majority of 
stroke participants had strokes localised to lacunar vessels (LACI) or secondary to partial 
occlusions of the vessels in the anterior cerebral circulation (PACI). Posterior circulation infarcts 
(POCIs) and total anterior circulation infarcts (TACIs) were in the minority in both HIV positive 
and HIV negative stroke groups. Overall, the distribution of the different types of strokes was not 
significantly different in the two stroke groups. 
 
Cardio-embolism and carotid artery dissection were two common causes of stroke in our study and 
were commoner in HIV negative young strokes. This is consistent with the findings in the literature 












causation in younger adults, “idiopathic” causes accounted for a significant proportion (~ 40%) of 
all strokes (Griffiths et al. 2011). Despite a similar ratio of “idiopathic” stroke amongst the two 
stroke groups, other causes of stroke differed significantly. Unlike the HIV positive young stroke 
group, the HIV negative young stroke group had aetiologies that are commonly known causes of 
stroke and more frequently applicable to older stroke sufferers. These include hypertensive small 
vessel disease and large vessel atherosclerosis. The HIV positive young stroke group were 
significantly more likely to have varicella vasculopathy as a cause for their stroke. Infection with 
varicella zoster virus (VZV) is a known occurrence in HIV positive individuals, and its association 
with stroke causation has been previously described in children as well as in adults (Vafai et al. 
2001; De La Blanchardiere et al. 2000; Stanley et al. 2012). Nagel et al (2011) described 3 cases of 
stroke that were histologically confirmed to be secondary to varicella vasculopathy, with one 
participant having AIDS. Stanley et al. (2012) described a case from our hospital (Groote Schuur 
Hospital) of an aneurysmal vasculopathy-associated stroke in an HIV-infected individual with 
concomitant VZV. They emphasised the importance of investigating for the presence of VZV in 
these cases (Stanley et al. 2012). Our study confirms this increased frequency of varicella 
vasculopathy infection associated with stroke. 
 
Within the “idiopathic” causes for the HIV positive young stroke group, there were 3 participants 
who suffered a stroke attributable to HIV-associated vasculopathy. This represents 15% of our HIV 
positive young stroke participants and closely matches the 20% of HIV positive strokes attributed 
to HIV-associated vasculopathy in a study by Tipping et al. (2007) conducted at Groote Schuur 
Hospital. Our findings therefore add to the growing literature on this entity of HIV-related 
vasculopathy and its link with stroke. In conclusion, although the “idiopathic” groups were 
sizeable in both HIV positive and HIV negative young strokes, the HIV positive group had a 
greater diversity of causes, including VZV and HIV-associated vasculopathy. 
 
There were few observable complications associated with stroke in our study. This might relate to 
the fact that LACI and PACI strokes are generally associated with a good prognosis. 
 
7.1.3 Co-morbidities and relevant medical history 
When comparing HIV positive and HIV negative stroke groups, three traditional stroke risk factors 
viz. hypertension, diabetes and cardiovascular disease, were not significantly different. Nor was 
current TB infection or a previous coagulopathy different between the two groups. All three 
participant groups were comparable with respect to cigarette smoking, alcohol use and illegal 
substance use. We might have expected the latter to be higher in the HIV positive stroke group, 












risk and increased HIV infection. However, validity of the reports could be questioned, given the 
perceived legal implications on the part of the patient. 
 
7.1.4 CD4 count 
The median CD4 count for all the HIV positive participants was 326 cells/mm
3
. The cut-off CD4 
count for initiation of HAART in South Africa is < 350 cells/mm
3
, yet none of the participants had 
commenced treatment with ART yet. We had, of course, selected our participants on the basis of 
their being HAART-naïve, yet a substantial number of the HIV positive participants should have 
been eligible for HAART given their most recent CD4 count. Reasons for sub-optimal ART 
initiation in our participants included poor follow-up clinic attendance, lack of routine CD4 count 
monitoring at local clinics, fear of taking ART due to its side-effects and stigmata associated with 
its use. These facts reflect poorly on the state of the ARV roll-out plan in South Africa. We 
referred all eligible participants to their local clinic for the initiation of HAART. 
 
The evidence from the literature suggests that stroke in HIV infection tends to be associated with 
advanced immunosuppression and therefore lower CD4 counts (Dobbs et al. 2009). Our results 
tended to show that the HIV positive stroke group had lower median CD4 counts compared with 
HIV positive non-stroke controls (234 vs. 383 cells/mm
3
). The difference did not quite reach 
statistical significance (p = 0.058). 
 
7.1.5 Weight and BMI 
Median weights and median overall BMIs were lower in the HIV positive groups (stroke and non-
stroke) compared with the HIV negative young stroke group. The association between HIV and 
weight loss/wasting is well known, and BMI measurement is considered a useful prognostic tool in 
individuals with HIV (Wanke et al. 2000; Grinspoon et al. 2003; van der Sande et al. 2004). The 
higher obesity levels in the HIV negative young stroke group would also explain the greater 
prevalence of co-morbid hypertension, diabetes and CVD in this group. There were no significant 
differences when comparing HIV positive strokes with HIV positive controls. We might have 
expected more underweight individuals in the HIV positive stroke group, given the association 
between stroke and advanced disease. This was not the case. There were, however, 8 exclusions 
from the weight and BMI analyses (5 from the HIV positive young stroke group) because of lack 















For the most part, the differences between the groups were not entirely unexpected and many of 
our findings are consistent with those reported previously in the literature. There are three striking 
aspects with respect to the data on participant characteristics. Firstly, there are socio-economic 
discrepancies between HIV positive and HIV negative individuals and this reflects the need for 
social reform in South Africa itself. Secondly, more than 40%, a sizeable proportion of young 
strokes (both HIV positive and HIV negative) end up without an identified cause (“idiopathic”) 
despite extensive investigation. Finally, there are some stroke causes peculiar to HIV infection, 


















In this chapter, I shall firstly summarise the key findings and then discuss and interpret the results. 
 
8.1 Key findings 
 





HIV positive young stroke participants had significantly higher levels of VWF in their plasma 
(VWF:Ag) compared with HIV negative young stroke participants. 
In the subgroup analysis of “idiopathic” strokes, there was no significant difference in the VWF 
levels between the two groups (H1a). 
Hypothesis 2 
(H2) 
HIV positive young strokes tended to have high levels of VWF compared with HIV positive 
non-stroke controls. This tendency nearly reached statistical significance. 
Hypothesis 3 
(H3) 
There was no significant difference in the activity of VWF as measured using the VWF:CB 
assay between the young HIV positive and HIV negative stroke groups. 
In the subgroup analysis of “idiopathic” strokes, there was no significant difference in the VWF 
activity between the two groups (H3a). 
Hypothesis 4 
(H4) 
There was no difference between the HIV positive young stroke group and the HIV positive 
young non-stroke controls with regards to VWF activity as measured by the VWF:CB assay. 
Hypothesis 5 
(H5) 
ADAMTS13 levels were low in both HIV positive and HIV negative young stroke groups, but 
not significantly different when comparing the two groups. 
In the subgroup analysis of “idiopathic” strokes, there was also no significant difference in the 
ADAMTS13 levels between the two groups (H5a). 
Hypothesis 6 
(H6) 
The ADAMTS13 levels were significantly lower in the HIV positive young stroke group 
compared with the HIV positive non-stroke controls. 
Hypothesis 7 
(H7) 
CD4 count was negatively correlated with VWF levels in HIV positive participants (HIV 
positive young strokes and HIV positive non-stroke controls combined) (H7a). However, CD4 
count was not correlated with VWF activity (H7b) or ADAMTS13 levels (H7c) in HIV positive 
participants. 
Table 8.1 Key findings Abbreviations: von Willebrand factor (VWF), VWF antigen (VWF:Ag), VWF collagen binding 














8.2 Discussion of results 
 
8.2.1 VWF:Ag assay results 
The HIV positive young participants who had suffered a stroke had higher VWF levels in their 
plasma than the HIV negative young stroke participants (H1). This could mean that HIV positive 
individuals who have had a stroke have a hyper-coagulable/increased pro-thrombotic state 
compared with HIV negative young strokes. At the same time, HIV positive young stroke 
participants tended to have higher VWF levels compared with HIV positive non-stroke controls 
(H2). While the second finding did not quite reach statistical significance, the two results taken 
together suggest that stroke in the setting of HIV infection is associated with a hyper-coagulable 
state. These findings were established using the VWF:Ag assay, but were not confirmed using the 
VWF:CB assay (H3 and H4), which will be discussed later in section 8.2.2. 
 
The two important questions that have been raised by the findings of H1 and H2 are: 
1. What were the putative basal levels of VWF in the HIV positive and HIV negative 
participants with stroke, before the stroke occurred? 
2. Are they causal i.e. did the pro-thrombotic state precede and lead to stroke, or were the 
findings consequential upon the stroke. That is, did they result from the stroke itself e.g. as 
an acute phase reactant? 
 
Question 1 
Obviously, we did not have basal VWF levels for the stroke groups. Ideally, question 1 could only 
have been directly addressed had our study been a huge longitudinal cohort study. A baseline VWF 
level would then have been measured in non-stroke HIV positive and HIV negative participants 
and a repeat measurement would have followed in any participants who presented with a stroke. 
However, this would have required large participant numbers, with long-term follow-up. 
Ultimately, it would have been a very expensive study to execute. The lack of baseline VWF levels 
is therefore a limitation. However, the most practical alternative is to have an HIV positive non-
stroke control group in our study and to use an already defined population norm for a non-HIV 
non-stroke control group from a previous South African study (Meiring et al. 2012). The VWF 
levels in the HIV positive non-stroke control group acts as a surrogate baseline level for the HIV 
positive young stroke group, and the VWF levels in the HIV negative non-stroke group represents 
the putative baseline values of the HIV negative young stroke group. Ideally, of course, we would 
have liked the baseline norms of the HIV negative young stroke group to have been derived from 
the exact same population we studied. However, the values obtained from Prof Meiring’s study, 












Figure 8.1 represents a model to help understand question 1. In this graph, the findings of the 
VWF:Ag assays of all three participant groups, including the normal range of 50 - 150% based on 






Figure 8.1 Comparison of the median VWF levels of all participant groups measured using the 
VWF:Ag assay Median values are indicated at the median line, * indicates outlier values and                 shows the median change 
between groups. Abbreviations: von Willebrand factor (VWF), VWF antigen (VWF:Ag). 
 
From this model, we can see that HIV positive non-stroke controls had a median value of 129%, 
which, although greater than the normal median of 100% in a HIV negative, non-stroke population, 
was still within the normal range. 
 
This model, however, suggests that stroke is related to increased VWF levels in the following way: 
There were no major changes in VWF:Ag levels when a HIV negative young individual developed 
a stroke i.e. median of 100% increased to 135%. This reflects a small rise within the normal range 
only. However, the level of VWF in the HIV positive young stroke group was definitely greater 
The adjacent box indicates the normal 
range of 50 - 150% with a median of 
100% in a HIV negative non-stroke 
population 
150% 

















than that in HIV negative young strokes and statistically significantly different. Also, the median 
VWF levels in the HIV positive young stroke group were greater than that in the HIV positive non-
stroke control group, and the difference between these two groups tended close to statistical 
significance. 
 
Therefore stroke in HIV infection is associated with higher VWF levels and a pro-thrombotic state. 
 
Question 2 
Following on from question 1, we should like to know whether this pro-thrombotic state in HIV 
infection arose prior to the stroke or as a consequence of the stroke i.e. did it precede the stroke and 
was it causative, or was it secondary e.g. following an acute phase reaction? 
 
Figure 8.2 represents a model that attempts to answer this question. This model follows a 
hypothetical scenario whereby the VWF levels (based on our study findings and the previously 
accepted norms) are depicted in the progression from a HIV negative non-stroke state to a HIV-












Figure 8.2 Progression of VWF levels from a HIV negative non-stroke state to a HIV-infected 
stroke state Interquartile range is given in parentheses. Abbreviations: von Willebrand factor (VWF), A Disintegrin and 
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In addition, figure 8.3 aids the arguments that follow. It is a diagram that tracks VWF levels in 







Figure 8.3 Progression of VWF levels from an HIV negative non-stroke state to a HIV negative 
stroke state Interquartile range is given in parentheses. Abbreviations: von Willebrand factor (VWF), median (Mdn). 
 
Findings favouring a causative relationship for this pro-thrombotic state are as follows: 
The pro-thrombotic state in stroke with HIV infection is not a consequence of the stroke, because 
HIV negative individuals who develop a stroke had only a slightly raised VWF median level than 
those without stroke, but still within the normal range (see figure 8.3). When an HIV negative non-
stroke individual becomes infected with HIV, there is a slight increase from a median VWF level 
of 100% to 129%. This slight increase, however, remains within the normal range (see figure 8.2). 
A significant subsequent elevation from a median of 129 to 173% occurs in HIV-infected 
individuals with stroke (see figure 8.2). 
 
Infection with HIV therefore causes a slight rise in baseline VWF, still within the normal range. 
This rise in VWF may bring about a pro-thrombotic state that either results in a stroke or facilitates 
its advent with or without other causative factors. Aiding this causative theory are data indicating 
that raised VWF levels are associated with an increased risk for pro-thrombotic states (Sadler 
2005; Denis et al. 2012). There are, however, fewer data available on this association between 
VWF levels and thrombosis in HIV-infected individuals (Lafeuillade et al. 1992; Seigneur et al. 
1997). The majority of the literature is centred on the influence of ART on VWF levels (Wolf et al. 
2002; Aukrust et al. 2000; de Gaetano Donati et al. 2004; van Vonderon et al. 2009). Our findings 
now go one step further, reporting on HIV positive young individuals with stroke. They suggest 
that these individuals have a greater potential for a preceding hyper-coagulable state than their 
stroke counterparts who are not infected with HIV. Furthermore, from our demographic data, there 
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chapter 5, section 5.2.3). It is therefore reasonable to surmise that our findings are a function 
primarily of HIV infection. 
 
Also supporting a causal role for the pro-thrombotic state in stroke in HIV-infected individuals are 
the following: 
HIV infection is associated with a state of chronic immune activation (Appay et al. 2008). 
Therefore, elevated levels of “acute phase reactants,” such as ESR and CRP, have been noted in 
HIV-infected individuals (Nixon et al. 2010; Ndakotsu et al. 2009). VWF, an acute phase reactant 
itself, may therefore also be raised in the setting of chronic immune activation in HIV. However, it 
may be that only when the VWF levels reach a certain threshold/critical level, do they result in a 
pro-thrombotic state that may lead to complications which can include stroke. HIV positive stroke 
patients therefore represent a subgroup of HIV positive patients whose VWF levels have reached a 
critical pro-thrombotic level. 
 











Figure 8.4 VWF threshold/critical level model in HIV positive stroke Interquartile range is given in 
parentheses. Abbreviations: von Willebrand factor (VWF), A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, 
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However, a counter-argument to all of the previous theories can be made. This proposes that VWF 
elevation is secondary to an acute phase response following stroke and thus a consequence of 
stroke in HIV-infected individuals. The argument is as follows: 
The elevation in VWF in both stroke groups from an initial lower baseline (100 to 135% in the 
HIV negative young stroke group, and 129 to 173.5% in the HIV positive stroke group), may be 
due to the effects of the acute phase response that follows many acute illnesses. VWF has long 
been recognised as an acute phase reactant (Pottinger et al. 1989). This proposed consequential rise 
in VWF following a stroke may be secondary to an acute phase or inflammatory response initiated 
by the evolution of a stroke. The VWF median of 129% in the HIV positive non-stroke control 
group is within normal limits. Serial measurements following the initial baseline measurements 
would have allowed us to track any VWF progression, if present, in the HIV positive non-stroke 
control group. This would have allowed us to determine if it followed a similar course as other 
acute phase reactants in HIV infection. We did not have the resources to do this and this is a 
limitation of our study (see section 8.3). Therefore, the elevation in VWF levels measured post-
stroke in our study, may also have occurred secondary to the acute inflammatory reaction that 
follows a stroke (acute phase response). 
 
One possible way of resolving the question as to whether the findings are consequential upon the 
stroke, is to perform a kinetic study of VWF in the acute post-stroke phase. For example, it could 
be measured at 1, 3, 5 and 7 days post-stroke. Rapid rises and falls would favour the acute phase 
(consequential) explanation and a study of this kind should be considered in future research (see 
section 8.3). 
 
Despite these arguments, we also found additional data within our larger study that did not support 
the notion of an acute phase response being responsible for the elevated VWF levels: 
The elevated levels of acute phase reactants, such as ESR and CRP, as a result of the chronic 
immune activation conferred by HIV infection, have been mentioned earlier. CRP was not 
routinely tested in all our study participants. However, the ESR was measured in the majority of 
the participants. We performed a post-hoc analysis using the ESR measurements. Only ESR 
measurements performed within 7 days of stroke onset in the stroke participants and on day 0 of 
enrolment into the study for the HIV positive non-stroke control groups were used for the post-hoc 
analysis. Therefore, only 25 and 14 ESR measurements for the HIV negative young stroke group 
and the HIV positive young stroke group, respectively, could be used. ESR was measured in all 
HIV positive non-stroke control participants on day 0 (n = 40). The findings for the three 















young stroke  
(n = 14) 
HIV negative 
young stroke  
(n = 25) 
HIV positive 
young controls  











Median (mm/hr) 82 16 67 U = 48 
p < 0.0001 
r = 0.60 
p = 0.4 
IQR (mm/hr) 59 – 98 11 - 39 36 -107 
Table 8.2 ESR comparisons between the participant groups Abbreviations: erythrocyte sedimentation rate 
(ESR), millimetres per hour (mm/hr), sample size (n), versus (vs.), interquartile range (IQR), p value (p), U statistic (U), effect size (r). 
 
The table illustrates the ESR levels in all three participant groups. They were significantly elevated 
in the HIV positive young stroke group when compared with the HIV negative young stroke group 
[Mann-Whitney U test (U = 48, p < 0.0001, r = 0.60)]. The IQRs indicate that most of the ESR 
values in the HIV positive stroke group were much higher than the values in the HIV negative 
stroke group. Both HIV positive groups (stroke and non-stroke) had elevated ESRs. There was no 
significant difference when performing a between-group comparison of the HIV positive groups. 
Since ESR is elevated in the HIV positive individuals in our study, and the HIV negative stroke 
participants had significantly lower ESR values compared with the HIV positive stroke group, it 
does not appear that the acute phase response following a stroke could have caused the elevation in 
ESR in the HIV positive stroke group. 
 
Furthermore, post-hoc analysis correlating ESR with VWF showed that the ESR levels were not 
significantly correlated with VWF in either stroke groups. However, VWF was significantly 
positively correlated with ESR in all HIV positive participants [Spearman’s Rank Order correlation 
rs(54) = 0.57, p < 0.0001] and especially in the HIV positive non-stroke control group [Spearman’s 
Rank Order correlatio  rs(40) = 0.58, p < 0.0001] i.e. VWF levels increased as ESR levels 
increased (see figures 8.5 and 8.6). Therefore, VWF is positively associated with ESR in HIV 
positive participants. Thus, VWF behaves in a similar manner to ESR i.e. it is elevated in HIV 
infection due to the state of chronic immune activation and is independent of an acute stroke event. 
Elevated VWF levels observed in HIV positive participants following a stroke may well therefore 














Figure 8.5 ESR and VWF correlation in all HIV positive participants Abbreviations: erythrocyte 
sedimentation rate (ESR), millimetres per hour (mm/hr), von Willebrand factor (VWF), VWF antigen (VWF:Ag). 
 
 
Figure 8.6 ESR and VWF correlation in HIV positive non-stroke control group Abbreviations: 












Using data on stroke classification i.e. big (TACI and PACI) versus small stroke (LACI), we were 
able to investigate question 2 further. If the rise in VWF was part of an acute phase response to the 
stroke, then one might have expected larger strokes such as TACIs and PACIs to show a greater 
rise in VWF compared with small lacunar strokes as the inflammatory response could be expected 
to be larger in a bigger stroke. I did another post-hoc analysis comparing post-stroke VWF levels 
in big strokes (PACIs and TACIs) versus small strokes (LACIs) in all stroke participants (HIV 
positive and HIV negative). This showed no statistically significant differences in the VWF levels 
when comparing big with small strokes. These facts add to the argument favouring a causative 
relationship i.e. the pro-thrombotic profile preceded the stroke event. 
 
It may, however, be that this pro-thrombotic state seen in HIV infection both precedes stroke onset 
and also partly arises as a consequence of the stroke i.e. the two explanations may not be mutually 
exclusive. We need a larger study to answer this question. An ideal study would have been a large 
longitudinal prospective cohort study, in which baseline VWF and ADAMTS13 levels would be 
available for all participants. This, however, would have been impossibly large, expensive and 
require a long follow-up time. Practically, however, a 6 months post-stroke VWF measurement, 
allowing for the acute effects of stroke to subside, will have provided data that might have better 
reflected pre-stroke baseline levels (see section 8.3). 
 
Question 3 
Most of our data suggests a causative role for the pro-thrombotic state in HIV-associated stroke. 
The next question that arises is whether this rise in VWF levels preceding a stroke is a slow 
progressive one that follows infection with HIV or whether it results from a specific insult or 
insults at particular point(s) in time? 
 
We suggest the following model shown in figure 8.7. It proposes that this rise is multifactorial with 
the combination of a slow rise associated with advancing, untreated HIV infection and punctuated 
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This model shows the slow background rise in VWF, with advancing HIV and its concomitant 
declining CD4 count/worsening endothelial dysfunction, punctuated by acute insults. The latter 
may include superimposed opportunistic infections, haemostatic defects and HIV-related TTP 
which accelerates the rise in VWF. 
 
Data from our study favour the notion that the cause for this pro-thrombotic state is partly due to a 
slow steady rise in VWF following infection with HIV: 
CD4 count is often used as a proxy marker of immunosuppression and the decline in CD4 count is 
an indicator of advancing immunosuppression. We have shown that the CD4 counts of the HIV 
positive HAART-naïve participants in our study were negatively correlated with VWF levels 
(H7a). We can therefore surmise that as CD4 counts fall, VWF levels increase. Raised VWF levels 
are therefore a function of advancing immunosuppression. This has been noted previously by 
Lafeuillade et al. (1992) and Seigneur et al. (1997) who commented on the effects that higher viral 
loads and lower CD4 counts had on elevation of the VWF levels. Therefore, advancing 
immunosuppression represented by the usual slowly progressive decline in CD4 count in HIV 
infection (unless the CD4 count is rapidly lowered by an acute insult), may be the reason for the 
slow build-up of a pro-thrombotic state that precedes the stroke. 
 
Two other factors that support the notion of a slow progressive rise in VWF following infection 
with HIV are endothelial dysfunction and pro-inflammatory cytokine release: 
In HIV-infected individuals, endothelial dysfunction is a vascular disease process with a complex 
and as yet not fully understood aetiology (Subbarao et al. 2011; Monsuez et al. 2009). It is an 
insult that is multifactorial in aetiology and may worsen over time. VWF is a marker of endothelial 
dysfunction and raised levels in the HIV positive young stroke group may reflect the presence and 
evolution of this complex disease process. The HIV-induced inflammatory cascade which is a 
function of the chronic state of immune activation conferred by HIV infection [specifically CRP, 
tumour necrosis factor alpha (TNFα), interleukin 6 (IL-6)] and adhesion markers (ICAMs and 
VCAMs) have been linked to the pathogenesis of HIV-related endothelial dysfunction (Subbarao et 
al. 2011). 
 
Certain disease processes that are more likely to occur in the setting of HIV infection may prove to 
be the insults that tip the scales in favour of thrombosis and stroke presentation. While the 
difference between the CD4 counts only tended toward significance when comparing the two HIV 
positive participant groups, the median CD4 counts were lower in the HIV positive young stroke 
group compared with the HIV positive young controls (234 vs. 383 cells/mm
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advanced immunosuppression, reflected by the lower CD4 counts in the HIV positive young stroke 
group, coupled with the following additional insults, may account for the rise in VWF levels that 
led to a pro-thrombotic state: 
One of the very few predictable facts about HIV is that opportunistic infections become more 
prevalent as the CD4 count declines. It is a sign of increasing immunodeficiency (Kovacs et al. 
2000). A more abrupt increase in VWF may thus occur following an opportunistic infection(s) and 
the pro-inflammatory milieu they create. Defects in the haemostatic system e.g. protein C and 
protein S deficiency, that may lead to pro-thrombotic states in HIV-infected individuals, are known 
to correlate with the degree of immunosuppression measured by CD4 cell counts (Saif et al. 2001). 
Elevated VWF levels may be a function of these aberrant haemostatic processes. The effect of 
HIV-related TTP and decreased ADAMTS13 levels may also play a role, but will be discussed in 
section 8.2.3. 
 
Once again, our model must be investigated in a large longitudinal cohort study in order to verify 
our theories. 
 
8.2.2 VWF:CB assay results 
The intention of H3 and H4 were not to quantify the VWF levels as previously done in H1 and H2, 
but rather to provide an assessment of the functional activity of the VWF. The VWF:CB assay is 
therefore a surrogate test for the presence of ULVWF multimers. This, in turn, should reflect the 
thrombotic activity occurring in an individual as the ULVWF multimers are known to be 
functionally more haemostatically active and therefore pro-coagulant. 
 
The results for H3 and H4 did not mirror that which were found in H1 and H2. We had expected to 
see a similar pattern of results with the VWF:CB assay. However, both sets of results were not 
statistically significant with no between-group differences and with median values all within the 
normal range. 
 
The findings for VWF:CB tests of all three participant groups are summarised in the form of a box 
and whisker plot shown in figure 8.8. The median values for all three groups were within the 
normal range. 
 
One interpretation of these findings of similar VWF collagen binding activities is that levels of the 
larger VWF multimers were normal in all three participant groups. None of the groups therefore 












multimers. However, this does not exclude the possibility that other types of VWF molecules 
contribute to the elevated VWF levels found in the HIV positive young stroke group, as seen in 
H1. VWF molecules in the blood include an array of molecules of varying sizes. It is known that 
the ULVWF multimers are the most pro-thrombotic (see chapter 2, section 2.5.3), but all the other 
smaller molecules of VWF themselves are also conducive to clotting in various degrees. Therefore, 
had we measured all the forms of VWF for our participants, we might have identified a different 
form of VWF that could be associated with an even higher tendency for thrombosis in individuals 
with HIV. 
 
The results of our VWF:CB assay were verified using the same test with a different type of 
collagen from that described in the methods section. Both sets of results were similar. However, we 
also need to consider whether our results might have arisen due to some other technical difficulty 
when performing the test. This appears to be highly unlikely though, considering that the tests were 
conducted in a laboratory which routinely ran them and they were performed by personnel familiar 
with the methods. Could there be a substance in HIV-infected plasma, such as an auto-antibody 
perhaps, that is interfering with the collagen binding? To answer this, one would have to perform 



















Figure 8.8 Median VWF:CB assay values for all participant groups Median values are indicated at the 
median line, * indicates outlier values. Abbreviations: von Willebrand factor (VWF), VWF collagen binding (VWF:CB). 
 
8.2.3 ADAMTS13:Ag assay results 
The result of testing H5 was not statistically significant. We had initially stated that HIV positive 
young stroke sufferers would have lower levels of ADAMTS13 compared with HIV negative 
young stroke sufferers. Interestingly, what we detected was that both stroke groups had very low 
levels of ADAMTS13 with median values of 0% for both stroke groups. As mentioned previously, 
a value of 0% does not mean that there is a complete absence of ADAMTS13 in an individual’s 
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used. This implies that the occurrence of a stroke in HIV positive and HIV negative individuals is 
associated with a decrease in ADAMTS13 levels. 
 
In contrast, H6 was statistically significant. The HIV positive non-stroke control group already had 
considerably lower ADAMTS13 levels (23.5%) than the HIV negative non-stroke controls (100%). 
However, the 0% measurement in the HIV positive young stroke group proved to be significantly 
lower than the levels of HIV positive non-stroke control group (23.5%). 
 
The following important questions have been raised by the findings of H5 and H6: 
4. What were the basal levels of ADAMTS13 in the HIV negative and HIV positive stroke 
participants, before the stroke occurred? 
5. Why are the ADAMTS13 levels that have been measured in our stroke study participants 
at such low levels and are these findings causal i.e. did the low levels precede and lead to 
stroke, or were the findings consequential upon the stroke i.e. did they result from the 
stroke itself? 
6. What causes the low ADAMTS13 levels in HIV positive non-stroke individuals and why 
or how did they drop so much lower in HIV positive patients with stroke? 
 
Question 4 
We have already discussed the difficulties surrounding the lack of basal values for all three 
participant groups in our study in the VFW:Ag section of the discussion (see section 8.2.1). The 
same discussion applies here. Also, we used the same HIV negative non-stroke population for 
ADAMTS13 norms as we did for the VWF. 
 
Figure 8.9 is a suggested model to help understand question 4. In this graph, the findings of the 
ADAMTS13:Ag assays of all three participant groups, including the normal range of 50 - 150% 
















Figure 8.9 Comparison of the median ADAMTS13 levels of all participant groups measured 
using the ADAMTS13:Ag assay Median values are indicated at the median line, * indicates outlier values and           shows 
the median change between groups. Abbreviations: A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 
13 (ADAMTS13), ADAMTS13 antigen (ADAMTS13:Ag). 
 
From this model, we can see that the baseline median ADAMTS13 level in the HIV positive non-
stroke group (23.5%) was lower than the baseline in a HIV negative non-stroke control population 
(100%). This model suggests the presence of an even lower than normal baseline ADAMTS13 
level in HIV-infected non-stroke individuals compared with the baseline of an HIV negative non-
stroke population. The potential reasons for this will be discussed in question 6. 
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Our findings of a median ADAMTS13 value measured at 0% in both stroke groups, warrants 
further investigation. These data represent a “floor effect” i.e. the inability of the ELISA assay to 
detect very low levels of ADAMTS13 in the plasma. 
 
Another factor to consider is the effect that aberrant liver function may have on ADAMTS13 
levels, since it is known to be synthesised in the liver (see chapter 2, section 2.6.2). We did not 
perform routine liver function tests, but the INR was measured in 93 study participants. We 
reviewed these values post-hoc. INR is used in clinical practice as a marker of synthetic liver 
function, and after excluding INR values that were done after 7 days from stroke onset/enrolment 
and in patients on warfarin, the 80 remaining participants had INR values that were all within the 
normal range. We can therefore assume that the majority of our participants had normal synthetic 
liver function. Therefore, we can surmise that abnormal liver functioning was not the cause for the 
low ADAMTS13 levels in our study participants. 
 
To determine whether low levels of ADAMTS13 in the stroke groups were causative or 
consequential, the timelines in figure 8.10 and 8.11 have been devised. Figure 8.10 follows the 
hypothetical scenario whereby ADAMTS13 levels (based on our study findings and the previously 









Figure 8.10 Progression of ADAMTS13 levels from a HIV negative non-stroke state to a HIV-
infected stroke state Interquartile range is given in parentheses. Abbreviations: A Disintegrin and Metalloproteinase with a 
Thrombospondin type 1 motif, member 13 (ADAMTS13), thrombotic thrombocytopaenic purpura (TTP), median (Mdn). 
 
Figure 8.11 indicates the progressing ADAMTS13 levels in HIV negative participants from a non-
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Figure 8.11 Progression of ADAMTS13 levels from a HIV negative non-stroke state to a HIV 
negative stroke state Interquartile range is given in parentheses. Abbreviations: A Disintegrin and Metalloproteinase with a 
Thrombospondin type 1 motif, member 13 (ADAMTS13), thrombotic thrombocytopaenic purpura (TTP), median (Mdn). 
 
Low ADAMTS13 levels result in diminished cleavage of the pro-coagulant ULVWF multimers 
and may thus bring about a pro-thrombotic state. Plausible reasons favouring a causative 
relationship between this pro-thrombotic state and stroke causation are as follows: 
Prior to the stroke episode, the baseline levels of both non-stroke groups (HIV negative non-stroke 
and HIV positive non-stroke controls) might have been higher than when measured post-stroke. It 
may be that these stroke participants had been affected by some form of sub-clinical TTP, which 
had not been clinically identified earlier. This may account for the low ADAMTS13 levels and 
increased potential for thrombotic episodes. 
 
Other factors such as sepsis, DIC, liver disease, infection with plasmodium falciparum, 
transplantation and immunosuppres ion with cyclosporine and sickle cell disease are also known to 
cause low ADAMTS13 levels (Tsai 2010; Turner et al. 2012). These factors, however, were not 
known to be present in our study groups (see chapter 5). 
 
Zhao et al. (2009) and Fujioka et al. (2010) have explored the role of ADAMTS13 in murine 
models. Deficiency of ADAMTS13 in mice appears to increase the susceptibility of these animals 
to cerebral ischaemia and can exacerbate ischaemic brain injury, with infusion of ADAMTS13 
having a protective role to play in infarct size reduction. With the findings of low levels in both 
stroke groups, it may be that we are seeing a similar pattern of low levels of ADAMTS13 having 
caused an increased susceptibility of our human participants to cerebral ischaemia as seen in 
murine models. Stroke therefore occurs in a select group of patients whose ADAMTS13 levels fall 
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A post-hoc analysis comparing big versus small strokes described previously in the VWF:Ag 
discussion (see section 8.2.1, question 2), was also performed in relation to ADAMTS13 levels. It, 
too, showed no statistically significant differences between stroke sizes and ADAMTS13 levels. 
One might have expected larger strokes to show a greater drop in ADAMTS13 levels compared 
with smaller strokes due to the larger inflammatory response that might accompany a big stroke. 
These findings therefore tend to negate the explanation of a consequential inflammatory response 
and support a causative relationship for a pro-thrombotic state conferred by low ADAMTS13 
levels. 
 
However, a strong counter-argument favouring the notion of low ADAMTS13 levels being a 
consequence of an acute phase response following stroke is as follows: 
The levels of ADAMTS13 fall to low/undetectable levels in both HIV positive and HIV negative 
stroke groups. These findings support the idea that it is a reaction to the stroke. 
 
A kinetics study of ADAMTS13 in the acute post-stroke phase, like that of VWF described 
previously (see section 8.2.1, question 2), is a possible way of resolving the question of causality 
versus consequence and should be considered in future research (see section 8.3). 
 
Bongers et al. (2006) conducted the first study to measure ADAMTS13 in patients with ischaemic 
stroke. Using a different technique from the one used in our study, they found that levels of 
ADAMTS13 were slightly lower in patients with ischaemic stroke compared to controls. In 
addition, participants with the lowest levels of ADAMTS13 were at greater risk for stroke 
compared with participants who had the highest ADAMTS13 measurements (Bongers et al. 2006). 
They did not manage to determine if the reduced levels of ADAMTS13 was causative or 
consequential from their study. 
 
Lambers et al. (2013) reported that reduced ADAMTS13 activity posed a risk for the development 
of arterial ischaemic stroke in children. ADAMTS13 was measured 6-12 months following the 
stroke. ADAMTS13 activity was significantly lower in patients compared with controls. There 
were significantly more patients with ADAMTS13 levels below the 10th percentile in the stroke 
group compared with the control group (Lambers et al. 2013). It is important to note that this study 













Our study cannot answer the question of causation versus consequence with certainty, and the 




What causes the low ADAMTS13 levels in HIV positive non-stroke individuals and why or how 
did they drop so much lower in HIV positive patients with stroke? We have to consider that this is 
a function of infection with HIV itself. The virus itself may drive this initial drop by a variety of 
mechanisms. 
 
The findings of hypothesis 6 could be related to the concept of HIV-associated TTP. HIV-
associated TTP is a well-known entity (Blazes et al. 2004; Opie 2012; Novitzky et al. 2005; 
Gunther et al. 2007). Our findings of diminished ADAMTS13 levels in the HIV positive 
participants may be explained by this phenomenon, even in a sub-clinical form. Meiring et al. 
(2012) proposed a mechanism by which HIV-related TTP arises. She described a dynamic 
mechanism by which HIV infection itself results in increased cytokine release, micronutrient 
deficiency and the production of auto-antibodies to ADAMTS13. This, in turn, results in a cascade 
of events that interplay to create an environment of increased VWF synthesis, decreased 
ADAMTS13 synthesis and release by endothelium, and the production of inhibitory antibodies to 
ADAMTS13, with the subsequent haematological events that give rise to HIV-associated TTP 














Figure 8.12 Proposed mechanism for the initial onset of HIV-associated TTP (From: Meiring et al. 
2012) Abbreviations: A Disintegrin and Metalloproteinase with a Thrombospondin type 1 motif, member 13 (ADAMTS13), thrombotic 
thrombocytopaenic purpura (TTP). 
 
A possible reason for our findings in the HIV positive participants could therefore relate to the 
presence of an as yet undiagnosed HIV-related TTP in these individuals. This hypothesis would 
have been supported by the finding of auto-antibodies to ADAMTS13. This is definitely a factor to 
consider for future studies as the concept of HIV-related TTP gains ground (see section 8.3). 
 
Furthermore, CD4 count did not correlate positively with ADAMTS13 i.e. ADAMTS13 levels did 
not decrease with decreasing CD4 counts (H7c). But, an obvious lower median CD4 count in the 
HIV positive stroke group, with the difference between the two HIV positive groups tending 
towards significance, suggests that lower ADAMTS13 levels are related to advancing 














8.2.4 The joint influence of VWF and ADAMTS13 on stroke causation/risk 
In the HIV positive young stroke group, the VWF median was reported above the upper limit of 
normal, with the ADAMTS13 level below the lower limit of normal. There are data to support the 
idea that a combination of high VWF levels and low ADAMTS13 level confers a greater stroke 
risk than either finding in isolation in a single individual (Andersson et al. 2012). This combined 
abnormal finding is not present in the HIV negative young stroke group. However, it is present in 
the HIV positive young stroke group, and may be a mechanism underlying stroke causation. This 
combined finding should be investigated further in future studies (see section 8.3). 
 
8.2.5 Hypotheses related to “idiopathic” strokes 
The sub-hypotheses, H1a, H2a and H3a aimed to investigate whether VWF and ADAMTS13 
played a role in stroke causation in those individuals in our study with “idiopathic” stroke. Close to 
half of the participants in either stroke group were classified as “idiopathic.” We might have 
expected the associations in our main hypotheses to apply especially to the “idiopathic” stroke 
group, where no obvious cause could be identified, but this was not the case. None of the 
hypotheses was confirmed, suggesting that stroke causation is multifactorial in these groups. 
 
8.3 Study limitations and recommendations 
 
Our study had a number of limitations. In this section, I shall discuss these and how we attempted 
to best deal with them. In addition, recommendations for future studies will also be discussed. 
 
Firstly, the number of participants in our study was small. The reasons for this was that this was a 
pilot study and participant numbers for the HIV positive young stroke group were self-limiting i.e. 
there were only 20 eligible HIV positive strokes enrolled during our study enrolment period (see 
chapter 4, figures 4.5 and 4.6). 
 
Secondly, some selection bias is present. We only included participants who were HAART-naïve 
in our study. However, this allowed us to interpret our findings in the context of HIV infection 
itself, without having to account for the confounding factor of ARVs with their known increased 
cardiovascular risk/stroke risk and metabolic side effects. This is a major strength of the study as it 
is probably not possible to perform such a study in an industrialised country where ART 
availability is more widespread. Future studies should include an HIV positive stroke group on 













In addition, the stroke participants were recruited from tertiary and secondary public hospitals 
located in the Western Cape, South Africa. This means that only cases that presented to these 
facilities were eligible for inclusion in the study. This could have resulted in people who had an 
HIV-related stroke, but who did not seek medical attention, being excluded from the study. Stroke, 
however, is a condition that in most instances results in the patient affected or his/her relatives 
seeking medical attention. Therefore, stroke patients generally end up in hospitals. Also, the fact 
that we recruited participants from more than one facility, each serving the people of a varied and 
vast geographic area, means that we were able to obtain participants from a large population that 
was representative of the Western Cape region. 
 
Another possible but practically irremediable source of selection bias may have occurred if patients 
with large strokes died within a few hours post-stroke. Our study would not have included these 
participants and one might therefore argue that recruitment was biased against large severe strokes. 
These patients might have had massive thromboses with very high VWF and very low 
ADAMTS13 levels. 
 
The fact that control participants were recruited from primary (public) health care facilities might 
have resulted in control participants who were in a better state of general baseline health compared 
with the stroke cases at the time of enrolment into the study. That is, there may have been a 
selection bias in the controls. 
 
Our study was limited to public (state) health care facilities and this may be considered a 
limitation. However, HIV infection generally affects people of lower socio-economic status in 
South Africa who mostly use the public (state) health care facilities. 
 
Time and financial constraints also limited the study. Despite the element of selection bias, our 
groups were nonetheless comparable. Cases and controls were well matched with regards to age 
and sex. Age inclusion criteria limitations were part of the study so as to avoid the confounding 
effects of age-associated cerebrovascular and neurodegenerative diseases. 
 
A third limitation was that we did not have baseline VWF and ADAMTS13 levels for the stroke 
groups. Our study lacked HIV negative non-stroke population norms that were specific to our 
study population. We used the HIV positive non-stroke control group from our study and the HIV 
negative non-stroke controls from another South African study by Meiring et al. (2012), as proxy 












the groups would have also provided potential surrogate baseline levels for the stroke groups. 
Therefore, future studies should include a HIV negative non-stroke control group and 6 months 
post-stroke measurements. 
 
Ideally, a large longitudinal cohort-study, with a long follow-up time, will address the limitations 
regarding small study population numbers, selection bias, population norms and baseline levels. In 
addition, it will allow for paired tests and repeated measures to be conducted. This type of study 
will, however, be very expensive. The idea of a 6 month post-stroke follow-up of the factors of 
interest is a more practical solution. Our pilot study has been useful in bringing these issues to 
light. 
 
Given the fact that high VWF levels and low ADAMTS13 levels in combination are associated 
with a greater stroke risk than either finding alone (see section 8.2.4), a composite score of these 
two factors could be derived. Future stroke studies could then determine if any statistically 
significant differences exist with regard to this composite score between participant groups. 
 
The measurement of cytokines and inhibitory ADAMTS13 auto-antibodies should be considered 
for future studies, as they may provide more insight into the association between HIV-related TTP 
and stroke. Since ADAMTS13 is synthesised by the liver, other tests of synthetic liver function 
should perhaps also be performed. 
 
A kinetic study of VWF and ADAMTS13 in the acute phase post-stroke (see section 8.2.1, 
question 2 and section 8.2.3, question 5), might be able to resolve the issue of causality versus 
consequence. 
 
Another recommendation is to perform the assays using various dilutions of plasma (see section 
8.2.2). A substance might be present in HIV-infected plasma that might have interfered with 
collagen binding. Serial dilutions should be able to minimise the interfering effect of this substance 
and provide more accurate measurements. 
 
ABO blood group typing of participants should also be considered in future studies. There is 
evidence that individuals with blood group O have lower VWF levels and that non-blood group O 
(A, B and AB) individuals have an increased incidence of arterial and venous thrombotic disease, 













Finally, to better answer the question of causality or consequence, other acute phase reactants, such 
as CRP, should also be routinely measured and correlated with VWF and ADAMTS13 levels. 
 
8.4 Summary of discussion 
 
VWF and ADAMTS13 appear to be associated with HIV-related young stroke. Our findings 
indicate that: 
 Stroke in HIV infection is associated with a pro-thrombotic state. 
 This pro-thrombotic state, resulting from raised VWF and lowered ADAMTS13 levels, is 
probably causal rather than consequential upon the stroke in HIV infection. 
 The chronic state of immune activation associated with HIV may increase VWF and 
decrease ADAMTS13 levels as CD4 counts fall with advancing, untreated HIV infection. 
 HIV-related TTP is a potential driving force behind this pro-thrombotic state in HIV 
infection. 
 Stroke occurs in those individuals whose VWF and ADAMTS13 concentrations reach a 
critical pro-thrombotic level. 
 
Our proposed models based on our study findings indicate that raised VWF and low ADAMTS13 
levels contribute to a pro-thrombotic state that can cause stroke in young HIV-infected individuals. 
However, we cannot entirely exclude the notion that our findings are due to an acute phase 
response post-stroke. It may be that high VWF and low ADAMTS13 are both causal and partly 















The present period is an ideal time to conduct research in the field of HIV-related stroke. The 
global HIV/AIDS epidemic has taken firm root in sub-Saharan African which bears the brunt of 
the epidemic. South Africa, in particular, has the largest number of people living with HIV in the 
world (UNAIDS 2011). 
 
The list of diseases complicating HIV infection is long and continues to expand. Stroke in HIV 
positive patients is a recent addition to this list. It affects young people especially and thus adds 
significant years of disability and unemployment to an already struggling population. The causes of 
HIV-associated stroke in the young are probably many and varied. HIV-associated vasculopathy is 
an ill-understood entity which accounts for at least some of the cases. 
 
This study aimed to further our knowledge about the aetiology of HIV-associated stroke by 
investigating factors that have recently begun to be studied in the fields of stroke and HIV 
infection, respectively. However, to our knowledge, none of these two factors, viz. VWF and 
ADAMTS13, has been studied together in a group of young patients afflicted by both HIV and 
stroke. Furthermore, ADAMTS13 is a relatively new area of research, having only recently been 
identified and characterised. 
 
Our results suggest that elevated VWF and low ADAMTS13 levels contribute to a pro-thrombotic 
state in HIV-infected individuals. The precise mechanisms by which this happens are not entirely 
clear. The question of whether our findings are causative or a consequence of stroke has not yet 
been resolved, but our findings tend to favour a causative explanation. However, larger studies will 
be required to verify the results of this initial study. 
 
Despite our study limitations, the results are interesting and provide new insights into HIV-related 
stroke in young adults. Studies of VWF and ADAMTS13, especially in the context of HIV 
infection, are seldom performed in South Africa. We have added in a small way to both HIV and 
haematological research in the country. 
 
While there is a growing international body of literature on VWF and ADAMTS13, these do not 
necessarily apply in the context of South Africa, with its specific circumstances and divergent 
demography. But our study was prompted by the international literature and it can also add to the 












We hope that our own study and the recommendations we made for future studies will encourage 
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